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ABSTRACT OF THE DISSERTATION 
AN INVESTIGATION OF THE RELATIONSHIP BETWEEN ANTEMORTEM AND 
POSTMORTEM DRUG CONCENTRATIONS IN BLOOD  
by 
Samantha Shirelle Tolliver 
Florida International University, 2010 
Miami, Florida 
Professor Kenneth Furton, Major Professor 
In the field of postmortem toxicology, principles from pharmacology and 
toxicology are combined in order to determine if exogenous substances contributed to 
ones death.  In order to make this determination postmortem and (whenever available) 
antemortem blood samples may be analyzed.  This project focused on evaluating the 
relationship between postmortem and antemortem blood drug levels, in order to better 
define an interpretive framework for postmortem toxicology.  To do this, it was 
imperative to evaluate the differences in antemortem and postmortem drug 
concentrations, determine the role microbial activity and evaluate drug stability. 
 Microbial studies determined that the bacteria Escherichia coli and Pseudomonas 
aeruginosa could use the carbon structures of drugs as a source of food.  This would 
suggest prior to sample collection, microbial activity could potentially affect drug levels.  
This process however would stop before toxicologic evaluation, as at autopsy blood 
samples are stored in tubes containing the antimicrobial agent sodium fluoride.  Analysis 
of preserved blood determined that under the current storage conditions sodium fluoride 
 viii 
 
effectively inhibited microbial growth.  Nonetheless, in many instances inconsistent drug 
concentrations were identified.  
 When comparing antemortem to postmortem results, diphenhydramine, morphine, 
codeine and methadone, all showed significantly increased postmortem drug levels.  In 
many instances, increased postmortem concentrations correlated with extended 
postmortem intervals.  Other drugs, such as alprazolam, were likely to have concentration 
discrepancies when short antemortem to death intervals were coupled with extended 
postmortem intervals.  While still others, such as midazolam followed the expected 
pattern of metabolism and elimination, which often resulted in decreased postmortem 
concentrations.  The importance of drug stability was displayed when reviewing the 
clonazepam/ 7-aminoclonazepam data, as the parent drug commonly converted to its 
metabolite even when stored in the presence of a preservative.  In instances of decreasing 
postmortem drug concentrations the effect of refrigerated storage could not be ruled out.  
A stability experiment, which contained codeine, produced data that indicated 
concentrations could continue to decline under the current storage conditions.  The 
cumulative data gathered for this experiment was used to identify concentration trends, 
which subsequently aided in the development of interpretive considerations for the 
specific analytes examined in the study. 
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1.0 Introductory Concepts of Postmortem Toxicology 
1.1 Medical Examiner Department  
The present study examined cases that fell under the jurisdiction of the Miami-
Dade County Medical Examiner’s (MDME) Department.  The MDME is included within 
the 11th District of the Florida State Judicial System (1).  As described by the Florida 
Department of Law Enforcement (FDLE) – Medical Examiners Commission, Chapter 
406 section 11, cases fall within the Medical Examiners jurisdiction when a person dies 
of violence, accident or suicide.  Additional factors include persons of seemingly good 
health who die suddenly, those in police custody or anyone dying under suspicious or 
unusual circumstance (2).  As part of the medicolegal death investigative process, 
pathologists conduct autopsies of the body, in order to identify any anatomic reason for 
death.  During this process, biological fluids and tissues are collected and sent for 
toxicological analyses.  The cases utilized for this study were submitted for toxicologic 
analysis to the MDME – Toxicology Laboratory. 
 
1.2 Medical Examiner’s Toxicology Laboratory 
 Biological samples submitted to the laboratory are handled under a chain of 
custody.  The pathologist assigned to the case submits written documentation of each 
sample (antemortem and postmortem) submitted per case.  The collection site for each 
postmortem blood specimen is specified on the tube and documented within the chain of 
custody for a given case.  Upon receipt of the specimens, laboratory staff members 
review the submitted documentation, indicate the volume or mass of the specimen 
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received and then initial the form.  Postmortem blood specimens are received in gray-top 
vacutainer tubes (total volume 10 mL) and in 50 mL screw cap polypropylene (red-top) 
centrifuge tubes.  Both tubes contain the anticoagulant potassium oxalate and the anti-
microbial agent sodium fluoride.  In addition to blood, urine, bile, vitreous humor and 
gastric contents are routinely submitted.  Brain and liver specimens are submitted at the 
discretion of the pathologist.  These additional biological matrices are received in 
vacutainer tubes or plastic containers without preservatives.  Upon receipt, all samples 
are stored in a walk-in refrigerator at 2 °C.   
 While the toxicology laboratory specializes in postmortem toxicological analyses, 
antemortem samples from medical examiner cases are also analyzed.  Area hospitals 
provide antemortem (AM) samples to the Medical Examiner Department upon request.  
Those AM samples collected close to the time of arrival at the hospital are analyzed as a 
part of routine analysis within the toxicology laboratory.  It is most important to analyze 
arrival specimens as they are reflective of the substances affecting the person when the 
terminal event was initiated.  A specimen referred to as ‘delayed’, that is those specimens 
collected during an extended stay in the hospital, can also be obtained upon request.  
These specimens are analyzed on a case-by-case basis, as they typically only contain 
medications administered by hospital staff.      
Biological fluid and tissue samples, collected at autopsy and area hospitals, are 
analyzed for the purpose of identifying and quantifying drugs/ toxins within the body.  
The laboratory first conducts a presumptive screen analysis to identify the presence or 
absence of drugs or drug classes within each sample.  Those substances that were 
detected in the screen are then submitted for confirmatory testing.  Drug confirmation 
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conclusively identifies specific drugs (as opposed to classes) found in the screening stage 
of analysis.  However, in keeping with good laboratory practices, the confirmatory 
technique must be analytically different from that utilized in the screening process.  Once 
the presence of a drug has been confirmed, quantitation may be required.  Drug 
quantitation is the determination of the amount of drug present within a sample.  In some 
instances, quantitation is done at the time of confirmation.  In these situations, calibration 
curves for specific analytes are run as part of the batch analyses.  Sample concentrations 
are then calculated by linear regression.  When dual confirmation/ quantitation is not 
possible, separate quantitative analyses must be prepared.  Pathologists submit multiple 
biological specimens for toxicological analysis.  However a peripheral blood sample 
(venous blood collected from the extremities (e.g. iliac vein)) as opposed to the central 
cavity (e.g. heart blood) is often the desired specimen for quantitative analysis.  The 
reasons for this will be discussed in greater detail in section 1.6.  
  The information gathered from toxicological analyses is used in the death 
investigative process to determine if the presence or absence of exogenous substances 
contributed to ones death.  The MDME- toxicology laboratory uses modern analytical 
instrumentation including, but not limited to gas and liquid chromatographs, as well as 
mass spectrometers, electron capture detectors and nitrogen phosphorus detectors (3) to 
facilitate the identification process.      
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1.3 Forensic Toxicology 
 In general terms, toxicology is the study of toxic (or adverse) effects of 
compounds on biological systems.  The field of forensic toxicology works to analyze 
biological materials for the purpose of identifying toxic substances (including drugs and 
alcohol) and interpret the results as described by law (4).  Forensic toxicologists must 
maintain objectivity to accurately and justly determine the truth (5).   
 The three main subsections of forensic toxicology are human-performance, urine 
drug testing and postmortem.  Human-performance forensic toxicology relies on analyses 
of biological fluids or breath to determine the presence of performance or mood 
modifying substances.  Urine drug testing analyzes urine to determine if drugs and/ or 
their major metabolites have been used recently.  Post-mortem forensic toxicology is the 
practice of analyzing biological fluid and tissues of deceased persons in order to 
determine if drugs, chemicals or toxins caused or contributed to death.  Since this project 
focuses on postmortem forensic toxicology, the other subsets will no longer be 
considered.    
 
1.4 Pharmacology  
Clinical pharmacology studies in living people have given researchers a strong 
framework to interpret drug concentrations and their effects.  By monitoring both dose-
response and pharmacologic processes, relationships between drug concentrations and 
effects in humans have been better identified. 
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Pharmacological response has two main components, pharmacodynamics and 
pharmacokinetics.  Pharmacodynamics is the study of what a drug does to the body once 
the target site is reached.  Conversely, pharmacokinetics examines how the body absorbs, 
distributes, metabolizes and eliminates drugs from the system.  Both pharmacodynamics 
and pharmacokinetics are directly related to the dose – response relationship.   
 
1.4.1 Dose-Response Studies 
 Dose-response studies monitor the response an individual or population has to 
known doses (concentrations) of drugs.  Typically, the magnitude of the response is 
directly related to the given dose.  Preliminary dosing experiments involve the use of 
animals, most commonly mice and rats.  In these experiments, the animals are 
administered known concentrations of drug.  The data produced are used to determine the 
median lethal dose (LD50).  The LD50 is the dose required to kill 50% of the population.  
Once the LD50 is established, animal studies are often extended for a period of years.  
During this time, side-effects and identification of toxic ranges are determined.  Those 
concentrations determined to be toxic in animal trials can be applied to humans if 
properly calculated.  To do this, the dose per unit of body surface must be measured (6).  
In order to expand a drug trial to human subjects, it must be determined if the benefits of 
the drug outweigh the potential risk to human health and safety (e.g. allergic reactions or 
carcinogenicity).  If it can be determined that it does, the drug may be eligible for human 
testing. 
Clinical trials involve the use of human subjects.  Since animal trials were used to 
determine toxic and lethal doses, the primary goal of the human trials is to determine 
 6 
 
which concentrations effectively illicit the desired response.  Among other 
considerations, the data collected from trial participants can be used to determine both 
drug potency and efficacy.  The data can be displayed in a logarithmic curve as seen in 
Figure 1.  In Figure 1 two drugs, A and B are displayed.  The x-axis is a measurement of 
drug concentration and is used to measure potency.  Drug A is effective at lower 
concentrations than drug B, making A more potent than B.  The y-axis is a measurement 
of maximum effect.  Drug A effects approximately 95% of the individuals in a trial, 
while drug B effects only 60%.  This makes drug A more effective than B. 
 
Figure 1: Dose-Response Curves for Drug A and Drug B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug A is both more potent and more effective than drug B 
    100      200      300      400      500      600 
Dose (mg) 
M
ax
im
um
 E
ff
ec
t (
%
) A 
B 
100 
80 
60 
40 
20 
 7 
 
1.4.2 Pharmacodynamics 
 Pharmacodynamic studies account for both physiological and biochemical effects 
chemicals impose on a system.  In order for a chemical or drug to impose an effect, it 
must reach its target site and bind to a receptor.  As the name suggests, receptors are  
 
Figure 2: Drug and Receptor Relationship 
 
 
 
 
 
 
 
 
 
substances that are receptive to being bound to chemical agents (7).  The combination of 
drug and receptor binding (Figure 2) determines how a drug will affect the body.  As a 
result, chemical agents have been categorized as agonists, antagonists, partial agonists 
and inverse agonists.  
Agonists are chemicals that, when bound to their receptor sites illicit, a 
biochemical or physiological response.  The given response mimics the effects of 
endogenous substances.  The intensity of the response however, can vary.  If the resultant 
effect does not reach its full intensity, the agonist is referred to as a partial agonist (8). An 
inverse agonist (antagonist) imposes the opposite effect of the agonist in Figure 3.  When 
an antagonist is bound to a receptor, it inhibits the effects of the agonist by blocking its 
action.   Antagonists are important to the medical community because they can be given 
Drug Receptor 
Unbound Bound 
Receptor Drug 
Upon drug and receptor binding, the drug can impose its effect 
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to counteract the deleterious effects of drugs.  Agonists and antagonists can exist in the 
system at the same time.  In those situations, the chemical with the highest affinity to the 
receptor will be bound.  The resultant effect is dependent upon which compound is bound 
to the receptor. 
 
Figure 3: Cellular Response as a Result of Drug and Receptor Binding 
  
 
 
 
 
 
        
 
  
 
1.4.3 Pharmacokinetics 
Drugs and other chemical substances can be administered in a multitude of ways, 
including but not limited to oral ingestion, parenteral injection, inhalation, transdermal 
absorption or by insufflation.  Upon administration, the first task of a chemical substance 
is to cross the cellular membrane.  The membrane is composed of a lipid bilayer, made of 
hydrophilic heads and hydrophobic tails.  In general, chemical compounds can traverse 
the bilayer either by passive diffusion or active transport.  Those chemicals that are small, 
In
cr
ea
si
ng
 R
es
po
ns
e 
 
Full Agonist 
Partial Agonist 
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Decreasing Concentration  
The partial agonist is imposing the same effect as the full agonist, 
except with a diminished response.  The antagonist (inverse 
agonist) is exerting the opposite effect of the agonist. 
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unbound and nonionized have a greater possibility of passively diffusing across the 
membrane.  In passive diffusion, the chemical agent moves in response to a concentration 
gradient (from high to low) without requiring an expenditure of energy (9).  Those 
molecules that are not amenable to diffusive mechanisms move via active transport.  The 
active translocation of chemicals across the cellular membrane requires energy, partly 
because the chemicals are moving against the concentration gradient (from low to high) 
(8).  Whether by passive or active transport, once a chemical has crossed the lipid bilayer, 
it has been absorbed into the system.   
After absorption, a drug is able to distribute throughout the body.  Typically, 
highly vascularized tissues (e.g. liver, brain and kidneys) receive the drug first.  Muscle, 
fat and skin are secondary recipients for the drug (10).  Chemical compounds 
preferentially distribute themselves either in the tissues or in the blood stream.  The 
solubility of the drug and the pH gradient established between the blood and tissues are 
determining factors.  In order to identify the extent to which a drug has distributed itself, 
the apparent volume of distribution (Vd) can be determined.  The apparent volume of 
distribution is the volume of blood into which a drug appears to be distributed.  It is not 
based on the actual volume of fluid present within a person, but rather the volume needed 
for a drug to be evenly distributed between tissues and organs.  It has been argued that the 
higher the Vd, the more likely a drug is to be sequestered in body tissues rather than 
remain in circulation.  Conversely, those drugs that remain in circulation are susceptible 
for distribution, metabolism and elimination.  During this time, a drug’s elimination half-
life must be considered.  Elimination half-life (t½) is the amount of time it takes to reduce 
a drugs concentration by 50% (11).  Some drugs, such as heroin, have a relatively short 
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half-life (2-6 minutes), while others like methadone have a more prolonged half-life (15-
55 hours).  Knowing a drug’s half-life can be a useful tool in predicting the expected 
concentration of a drug in blood circulation after a given amount of time.   
During metabolism, the body converts foreign materials into polar, water soluble 
compounds that are easier to eliminate.  The liver, the primary organ of metabolism, has a 
substantial number of enzymes used to aid in this process.  Drug metabolism can occur in 
one of two mechanisms (first pass or post distribution) and in one of two phases.   
First pass metabolism primarily occurs in orally administered drugs.  After 
ingestion, the drug can be metabolized in part by the intestines, but primarily by the liver 
before systemic circulation begins.  The metabolism and subsequent elimination of a drug 
before distribution can significantly decrease its bioavailability.  Bioavailability is a term 
used to describe the remaining amount of drug available to affect the system post 
ingestion.  Bioavailability is an important factor to consider, because if a drug is highly 
susceptible to first pass elimination, its bioavailability will be significantly reduced.  
Drugs administered via intravenous injection, sublingual dissolution or insufflation are 
not affected by first pass metabolism as they directly enter the blood stream and are 
distributed upon absorption.  As a result, they are eliminated post distribution.  Whether a 
drug is eliminated by first pass or post distribution mechanisms, all drugs will eventually 
be metabolized.   
 Metabolism occurs in one of two phases.  Phase I reactions increase chemical 
polarity by either adding of modifying functional groups on the compound.  Phase I 
reactions can sufficiently rid the body of foreign materials on its own.  However, if the 
chemical elimination does not occur rapidly enough, a secondary reaction (Phase II) can 
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occur.  Phase II reactions add endogenous substances (e.g. glucuronic acid, sulfate, 
acetate or amino acid) to the exogenous chemical to form a conjugate (12).  Conjugation 
greatly increases polarity and water-solubility; thereby facilitating elimination.   
Chemical elimination is regulated by the kidney.  The kidneys excrete non-
volatile, water soluble, polar compounds in urine.  The rate of elimination depends on the 
chemical properties of the drug as these properties directly affect the speed and efficiency 
of the excretion process.  The phase I and II reactions work to metabolize chemical 
agents into a readily excretable form.  However, there are situations where instead of 
elimination a drug, is reabsorbed back into the system.   
The pH of the fluid in the kidneys is vital to its ability to eliminate drugs.  
Therefore, if the pH of the fluid is slightly basic, acidic compounds will become ionized 
and eliminated through urine.  However, any basic drugs present will remain nonionized 
allowing them to potentially be reabsorbed back into the body.  If reabsorption occurs, 
the body can again be affected by the drug’s presence.  However, the body will respond 
once more by trying to eliminate it metabolically.   
Pharmacological studies examine the relationship between physiological and 
biochemical response, as well as concentration and time.  Dose-response analyses 
measure concentration and response (13).  The combination of the information gained 
from both pharmacology and dose-response research has been used to develop the 
interpretive framework of toxicology.  The data produced in clinical pharmacology 
studies on living humans have aided in the development of analytical tools (e.g. tables 
and charts) which can help assess the effects of drugs at known concentrations.  This data 
has been used as a guideline in determining physical, psychological and pharmacological 
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effects of drugs.  When applying this information to living subjects, these studies have 
proven useful.  However, attempting to apply the same information to postmortem drug 
concentrations in deceased subjects has led to substantial errors.   
 
1.5 Postmortem Processes 
 Just as living people have body processes, so do deceased persons.  However, 
these processes are significantly different.  Upon death, the body no longer receives a 
flow of blood carrying oxygen and nutrients and removing wastes.  As a result, cells 
begin to die and the process of decomposition has begun.   
 Human decomposition can begin within five minutes of death and is governed by 
autolysis.  Autolysis, otherwise known as self digestion, is the breakdown of cellular 
materials by enzymes (14).  This process begins within the intestines.  The lack of 
oxygen in the body allows for anaerobic bacteria and enzymes to take over and digest the 
intestine.  As the digestion continues, the enzymes will break out of the intestine and 
begin digesting the surrounding organs and other body tissues.  As the cells within the 
body die, they release drugs, toxins and other substances.   
While the cellular breakdown of the body is not immediately visible, with time it 
does show itself on the outside of the body in the form of skin blisters and slippage (large 
pieces of skin separating from the body) (15).  In addition to the anaerobic and enzymatic 
activity, internal changes including body temperature decrease, blood settling in the 
direction of gravity (causing skin discoloration) and rigor mortis (body stiffening) occur.   
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 After these initial changes, the body will bloat as a result of the production and 
build up of gas inside.  During bloat, insect activity flourishes, resulting in the 
acceleration of organ and tissue breakdown.  Eventually, the gas is expressed and the 
body collapses (decay).  In addition to gases, the liquefied tissues of the body are released 
as well.  The drainage of the liquids allows the body to dry out and depending on the 
environmental conditions mummification or skeletonization ensues.   
 The rate of decomposition can vary from weeks to years, depending on the 
environment surrounding the body.  Climate, precipitation, trauma and insect activity can 
all contribute to the rate of decomposition (16).  In warmer, more humid environments 
decomposition can be accelerated, compared to cool, dry environments.  This is in part 
the result of increased insect activity, as insects flourish in these types of environments.  
Maggots are largely responsible for the digestion of body tissues (17).  Eggs are 
deposited into body orifices (e.g.eyes and mouth) as well as areas of traumatic injury, as 
these open areas are easily accessible.  Conversely in situations where the body is buried, 
encased, wrapped or located in a cold or dry climate, insect activity is diminished, 
thereby retarding the rate of decomposition (16). 
 Cases analyzed for this study were obtained in Miami-Dade County in Miami, 
Florida, USA between the years of 2004 through 2008.  Summers (June through 
September) during those four years in Miami, FL had an average temperature of 82.6 °F 
(Chart 1) with an average monthly rainfall of 0.29 inches (18).  As a result, the relative 
humidity in Miami can well exceed 85% during summer months (19).  Winters 
(December through February) in Miami tend to be milder, with the average monthly 
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Chart 1: Average Monthly Temperature in Miami, FL from January 2004 – 
December 2008  
 
 
 
 
 
Chart 2: Average Monthly Precipitation in Miami, FL from January 2004 – 
December 2008 
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winter temperature and precipitation (2004-2008) being 69.9 °F and 0.06 inches, 
respectively (19).  The average monthly precipitation for the years 2004 – 2008 are 
displayed in Chart 2.   
As a result of the climate, depending on the conditions of the body (e.g. indoors, 
outdoors or wrapped) advanced decomposition can occur within 24 hours after death.  In 
terms of toxicology, decomposition fluid has very limited value as it is a mixture of 
degraded tissues and organs.  As a result, any quantifiable data obtained is a result of a 
contaminated sampling pool.  Therefore, samples containing decomposition fluid were 
not used for this study. 
The body processes in living people (as discussed in section 1.4 Pharmacology) 
are vastly different from those processes occurring in deceased persons.  Even in the 
earliest stages of decomposition, the processes of the body are dissimilar to those 
occurring in a living person.  The effects these distinctively different processes have on 
the body are what make it virtually impossible to apply the same interpretive parameters 
to both living and deceased people.  A thorough guide exists for clinical toxicologists; 
however, one is still needed for postmortem toxicologists.  The lack of an accurate and 
reliable interpretive framework for PM toxicology has opened the field up to gross errors 
and mis-steps.    
 
1.6 Interpretive Considerations of Postmortem Toxicology 
 As was discussed in sections 1.4 and 1.5, there are unique considerations for 
interpreting drug concentrations for both living and deceased persons.  One of the goals 
of this project was to gain a better understanding of postmortem drug interpretation.  In 
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doing so, some fundamental concepts must be understood.  These include the effect of 
specimen choice, postmortem interval, postmortem redistribution, and drug stability.  All 
of these factors influence a toxicologist’s ability to interpret postmortem drug 
concentrations.   
 
1.6.1 Specimen Choice (Whole blood) and Postmortem Phenomena 
 In postmortem toxicology, quantitative analysis is usually conducted on whole 
blood.  Those drugs identified in blood samples are believed to be reflective of the 
substances potentially affecting a decedent at the time of death.  This is an extremely 
important detail when trying to determine if the presence or absence of drugs contributed 
to ones death.   
 At autopsy, both central and peripheral blood samples are collected when 
possible.  Central sourced blood is collected from the trunk of the body (e.g. heart or 
aorta).  Blood collected from the body’s extremities is considered to be peripheral blood.  
Common examples of peripheral blood include that from the femoral or iliac veins.  
Since blood can be collected from any number of areas, the samples submitted for 
analysis are labeled with the appropriate source.  The correct designation of the source is 
important because a phenomenon known as postmortem redistribution can cause 
inconsistent quantitative results among blood and tissues collected within the same body. 
 Postmortem redistribution (PMR) is a term used to describe a complex array of 
variables that can lead to the redistribution of drugs after death, which in turn can result 
in quantitative concentration discrepancies.  In general, postmortem blood concentrations 
can vary depending on collection site and the time interval between death and autopsy.  
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As a result, postmortem blood concentrations are not believed to be reflective of blood 
concentrations present at, and around, the time of death.  The combination of 
physiochemical drug characteristics, cellular and tissue breakdown during decomposition, 
as well as the proximity of internal organs and vessels (20) all contribute to a drug’s 
ability to redistribute itself in the postmortem.  Since upon death, the body is no longer 
able to produce energy, it is believed that passive diffusion of drugs (down the 
concentration gradient) is responsible for their movement (21). 
 Postmortem redistribution occurs more extensively in areas of the body where 
drug storage depots and vessels are in direct contact with each other.  Not only are the 
liver, lungs and gastrointestinal tract well known drug reservoirs (20), but their proximity 
to each other (as well as vessels) can facilitate a more extensive redistribution effect (22).  
In contrast, peripheral vessels have limited contact with adipose and skeletal muscle.  
Both of which are susceptible to the decomposition processes at a much slower rate than 
the central organs.  Therefore, peripheral blood sources, which are believed to be 
protected from the initial putrefactive processes, are the preferred sampling sites for 
postmortem quantitative work. 
  The extent to which a drug is able to redistribute itself is often governed by its 
apparent volume of distribution (Vd), which is mathematically calculated in Equation 1 
(23).  The Vd value accounts for drug chemistry as some drugs remain in the vessels 
(hydrophilic) while others preferentially store themselves within the tissue (lipophilic).  
Higher values for the Vd reflect a greater preference of a drug to concentrate itself in the 
tissues rather than in blood (24).  Thus it is believed that drugs with higher volumes of 
distribution can be released from their storage tissues and diffuse into the vessels and 
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surrounding tissues during redistribution.  For that reason, blood collected from the major 
vessels in the central cavity of the body, is more likely to be contaminated by the drug 
concentrations of the surrounding organs (e.g. liver and lungs).   
 
 
Equation 1: Apparent Volume of Distribution Calculation 
 
 
 
 
 
 The extent of PMR can also be influenced by the postmortem interval (PMI).  
This is the time between death and sampling at autopsy.  Greater time intervals result in 
increased time for drug release and redistribution to occur.  Although central blood is not 
the preferred source for quantitative analysis it is not without value.  Typically the 
volume of the central blood available is far greater than that of peripheral blood.  
Therefore, central blood can be utilized for initial qualitative analysis, followed by 
peripheral blood when additional interpretive information is needed (25).   
 The quantitative differences between central and peripheral sources is known as 
the central to peripheral (C:P) ratio (22).  As previously mentioned, the central source 
blood is more prone to redistribution and thus contamination.  On the basis of the central 
to peripheral theory, when redistribution occurs the central sourced blood will have a 
higher concentration than the periphery, which leads to a C:P ratio greater than 1.  
Another ratio used to measure the extent of PMR is the postmortem to antemortem 
Amount of drug in the body 
Concentration of drug in the blood or plasma 
 
 
Vd =
  
The result reflects a theoretical volume needed for a drug 
to evenly distribute between blood and tissue 
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(PM:AM) ratio.  Similar to the C:P ratio, when redistribution is believed to be present, 
the PM to AM ratio should be greater than 1.  The PM: AM ratio are believed to be more 
susceptible to the PMI, meaning the greater the interval, the greater the chances of 
redistribution.  While the C:P ratios are believed to be more influenced by the anatomical 
location of the blood sources.  Regardless of which ratio is used, PMR in and of itself 
does not always respond in a predictable manner (26); therefore, neither relationship will 
always hold true.     
  
1.6.2 Additional Biological Matrices 
 In addition to whole blood, urine, bile, vitreous humor and gastric contents are 
also routinely collected at autopsy.  Urine analysis provides qualitative information about 
recent drug use.  It is not used for quantitative work because the drug content present in 
urine has already been metabolized and removed from blood circulation.  As a result, 
drugs identified in urine are not reflective of what was actually affecting a decedent 
around the time of death.   Bile typically is used for qualitative analysis but has proven 
additionally useful as an alternate sample for quantitative ethanol testing (27).  The eyes, 
which are remotely located from the central cavity, work as a protective case for vitreous 
humor.  The location of the vitreous allows for both minimal contamination and bacterial 
degradation (27) (28).  The decreased bacterial fermentation makes vitreous a reliable 
quantitative sample for ethanol analysis.  Additionally, quantitative analysis of gastric 
contents can identify drug overdoses and distinguish between accidental and intentional 
overdose (29).  
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 When interpreting postmortem drug concentrations the information gained from 
the above biological matrices aids in developing the full toxicological spectrum of each 
case.  However, the scope of this project focuses solely on the direct comparison between 
antemortem (AM) and postmortem (PM) blood samples.  Additionally, bile, vitreous 
humor and gastric contents are not potential specimens for collection from living patients.   
 
1.6.3 Drug Stability 
 Upon consumption, some drugs are more unstable than others.  Heroin, a 
synthetic opiate, is rapidly sequentially hydrolyzed to 6-monoacetylmorphine, then to 
morphine.  Both heroin (3,6-diacetylmorphine) and 6-monoacetylmorphine are very 
unstable in blood with half lives of 2 – 6 minutes and 6 – 25 minutes, respectively (30).  
One study, conducted on all male subjects, found that regardless of ingestion route 
(intranasal, parenteral or insufflation), heroin concentrations peaked within 5 minutes of 
ingestion and then fell below 1 ng/mL detection limits thirty minutes post ingestion (31).  
Because of the rapid hydrolysis of heroin and 6-monoacteylmorphine, in cases where a 
fatal heroin overdose is suspected, factors such as the postmortem interval (PMI) and the 
time between ingestion and death usually preclude an analyst’s ability to detect heroin.  
In such situations, metabolite detection is far more likely.   
 
1.6.4 Drug Interactions 
 When interpreting toxicological data, it is important to consider the total effect of 
all drugs present (29).  While some drugs may not contribute to death, others may impose 
additive or synergistic effects resulting in a deadly outcome (24).  When two or more 
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substances additively interact, they produce a total effect that would be equal to the sum 
of the effects of each drug if given separately.  Synergistic interactions have enhanced 
toxicity as their cumulative effect is greater than would be expected of either substance if 
given separately.  Synergism is often displayed when substances imposing the same 
effect are taken in combination.  For example, narcotic analgesics (e.g. fentanyl), 
benzodiazepines (e.g. alprazolam) and ethanol can all cause respiratory depression.  
When taken in combination, fatal results can occur at concentrations both within and 
below therapeutic levels (24) (32).   
 
1.6.5 Donor Cases 
 Donor cases are those in which the decedent’s body was used for organ donation.  
In these situations, a hospitalized patient must first be pronounced dead.  The term 
‘death’ refers to brain death.  Up until the time of brain death, a patient may be receiving 
medications and treatment by the hospital staff to help maintain life.  Medications, such 
as corticosteroids, are given to help reduce the swelling of the brain in order to preserve 
its integrity and function.  A side effect of this treatment is that the organs of the body 
will dehydrate, thereby compromising their function.  However, at the time of brain death 
the use of such medications are ceased.  Organ functions (including the beating of the 
heart, kidney filtration and liver metabolism) are maintained artificially with the aid of 
medical equipment.  As a result, body processes such as metabolism and urine production 
are still active.  In addition, in preparation for organ procurement, the body is infused 
with fluids to rehydrate the organs.  A donor may receive fluids and be maintained on life 
support for a matter of hours or even days after brain death. 
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 Organ harvesting is a surgical procedure that occurs in a sterile, surgical 
environment.  Just prior to the surgery, blood and urine samples are collected.  These 
samples are often obtained by the MDME’s toxicology laboratory.  However, infusions 
of hospital fluids severely dilute the concentration of drugs of toxicological importance.  
Additionally, those drugs that are identified and/ or quantified in donor cases are typically 
those administered by the hospital.  Therefore, their presence may render little insight 
into the cause of death.  As a result, donor samples are obtained and stored, but often not 
tested as a part of routine analysis.         
 
1.7 Drug and Drug Classes of Interest 
1.7.1 Benzodiazepines 
 Benzodiazepines are a class of drugs which fall under the category of central 
nervous system (CNS) depressants.  Chlordiazepoxide (Librium®), the first 
benzodiazepine, was introduced to the world in the 1960’s; diazepam (Valium®) soon 
followed.  Benzodiazepines were first used as a replacement for barbiturates (a class of 
sedative hypnotic drugs).  Barbiturates, while effective, required higher doses, had more 
severe withdrawal symptoms and had higher incidence of unintentional overdose than 
benzodiazepines.  The perceived increased safety offered by benzodiazepines along with 
their wide array of uses (e.g. anti-anxiety, antidepressant and anticonvulsant), has now 
made them among the most frequently prescribed medications in the United States.  
Structurally, all benzodiazepines have the same heterocyclic ring structure, 
consisting of a benzene ring fused to a 7-member diazepine ring.  However, they have 
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variations which include 1,4 –benzodiazepines (e.g. diazepam), 7-nitro-1,4 
benzodiazepines (e.g. clonazepam) and –azolo benzodiazepines (e.g. midazolam and 
alprazolam) (33).  While the actual effectiveness of benzodiazepines has been questioned 
in recent years (34), they are still widely prescribed for their sedative, hypnotic and 
antiepileptic properties.  However, studies have suggested that their long-term use can 
result in cognitive dysfunction, psychomotor impairment and physical dependency (35) 
(36). 
   
Table 1: Benzodiazepines of Interest 
 
Chemical Name Trade Name Usage Duration 
7-aminoclonazepam* N/A N/A N/A 
Midazolam Versed® 
Sedation, 
amnesiac 
properties 
short-acting 
Nitrazepam ISTD Mogadon® Sedative long-acting 
Clonazepam  Klonopin® Anticonvulsant long-acting 
Alprazolam Xanax
® Antidepressant 
& Anxiolytic short-acting 
Nordiazepam  Stilny® Anxiolytic long-acting 
Diazepam  Valium® Anxiolytic long-acting 
Bromazepam ISTD Lectopam® Anxiolytic short-acting 
* 7-aminoclonazepam is the major metabolite of clonazepam and cannot 
be obtained by a separate prescription 
 
 
 
 Dosing amounts of benzodiazepines are largely reflective of their intended 
treatment.  Generally, high doses are used as hypnotics, moderate doses as anxiolytics 
and low doses are employed for their sedative properties (37).  When taken as prescribed, 
benzodiazepines rarely cause toxicity.  However, it has been well documented that when 
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taken in conjunction with other central nervous system depressants, they can be highly 
toxic (24) (32).   Additionally, while some benzodiazepines are metabolites, they may 
still be pharmacologically active.   For example the parent drug diazepam (Valium®) can 
metabolize to nordiazepam (Chlorazepate®), temazepam (Restoril®) and oxazepam 
(Serax®).  All four drugs are available by prescription as they all effectively treat anxiety.  
As a result, blood analysis for this class of drugs can be rather extensive.  Table 1 
outlines the benzodiazepines analyzed for this study.  
 
1.7.2 Opiates 
 Opiates are a class of drugs derived (either naturally or synthetically) from opium 
poppy.  Opiates are often referred to as narcotic analgesics as these highly addictive 
medications are a potent remedy for severe pain.  While opiates are the most effective 
pain management medication available, they offer many undesirable effects including 
stupor, nausea, vomiting and respiratory depression.  Opiate users (both licit and illicit) 
often build a tolerance to the medication, which can lead to abuse.  In terms of 
toxicology, tolerance makes it difficult to properly interpret the significance of opiate 
concentrations in blood (21).  For this study, hydrocodone, codeine, oxycodone, 
morphine, 6-monoacetylmorphine (6-MAM), hydromorphone and oxymorphone were 
monitored.  However, a sufficient amount of case data was only collected for morphine, 
codeine and 6-MAM.  Their results are discussed in the 6.1 Opiates section.  As a result 
of the lack of data, oxycodone and oxymorphone were no longer considered.  However, 
hydrocodone and hydromorphone are still included in the results section as they were 
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monitored in the stability experiment (refer to section 6.5).  Additionally, hydrocodone 
(in addition to codeine) was used in the microbial study (refer to section 6.4) as well.  
 Codeine and morphine each have their own analgesic properties; however,  6-
monoacetylmorphine is a major metabolite of heroin (3,6-diacetylmorphine) degradation.  
Heroin is not a naturally occurring opiate; rather it is synthesized from opium poppy.  
The poppy seeds, which are harvested from an opium plant, are sliced in order to allow 
their fluid to drain.  Contained within this fluid mixture are the naturally occurring 
opiates, codeine and morphine.  A non-specific extraction process is used to isolate both 
codeine and morphine from the fluid.  The compounds are treated with an acetylating 
agent, which when reacting with morphine produces heroin (3,6-diacetlymorphine).  
Codeine will react as well, resulting in the formation of the impurity acetylcodeine (38) 
(39).  Upon ingestion, heroin is rapidly converted to 6-MAM, then to morphine, while 
acetylcodeine is converted to codeine.  As a result, heroin usage often results in the 
detection of 6-MAM, morphine and codeine.  While heroin is currently a Schedule I drug 
(meaning it has no medicinal use in the United States (40)), it was once used to treat 
tuberculosis and cure morphine addiction (38).  However, its addictive nature caused the 
drug to be banned in the United States in 1956 (38).  Heroin screening is typically not 
part of routine analytical analyses as it is highly unstable in blood (refer to Drug Stability 
1.6.3).   
 While codeine and morphine can be used as markers of heroin abuse, they are 
also medications in their own right.  Codeine can be found in numerous formulations, 
including prescription cold remedies and antihistamines.  Morphine is the primary active 
ingredient in opium.  It is commonly used for pain management and in combination for 
 26 
 
preoperative sedation.  Its pain relieving ability is the standard used to measure the 
effectiveness of newer analgesics (41).  Table 2 lists the opiates evaluated in this study.   
 
 
Table 2: Opiates Evaluated for Research 
 
Chemical Name Trade Name Usage Treatment Origin 
Heroin1,2 N/A Illicit  N/A Semi-synthetic 
Codeine Codeine Antitussive - Natural 
Morphine Kadian® Analgesic  Moderate to severe pain Natural 
6-Monoacetylmorphine2 N/A N/A N/A Semi-synthetic 
Hydrocodone Vicodin
®, 
Narco® 
Antitussive 
& 
Analgesic  
Moderate 
pain 
Semi-
synthetic 
Hydromorphone Diluadid® 
Antitussive 
& 
Analgesic 
Moderate to 
severe pain 
Semi-
synthetic 
 
 
 
1Heroin detection was qualitative only 
2Not approved for medicinal usage 
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Figure 4: Acetylation Reaction of Morphine and Codeine 
 
 
 
 
opium 
poppy 
Codeine Acetylcodeine 
Morphine Heroin 6-Monoacetylmorphine 
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1.7.3 Additional Drugs of Interest 
 Diphenhydramine and methadone were of additional interest for this project.  
Diphenhydramine is a common over the counter medication.  Its properties relieve itchy 
and watery eyes as well as other allergy related symptoms (Benadryl®).  In addition, it 
imposes sedation and therefore has been used as a sleep aid in a number of formulations.  
Methadone (Dolophine®) has analgesic properties equal to that of morphine.  While it is a 
central nervous system depressant and works on the same receptors as the opiates, 
structurally it is not related to them.  Continued use of methadone can result in drug 
accumulation in the system, which can lead to severe sedation (42).  Therefore, 
methadone usage is controlled and almost exclusively used to treat narcotic addiction.   
 
 
 
2.0 History of Postmortem Interpretation 
Clinical toxicology is a broad field that encompasses the pharmacokinetic, 
pharmacodynamic and dose-response relationship that occurs between people and 
exogenous substances.  As a result of understanding these relationships, individualized 
interpretive guidelines have been developed to identify both physiological and 
psychological effects of a given drug at a known dosage.  The guidelines evolved into a 
clinical therapeutic index, which is used to identify therapeutic, toxic and lethal dosages 
(1).  For many years, it was these clinical models that were used as the basis of drug 
interpretation in the field of postmortem toxicology.      
 A postmortem toxicologist, just as a clinician, would compare drug levels to a 
clinical model and make a determination about how said drug(s) influenced a person at 
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the time of one’s death.  While clinical models have been invaluable tools for clinicians, 
they proved to be horribly inaccurate in postmortem work (2) (3) (4) (5).  Deceased 
persons do not undergo the same biological processes as living persons.  Consequently, 
the comparison of postmortem concentrations to clinical models resulted in large errors.  
However, in the early stages of postmortem interpretation this was not known.  Sporadic 
reports of drug concentration discrepancies began to emerge in the 1970’s.  Nevertheless, 
it was not until the late 1980’s when the concept of postmortem concentration change 
came to the forefront of many discussions.     
One of the most popular prescription medications in the 1970’s was digoxin.  
Digoxin replaced digitoxin as the primary treatment of heart failure related conditions.  
With the use of digoxin came several peer reviewed publications detailing analytical 
techniques for the appropriate extraction and identification of the drug (6) (7).  In 
addition some authors encouraged postmortem interpretation to be conducted on heart 
serum.  As it was believed by them, that heart serum most accurately reflected 
antemortem concentrations at the time of death (8) (9) (10).  Factors that could contribute 
to PM concentration changes (e.g. the apparent volume of distribution, antemortem to 
death interval and postmortem interval) were not thoroughly investigated at that time.  
However, in 1977 Vorpahl and Coe (11) published a study where they aimed to 
determine if discrepancies existed between antemortem and postmortem digoxin samples.  
In addition they considered both the influence of the postmortem interval as well as the 
role of the postmortem collection site on digoxin levels.  Ultimately, they determined that 
significant variations can exist between AM and PM digoxin concentrations.  However 
the length of the PMI could not be correlated to the magnitude of change within the PM 
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sample.  While Vorpahl and Coe published a fairly comprehensive study on digoxin, this 
type of evaluation of other drugs was still lacking.    
From the late 1970’s into the 1980’s scientific conferences became the forum in 
which postmortem toxicologists could discuss their interpretive issues.  Many early 
published articles detailing challenges stemming from postmortem change, by then 
referred to as postmortem redistribution, referenced talks presented at scientific 
conferences (12) (13) (14) (15) (16), rather than published sources.  With time and 
concurrence among the postmortem toxicology community, more articles emerged 
addressing the concentration inconsistencies among drugs such as tricyclic 
antidepressants (e.g. amitriptyline), ethyl alcohol, propoxyphene and methadone (17) (18) 
(19).  The reporting mechanism however was varied by author.  For instance a single case 
was published by Jones and Pounder (20), in which they analyzed a number of tissues, as 
well as cerebral spinal fluid, vitreous humor, arterial and venous blood concentrations of 
6 analytes.  Other authors chose to do compilation studies, where they presented data that 
had been collected over a period of years (18) (17) (21).  Compilation studies typically 
had an extensive amount of data presented in the form of tables.  Some studies presented 
both antemortem and postmortem results, while others focused solely on various 
postmortem specimens.  During that time ratio calculations, including PM:AM, C:P as 
well as liver: blood (11) (22) were conducted as a means to identify the source of the 
discrepancy.   
By the 1990’s a substantial amount of meetings and publications resulted in a 
shift in the interpretive process for postmortem work.  Toxicologists were now clearly 
aware of concentration discrepancies that could exist between postmortem and 
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antemortem samples.  The community strongly advised against using clinical models for 
interpretation.  The only exception to the elimination of the clinical models was the role 
of drug interaction and how those interactions could have affected someone around the 
time of their death.  Postmortem studies were indicating that certain drugs, particularly 
those with a high apparent volume of distribution, could disproportionately increase in 
concentration after death.  Factors such as the antemortem to death interval, postmortem 
interval and ratio calculations were being reported more frequently.  However, 
comprehensive articles about how all of these (and other) factors contributed to 
postmortem changes were still infrequent.  The goal of this project was not to interpret 
postmortem results, but rather to gain a better understanding for which factors can, and 
frequently do, influence postmortem results.  This comprehensive study was the first of 
its kind in which the role of microbial activity, drug stability in storage, antemortem 
intervals, postmortem intervals, postmortem specimen choice, apparent volume of 
distribution, postmortem to antemortem, as well as central to peripheral ratios were 
considered for seven commonly encountered  medications in postmortem work.  The end 
result both refuted and confirmed some ideals that are currently still in practice.  This 
study also identified the specific variables that have the highest likelihood of influencing 
each of the seven drugs of interest.  While understanding the dynamics of postmortem 
work may never be as simple as comparing a result to an individualized model, this study 
has certainly contributed to the understanding of postmortem change and by extension, 
the interpretation of postmortem results.        
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3.0 Research Objectives 
Cases included in this project were submitted with both antemortem (AM) and 
postmortem (PM) blood specimens.  The ideal case had an AM to death interval that did 
not exceed 24 hours, a postmortem interval within 48 hours and tested positive for at least 
one drug of interest (refer to section 1.7 Drug and Drug Classes of Interest).  Cases that 
both met and exceeded the time frame requirements were analyzed and the importance of 
time intervals was evaluated on a drug-by-drug basis in section 6.0 Results and 
Discussion.   
The first objective was to evaluate the differences in drug concentrations between 
antemortem and postmortem blood.  In order to achieve this, data comparisons between 
intra-case antemortem and postmortem quantitative results were conducted.  Whenever 
available, both postmortem central and peripheral bloods were tested and the impact of 
postmortem specimen choice was examined.  The cumulative data collected for each drug 
was used to identify concentration trends and ultimately make determinations about drug 
relationships.     
The second objective was to determine how sample preservation impacts drug 
stability.  While the postmortem samples analyzed were preserved in tubes containing the 
anti-microbial agent sodium fluoride, it was important to assess the effectiveness of the 
preservative.  To that end, a two-part microbial experiment was conducted.  One 
experiment evaluated the ability of microbes to use drugs as a food source, in the absence 
of a preservative.  The other tested the effectiveness of sodium fluoride under both 
aerobic and anaerobic conditions.    
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Thirdly, it was necessary to assess the stability of drugs after two months of 
refrigerated storage.  The samples analyzed for this study often had a two month (or 
greater) lapse between collection and analysis.  As a result, it was necessary to determine 
if storage conditions could contribute to concentration discrepancies between antemortem 
and postmortem samples. 
The final objective was to combine the information gained from the first three 
objectives and develop an interpretive framework for postmortem concentrations.  
Unfortunately, a set guidelines aiding in the postmortem interpretive process do not exist.  
The creation of one could be an extremely valuable tool, which could ultimately lead to 
the reduction of erroneous interpretive errors.   
 
 
4.1 Introduction: 
4.0 Materials, Methods and Instrumentation 
 All of the cases used in this project were initially screened and confirmed, as part 
of the routine analysis by the toxicology staff at the Miami-Dade County Medical 
Examiner (MDME) Department.  The laboratory adheres to strict standard operating 
procedures (SOPs).  All methods were validated prior to their use for case work.  In some 
instances, the initial quantitative data was also collected by the lab staff as part of the 
death investigative process.  This will be discussed in more detail in the results section.  
The following quantitative methods are those used within the MDME toxicology 
laboratory and in this project.    
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4.2 Benzodiazepines: Quantitative Blood Analysis by GC/ECD, HPLC/DAD and 
HPLC/MS 
 Benzodiazepine quantitation was conducted on three instruments, gas 
chromatography/ electron capture detector (GC/ECD), high performance liquid 
chromatography/ diode-array detection (HPLC/DAD) and high performance liquid 
chromatography/ mass spectroscopy (HPLC/MS).  All data collected as part of routine 
laboratory analyses were obtained from both the GC/ECD and HPLC/DAD.  The 
GC/ECD was utilized by the researcher for benzodiazepine quantitation until March 
2008.  After which, quantitative research testing was conducted solely on Thermo 
Finnigan’s LCQ Advantage HPLC/MS system. 
 The HPLC/DAD system was used to quantitate diazepam and nordiazepam 
(among other benzodiazepines) with a linear range of 0.1 – 10 mg/L.  The GC/ECD 
system had a quantitation method for alprazolam, clonazepam and 7-aminoclonazepam 
with a linear range of 0.01 – 0.2 mg/L.  In an effort to combine the two methods, the 
HPLC/MS was used to analyze the most frequently encountered benzodiazepines seen in 
this research project.  Those included midazolam, lorazepam, clonazepam, 7-
aminoclonazepam, diazepam, nordiazepam and alprazolam (linear range: 0.01 – 1.0 
mg/L).  The combination of the extended linear range and the four additional analytes 
made the HPLC/MS method a convenient alternative, which offered the same level of 
sensitivity and accuracy as the GC/ECD and HPLC/DAD.  Liquid-liquid extraction 
procedure was used for both the GC/ECD and HPLC/MS systems (Section 4.2.1 (a)), 
while solid-phase extraction (4.2.1 (b)) was utilized for the benzodiazepines analyzed by 
HPLC/DAD.    
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4.2.1(a) Standards and Extraction Procedure for GC/ECD and HPLC/MS 
Stock standards, obtained from Cerilliant Corporation (Round Rock, TX), were 
used to prepare working standards.  The working standards were serially diluted to 
comprise a five point calibration curve, ranging from 0.01 mg/L to 0.2 mg/L by GC/ECD 
and a six-point curve ranging from 0.01 mg/L to 1.0 mg/L by HPLC/MS.  After 
preparation, the standards were spiked in drug-free whole blood.  Whenever necessary, 
samples that exceeded the limits of quantitation were diluted, to bring their 
concentrations within range, and reanalyzed on the appropriate instrument.  Additional 
stock standards were purchased from Alltech Associates (State College, PA) to prepare 
controls.  A 0.05 mg/L working control was prepared for GC/ECD analysis, while 
0.1mg/L control was prepared for HPLC/MS analysis.  All standard and sample 
concentrations were calculated using linear regression.  
To each 1 mL blood sample, 100 µL of internal standard (GC/ECD = 0.4 mg/L of 
bromazepam; HPLC/MS = 4 mg/L of nitrazepam) followed by 1 mL of pH 9 saturated 
sodium borate buffer were added.  The samples were vortex-mixed and 10 mL of n-butyl 
chloride was added.  The mixture was capped and rotated for 15 minutes followed by 
centrifugation (3000 RPM) for 5 minutes.  The organic fraction was transferred to a clean 
tube and the solvent was evaporated at 40 ºC under a stream of nitrogen.  The dried 
extracts were reconstituted with 50 µL of toluene (GC/ECD) or 50 µL of mobile phase 
(HPLC/MS) and aliquoted into autosampler vials. 
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4.2.1 (b) Standards and Extraction Procedure for HPLC/DAD 
Stock standards, obtained from Cerilliant Corporation (Round Rock, TX), were 
used to prepare the calibration standards.  The calibration standards were serially diluted 
to comprise a four point calibration curve, ranging from 0.1 mg/L to 10 mg/L.  After 
preparation, 100 µL of each standard was spiked into drug-free whole blood.  Whenever 
necessary, samples that exceeded the limits of quantitation were diluted to bring their 
concentrations within range, and reanalyzed.  Additional stock standards were purchased 
from Alltech Associates (State College, PA) to prepare a 1.0 mg/L working control, 
containing both diazepam and nordiazepam.  All standard and sample concentrations 
were calculated using linear regression.  
To each 1 mL blood sample, 100 µL of nitrazepam internal standard 
(concentration = 0.1 mg/L) was added, followed by 4 mL of pH 6 sodium phosphate 
buffer (0.1M).  The samples were vortex-mixed and allowed to stand for 15 minutes.  The 
mixture was then centrifuged (3500 RPM) for 10 minutes.  The supernatant was 
transferred to a clean tube and submitted for automated solid-phase extraction preparation 
on Caliper Life Sciences (Hopkinton, PA) RapidTraceTM system. 
All solvents used for the rapid trace system were high purity grade.  Clean 
ScreenTM extraction columns (Worldwide Monitoring, Inc.) were first conditioned with 
an ethyl acetate: ammonia (98:2) elution solvent.  Additional conditioning was conducted 
by the sequential rinsing of the extraction columns with methanol, water and finally pH 6 
sodium phosphate buffer (0.1 M).  The blood samples were then loaded onto the columns 
(2 mL/min) and then rinsed with water and a 20% acetonitrile solution.  The columns 
were dried with ultra zero grade air.  Three milliliters of elution solvent was passed 
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through the column at 1 mL/min and the extract collected in a clean screw cap culture 
tube.  In an effort to clean up the extracts, three milliliters of deionized water was added 
to the eluent.  The mixture was rotated for 3 minutes, then centrifuged for 1 minute 
(speed = 3000 RPM).  The organic fraction was transferred to a 16 x 100 culture tube and 
evaporated to dryness at 40 ºC under a stream of nitrogen.  The dried extracts were 
reconstituted with 75 µL of mobile phase and aliquoted into autosampler vials. 
 
4.2.2 (a) Instrumentation: GC/ECD 
 Agilent technologies HP 6890N network GC model, equipped with dual electron 
capture detectors and a 7683B series injector was used for quantitative analysis.  Two 
columns (DB-5 and DB-17 both with the following dimensions: 30m X 0.32 mm ID X 
0.25 µm film thickness, Agilent technologies, Palo Alto, CA) were joined at the injection 
port through the use of a silica “Y” connector.  After sample injection, the columns were 
independent of each other and the flow was carried into their respective detectors.  The 
initial oven temperature of 120 °C was held for 2 minutes, then ramped at 20 °C/ minute 
to 290 °C and held for one minute using nitrogen (60 cc/min) as the makeup gas.  Both 
detectors remained constant at 325 °C.  Analyte identification was based on relative 
retention time identification in both columns.    
 
4.2.2 (b) Instrumentation: HPLC/MS 
The samples were analyzed in electrospray ionization (ESI) mode on a Thermo 
Finnigan LCQ Advantage HPLC/MS system.  The narrow-bore Agilent Eclipse – XDB 
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C18 column was held constant at 40 ºC.  Mobile phase, comprised of a mixture of 45% 
methanol to 55% formic acid (0.1%) in water, had a flow rate of 400 µL/ minute.  The    
 
Table 3: Benzodiazepines monitored by HPLC/MS/MS  
   
Segment Compound Name Molecular ion Qualifying Ions 
1 7-aminoclonazepam 286 250 BP, 222 Midazolam 326 291 BP, 244 
2 Nitrazepam ISTD 282 236 BP, 254 Clonazepam  316 270 BP, 288, 251 
 
3 Alprazolam 309 281 BP, 274, 251 
4 Nordiazepam  271 243 BP, 208, 165 
5 Diazepam  285 257 BP, 227, 182 
BP = Base Peak 
 
 
method searched for the seven analytes previously mentioned, including the internal 
standard, and was divided into five segments (Table 3).  Identification was based on mass 
spectral and retention time matches. 
 
4.2.2 (c) Instrumentation: HPLC/DAD 
The samples were analyzed on a Perkin Elmer (PE) 200 series HPLC system, 
equipped with a PE 235 C diode-array detector, 200 series pump and a 101 LC oven.  
The C-8 column was held constant at 30 ºC and the detector had a fixed wavelength of 
245 nm.  Mobile phase was comprised of a mixture of 16.5% acetonitrile to 57% pH 6, 
0.1 M sodium acetate buffer to 26.5% methanol and had a flow rate of 2.0 mL/ minute.  
The total run time of the method was 20 minutes.    
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4.3 Basic Drugs: Quantitative Blood Analysis by GC/NPD 
 The basic drug method was used to quantitate diphenhydramine, and methadone.  
Cerilliant Corporation (Round Rock, TX), stock standards were used to prepare working 
standards.  The working standards were serially diluted to comprise a four point 
calibration curve ranging from 0.1 mg/L to 2.0 mg/L.  If necessary, samples were diluted 
to bring their concentrations within the established limits of the curve.  Alltech 
Associates (State College, PA) stock standards were used to prepare a 0.5 mg/L working 
control.  Linear regression was used to calculate sample concentrations. 
Each 1 mL blood sample was fortified with 1 mL of mepivacaine internal 
standard (0.5 mg/L) and 1 mL of pH 9 saturated sodium borate buffer.  The samples were 
vortex-mixed, then 10 mL of n-butyl chloride was added.  The mixture was capped and 
rotated for 15 minutes followed by centrifugation (3000 RPM) for 5 minutes.  The 
organic fraction was then back extracted into 1.5 mL of 0.1 N HCl.  The solution rotated 
for 15 minutes, followed by centrifugation (3000 RPM) for 5 minutes.  The organic layer 
was aspirated to waste, after which, the aqueous layer was alkalinized with 2 mL of 
sodium carbonate/ sodium bicarbonate (pH 9.8) buffer and re-extracted into 10 mL of n-
butyl chloride.  The organic layer was transferred into a clean tube and evaporated down 
to approximately 3 mL at 40 ºC under a stream of nitrogen.  A 100 µL aliquot of 
concentrated HCl in methanol was added to each sample before drying to completion.  
The extracts were reconstituted with 50 µL of ethanol and aliquoted into autosampler 
vials for analysis. 
Hewlett-Packard’s 5890 Series II GC model, equipped with an NPD and a 7673 
autosampler was used for quantitative analysis.  A DB-1 (100% Methylpolysiloxane) 
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megabore column (15m X 0.53mm ID X 1.5µm film thickness, Agilent Technologies, 
Palo Alto, CA) was used for chromatographic separation.  The initial oven temperature 
was 120 °C for 1 minute then ramped at 10 °C/minute to 290 °C and held at for one 
minute.  Identification was based on relative retention times and previous GC/MS 
confirmation. 
 
4.4 Opiates 
 Three opiate methods have been used by the MDME- Toxicology laboratory since 
2006.  Originally the opiate method was divided into two separate assays.  Opiate I 
included morphine, codeine and 6-monoacetylmorphine (6-MAM).  Opiate II method 
included hydrocodone, hydromorphone and oxycodone.  As of January 2009, the opiate 
assay was combined into one comprehensive method to include all six of the previously 
mentioned opiates as well as the addition of oxymorphone.  Both Opiate I and Opiate II 
methods were analyzed by GC/MS utilizing single ion monitoring (SIM), each with a 
linear range of 10 – 1,000 ng/mL.  The comprehensive method was analyzed by 
GC/MS/MS and had a linear range of 5 – 500 ng/mL for hydrocodone and 5–1,000ng/mL 
for the remaining six opiate compounds.   
 
4.4.1 Preparation of Standards for Opiates by GC/MS (SIM) 
Stock standards, obtained from Cerilliant Corporation (Round Rock, TX), were 
used to prepare working standards.  The working standards were serially diluted to 
comprise a four point calibration curve for the Opiate I method and a five point 
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calibration curve for the Opiate II method.  Both methods had a linear range of 10–1,000 
ng/mL.  After preparation, the standards were spiked in drug-free whole blood.  
Whenever necessary, samples that exceeded the limits of quantitation were diluted, to 
bring their concentrations within range, and reanalyzed on the appropriate instrument.  
Additional stock standards were purchased from Alltech Associates (State College, PA) 
to prepare controls.  Both a high and a low working control (50 ng/mL and 500 ng/mL) 
were prepared for Opiate I, while a single 25 ng/mL working control was prepared for 
Opiate II.  All standard and sample concentrations were calculated using linear 
regression.  
 
4.4.2 Extraction Procedure for Opiates by GC/MS (SIM) 
4.4.2 (a) Extraction: Opiate I by GC/MS (SIM) 
 To each 1 mL blood sample, 100 µL of internal standard (morphine- D3, codeine- 
D3 and 6-MAM – D3; final concentration equaled 50 ng/mL) was added followed by 
4mL of pH 6, 0.1 M sodium phosphate buffer.  The samples were then vortex-mixed, 
followed by a 15 minute equilibration.  Afterwards, the samples were centrifuged (3500 
RPM) for 10 minutes.  The supernatant was transferred to a clean tube and submitted for 
automated solid-phase extraction preparation on Caliper Life Sciences (Hopkinton, PA) 
RapidTraceTM system. 
 
4.4.2 (b) Extraction: Opiate II by GC/MS (SIM) 
To each 1 mL blood sample, 100 µL of internal standard (hydrocodone- D3, 
hydromorphone- D3 and oxycodone – D3; final concentration equaled 25 ng/mL) was 
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added followed by 50 µL of methoxamine (MOX) reagent.  The samples were then 
vortex-mixed, followed by a 10 minute equilibration.  Afterwards, the samples were 
heated at 56 ºC for 15 minutes and allowed to cool.  Then 4 mL of 0.1 M, pH 6 sodium 
phosphate buffer was added.  The samples were vortex-mixed and centrifuged at 3500 
RPM for 10 minutes.  The organic fraction was transferred to a clean tube and submitted 
for automated solid-phase extraction preparation on Caliper Life Sciences (Hopkinton, 
PA) RapidTraceTM system. 
 
4.4.2 (c) Automated Extraction: Opiates I and II by GC/MS (SIM) 
All solvents used for the rapid trace system were high purity grade.  Clean 
ScreenTM extraction columns (Worldwide Monitoring, Inc.) were conditioned with the 
elution solvent.  Opiate I elution solvent consisted of methylene chloride: IPA: NH4OH; 
80:20:2.  Opiate II elution solvent was comprised of ethyl acetate: NH4OH; 98:2.  
Afterwards, the columns were additionally conditioned with methanol, followed by water 
and finally pH 6 sodium phosphate buffer (0.1 M).  The blood samples were then loaded 
onto the columns (2 mL/min) and sequentially rinsed with water, HCl and methanol.  The 
columns were dried with ultra zero grade air.  Three milliliters of elution solvent was 
passed through the column at 1 mL/min and the extract collected in a clean screw cap 
culture tube.  The eluent was evaporated to dryness at 40 ºC under a stream of nitrogen. 
 
4.4.3 Derivatization: Opiates I and II by GC/MS (SIM) 
Opiate I dried extracts were derivatized with 100 µL of 1,1,1,3,3,3- Hexafluoro-2-
propanol (HFIP) followed by 100 µL of pentafluoropropionic acid anhydride (PFAA).  
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Opiate II extracts were derivatized using 100 µL of acetic anhydride and 15 µL of 
pyridine.  The samples containing derivatizing reagent were then heated at 65 ºC and 
75ºC, for Opiate I and Opiate II, respectively.  Afterwards, all samples were cooled to 
room temperature, then dried to completion at 40 ºC under a stream of nitrogen.  All 
extracts were reconstituted with 50 µL of ethyl acetate and aliquoted into autosampler 
vials. 
 
4.4.4 Instrumentation: Opiates by GC/SIM-MS  
The Hewlett Packard 6890 series gas chromatograph coupled with a 5973 mass 
selective detector was utilized for quantitative analysis.  A deactivated capillary guard 
column (5m X 0.250mm) was connected to a DB-5 (5% phenyl methyl polysiloxane) 
analytical column (15m X 0.25mm ID X 0.25µm film thickness; Agilent Technologies, 
Palo Alto, CA) to achieve chromatographic separation.  The initial oven temperature was 
set for 65 °C and held for 1 minute, then ramped 15 °C/ minute to 300 °C.  The collection 
methods were divided into segments based on retention time of each analyte (Table 4).  
Identification was made on the basis of mass spectral matches of the appropriate ion 
ratios (± 20%).   
 
4.4.5 Opiates: Quantitative Blood Analysis by GC/MS/MS 
This method was utilized to quantify hydrocodone, oxycodone, codeine, 
hydromorphone, morphine, 6-monoacetylmorphine (6-MAM) and oxymorphone.  Stock 
standards obtained from Cerilliant Corporation (Round Rock, TX) were used to prepare 
working standards.  The working standards were serially diluted to comprise a six point 
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calibration curve ranging from 5 ng/mL to 1,000 ng/mL.  If necessary, samples were 
diluted to bring their concentrations within the established limits of the curve.  Alltech 
Associates (State College, PA) stock standards were used to prepare two working 
controls, 50 ng/mL and 500 ng/mL, respectively.  Linear regression was used to calculate 
sample concentrations. 
To each 1 mL blood sample, 100 µL of deuterated internal standard mix (Table 5) 
and 4 mL of 0.1 M, pH 6 sodium phosphate buffer were added.  The samples were 
vortex-mixed and centrifuged at 3500 RPM for 10 minutes.  The samples were then 
submitted for automated solid-phase extraction (SPE) on Caliper Life Sciences 
(Hopkinton, PA) RapidTraceTM system.  All solvents used were high purity grade.  Clean 
ScreenTM extraction columns (Worldwide Monitoring, Inc.) were conditioned with the 
elution solvent (methylene chloride: IPA: NH4OH; 80:20:2), followed by methanol, then 
water and, finally, pH 6 sodium phosphate buffer (0.1 M).  The blood samples were then 
loaded onto the columns (2 mL/min) and sequentially rinsed with water, HCl and 
methanol.  The columns were dried with ultra zero grade air.  Three milliliters of elution 
solvent was passed through the column at 1 mL/min and the extract collected in a clean 
screw cap culture tube.  The eluent was evaporated to dryness at 40 ºC under a stream of 
nitrogen.  The dried extracts were derivatized with 100 µL of propionic anhydride, 
catalyzed with 25 µL of pyridine, and heated at 60 ºC for 30 minutes.  The samples were 
then dried to completion at 40 ºC under a stream of nitrogen.   The extracts were 
reconstituted with 50 µL of ethyl acetate and aliquoted into autosampler vials. 
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Table 4: Opiate Compounds Quantitated Using GC/ SIM- MS 
 
Method Segment Analytes Molecular Ion Quantifying Ion Qualifying Ions 
Opiate I 
1 Morphine 577 414 430 Morphine- D31 - 417 - 
2 Codeine 446 282 445 Codeine – D31 - 285 - 
3 6-MAM 473 414 430 6-MAM – D31 - 417 - 
Opiate II 
1 Hydrocodone 329 328 297 Hydrocodone – D31 - 331 - 
2 Oxycodone 386 386 230 343 Oxycodone– D31 - 389 - 
3 Hydromorphone 356 356 283 314 Hydromorphone –D31 - 359 - 
 1 Only quantifying ions were collected for internal standards 
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A Varian CP-3800 gas chromatograph coupled with a 1200L Triple Quadrupole 
Mass Spectrometer and CP-8400 autosampler system was utilized for quantitative 
analysis.  A deactivated capillary guard column (5m X 0.250mm) was connected to a 
DB-5 (5% phenyl methyl polysiloxane) analytical column (15m X 0.25mm ID X 0.25µm 
film thickness; Agilent Technologies, Palo Alto, CA).  The initial oven temperature was 
set for 65 °C and held for 1 minute, then ramped 15 °C/ minute to 315 °C (total run time 
= 17.67 minutes).  The collection method was divided into four segments based on 
retention time for each of the seven analytes and their respective deuterated internal 
standards (Table 5).  Identification was made on the basis of mass spectral matches of the 
appropriate ion ratios (± 30%).   
  
 
Table 5: Opiate Compounds Quantitated Using GC/MS/MS 
 
Segment Analytes Molecular Ion 
Quantifying 
Ion 
Qualifying 
Ions 
1 Hydrocodone 299 242BP 270 299 Hydrocodone – D31 302 245 - - 
2 
Codeine 355 282BP 298 355 
Codeine - D31 358 285 - - 
Oxycodone 371 314BP 212 371 
Oxycodone – D31 374 215 - - 
3 
Hydromorphone 341 285BP 229 341 
Hydromorphone – D31 344 288 - - 
6-Acetylmorphine 383 327BP 204 383 
6-Acetylmorphine – D31 386 207 - - 
4 
Morphine 397 341BP 218 397 
Morphine – D31 400 221 - - 
Oxymorphone 413 357BP 284 413 
Oxymorphone – D31 416 360 - - 
- Deuterated internal standards did not require qualifying ions  
 
 
1Qualifying ions were not collected for the internal standards 
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4.5 Microbial Study 
4.5.1 Preparation of Nutrient Agar plates 
Five-hundred milliliters of double-distilled water was added to 11.5 grams of 
Becton, Dickinson and Company brand (Sparks, MD) nutrient agar.  The mixture was 
heated until the agar went into solution, then autoclaved for 15 minutes at 121 ºC.  After 
which, the solution cooled to approximately 50 ºC and was poured into 100 x 15mm petri 
dishes (Medegen Medical Products, Gallaway, TN).   The agar plates were stored at room 
temperature (25 ºC) for 24 hours, followed by refrigeration until use. 
 
4.5.2 Phosphate Buffered Saline Standards 
 For the stability and microbial studies, drug standards made in phosphate buffered 
saline (PBS) solution were needed.  Drug standards at the MDME- toxicology laboratory 
are often prepared in organic solvents (e.g. methanol or acetonitrile).  However, for the 
purpose of these experiments, it was disadvantageous to use standards that introduced 
additional carbon sources into the matrices.  As a result, powdered standards were mixed 
with 1X PBS solution and used as needed.   
 The procedure was conducted as follows: 25 mL volumetric flasks, individual 
1mg/ mL stock standards of diazepam, codeine and hydrocodone were prepared.  
Twenty-five milligrams of hydrocodone bitartrate (Endo Laboratiories, Inc., Garden City, 
NY), 24.9 mg of codeine sulfate (Lilly, Inc., Indianapolis, IN) and 25.2 mg of diazepam 
(La Roche, Inc, Nutley, NJ) were added to their respective volumetric flasks containing 
PBS solution. The solutions were vortex mixed.  Codeine and hydrocodone stock 
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standards were transferred into individual amber vials fitted with screw cap lids.  The 
diazepam standard however, would not dissolve.  Therefore, that mixture (in its flask) 
was sonicated for 45 minutes in a water bath.  The standard remained a heterogeneous 
mixture.  A review of the original container that held the powdered standard was only 
marked diazepam and did not give any additional information about its formulation.  
However, the diazepam powder was visibly different from that of the codeine and 
hydrocodone standards.  The diazepam powder was tan in color and had a consistency 
similar to a starch-based powder (e.g. baby powder), as opposed to the white, salt based 
opiate powders used.  Therefore, it was determined that the properties of the diazepam 
standard would not allow for the preparation of a homogenous solution.  A subsequent 
review of the literature revealed that diazepam (along with other benzodiazepines) is not 
soluble in water (43), therefore explaining its resistance to the water based PBS solution.  
Consequently, diazepam could no longer be used for this portion of the study. 
 One hundred micro-liters of codeine and hydrocodone stocks were added to 
individual 10 mL volumetric flasks and mixed with 9,900 µL of PBS solution to make 
0.01 mg/mL (10,000 ng/mL) working stock solutions.  The solutions were then 
transferred into amber vials fitted with screw caps and stored under refrigeration (2 ºC). 
 
4.5.3 Aerobic and Anaerobic Microbial Experiments 
 All of the postmortem blood used for this experiment was stored in tubes 
containing the anti-microbial agent sodium fluoride (NaF).  In an effort to test the 
effectiveness of the NaF, blood samples needed to be inoculated in a nutrient-rich 
environment to determine if any microbial activity would exist.  The PM blood used for 
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this part of the experiment was collected from the chest of a decomposing cadaver.  
Based on the odor and discoloration of the body, it was evident that microbial activity 
was flourishing.  The blood (green in color) was collected in 2 BD vacutainer gray-top 
tubes (10 mL each) and 1 red-top polypropylene tube (50 mL total).  The red-top 
contained NaF that was added by the MDME staff upon receipt of the tubes, while the 
gray-top was commercially prepared.  Upon sample collection, all of the tubes were 
inverted multiple times to ensure proper mixing of the NaF with the blood. 
Nutrient agar plates were inoculated in duplicate, each with 75 µL of chest blood 
from the red-top and gray-top tubes.  Additionally 75 µL of antemortem blood, stored in 
a gray-top tube was also inoculated.  Disposable sterile loops (Thermo Fisher Scientific, 
Waltham, MA) were used to streak the plates.  For the aerobic experiment, a set of 
duplicate plates were stored in the dark for 11 days at 17 °C.  For the anaerobic 
experiment, an additional set of duplicate plates were stored in a vented BBL® anaerobic 
system jar (Becton Dickinson Microbiology Systems, Cockeysville, MD).  In order to 
provide the anaerobic environment, BD GasPakTM EZ Anaerobe Gas Generating Pouch 
system with indicator (Becton, Dickinson and Company, Sparks, MD) was used.  Once 
the plates were properly positioned in the jar, the foil wrapping was removed from the EZ 
gas pouch.  The release of carbon monoxide (thereby providing an anaerobic 
environment) was activated when the pouch was open and exposed to air.  Upon 
activation, the lid was sealed and the jar was stored in the dark for 11 days at 17 °C.  
 
 
 50 
 
4.5.4 Assessing the Usefulness of Codeine and Hydrocodone as a Food Source for 
Bacteria 
 Since a major part of this project was to determine the reason for drug 
concentration changes among antemortem and postmortem samples, it was imperative to 
evaluate the role of microbial activity.  In an effort to determine if drug compounds could 
themselves be used as a food source for bacteria, the following procedure was employed. 
 A DH5α strain of Eschericia coli (E. coli) and a PAO1 strain of Pseudomonas 
aeruginosa (Pseudomonas) was plated onto LB agar plates and allowed to grow for 48 
hours at 37 ºC.  Individual colonies were transferred into two 50 mL polypropylene tubes 
(one for each bacteria) containing 8 mL of nutrient broth.  The suspension was rocked for 
24 hours, followed by 24 hour incubation (37 ºC).  The suspension was then centrifuged 
and the supernatant disposed.  The cellular precipitate was rinsed with phosphate 
buffered saline (PBS) solution.  That suspension was centrifuged and again the 
supernatant was disposed.  This step was repeated twice.  The cells were then re-
suspended in 5 mL of nutrient broth.  A 1 mL aliquot of both suspensions was reserved 
for photometric reading. 
 A 96 well MT plate (9x12), manufactured by Biolog (Haywood, CA), was 
arranged as shown in Figure 5.  Columns 3, 7, 11 and 12 were not used.  Negative and 
positive controls were setup in the first two columns.  One-hundred micro-liters of 
codeine and hydrocodone (prepared in 1X PBS solution) at concentrations of 100, 200 
and 600 ng/mL each were aliquoted into columns 4-6 and 8–10.  Afterwards, a baseline 
reading of the plate was taken using a Modulus Microplate reader (Turner Biosystems, 
Sunnyvale, CA) at a wavelength of 600 nm.  The plate was then refrigerated for 48 hours  
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Figure 5: Arrangement of the 96 Well MT Plate 
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while the bacteria (E. coli and P. aeruginosa) were prepared.  Upon which time, 50 µL of 
E. coli was inoculated in columns 4–6, with 50 µL Pseudomonas in columns 8–10.  After 
which, another density reading was taken.  Microplate readings continued daily for a total 
of 8 readings. 
The 1 mL aliquot reserved for photometric reading was analyzed using a 
BioPhotometer (Eppendorf AG, Germany) at a 600 nm wavelength.  This reading was 
taken to ensure the density of the bacteria population would be sufficient for use in this 
study.   
 
4.6 Drug Stability Study 
 The purpose of this experiment was to assess the stability of hydrocodone and 
codeine in whole blood when stored in refrigeration (2 ºC) for three months.  In the Peters 
article (44), four main types of drug stability were identified.  They include long-term 
stability (examination of drug stability in storage), freeze/thaw stability (examines the 
effect of re-analysis of samples that have been frozen), in-process or bench top stability 
(assesses the stability of a drug during the sample preparation procedure) and finally 
processed sample stability, which addresses the stability of a drug while awaiting 
instrument injection.  This experiment was solely focused on long-term stability.  While 
some of the cases analyzed for this project were obtained a year or more before the 
inception of this research, many were analyzed within three months of the sample 
acquisition.  The three month lapse typically accounted for the time required for routine 
laboratory analyses to be completed.  At the completion of routine testing, research 
analysis could begin.  An extended stability study (≥ 3 mon ths) was not conducted by the 
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researcher as several articles (21)(44)(45)(46)(47) have been published addressing the 
stability of drugs and drug classes used in this study (e.g. benzodiazepines, opioids and 
methadone).     
One milliliter each of codeine and hydrocodone working stocks (prepared as 
described in section 4.5.2 Phosphate Buffered Saline Standards) were spiked into 48 mL 
of chest blood to give a final concentration of 200 ng/mL each.  The mixture was rocked 
for 10 minutes to ensure equilibrium.  Twenty milliliters of the spiked blood was 
separated into two gray-top vacutainer tubes (each tube held 10 mL).  The remaining 
30mL of spiked blood was stored in a red-top polypropylene tube (50 mL capacity).  
Stock, working stock and spiked blood tubes were kept in refrigeration (2 °C) until 
further use.  Additionally, in an effort to correlate drug stability with microbial activity, 
the chest blood spiked for this experiment was the same blood inoculated (without the 
drug spike) on the nutrient agar plates in section 4.5.3 Aerobic and Anaerobic Microbial 
Experiments.  Similarly the hydrocodone and codeine standards were the same ones used 
in the MT plate experiment described in section 4.5.4.  
 
 
 
 
5.0 Calculations 
 In order to better interpret the significance of the data, statistical analyses were 
conducted.  Statistical testing was applied to the control data collected for each drug of 
interest.  The controls, as opposed to the actual case blood samples, were analyzed 
because they had enough data points generated to produce relevant population sizes.  
Conversely, the cases used for this study had a finite amount of blood available for 
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testing.  Therefore, analyzing multiple replicates over a period of days was not feasible.  
The controls, however, were extracted and analyzed with every batch, thereby allowing 
for more replicates over a period of months to years depending on the assay.   
 As the testing for this project was conducted over a three year period, control lot 
numbers, and, at times, instrumentation were changed.  The data that were produced for 
drugs analyzed on one instrument, but with multiple lot numbers, underwent one-way 
Analysis of Variance (ANOVA) testing, to test the hypothesis that the lot numbers were 
not different.   
 As an example, the diphenhydramine control (0.50 mg/L) was run forty-one times 
by GC/NPD and had three different lot numbers.  The population sizes for lots 1, 2 and 3 
were 15, 19 and 7, respectively.  To determine if each lot produced similar results a one-
way ANOVA with a 95 percent confidence interval, was calculated using Microsoft 
Excel’s Data Analysis Toolpak software.  The results given in Table 6 show both the 
summary and ANOVA analysis output.  Listed within the summary is a breakdown of 
each lot number, indicating its population size and average (Table 6) control 
concentration.  The ANOVA analysis results gave such parameters as the sum of squares 
(SS), degrees of freedom (df) and mean square (MS) values.  Of particular interest were 
the calculated values for F and F crit.  The F value is the F-test (Equation 3) result that 
was calculated by the ANOVA.  If F > Fcrit, it was determined that a significant 
difference between the populations existed.  The F value for the diphenhydramine 
calculation was 2.839, while Fcrit equaled 3.244.  Therefore, in this example, F was less 
than Fcrit, indicating that the populations were not statistically different.  As a result, the 
data produced by all 3 lot numbers were treated as one population.   
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The control data for each drug was evaluated as described above.  Once it was 
determined that the data could be combined, the population standard deviation (Equation 
4) was calculated.  After which, the coefficient of variation (CV), that is the percent 
relative error, was determined for each drug by using Equation 5.  In keeping with the 
diphenhydramine example, the population mean and standard deviation values were 0.55 
and 0.08, respectively.  Therefore the CV, for this drug was approximately 15%.  The CV 
was used as a way to measure ‘significance’ among the intra-case data.  In order to make 
a determination as to whether or not the concentration differences observed (within any 
given case) was statistically significant, the CV value was applied.  If the differences in 
sample concentrations fell within the established CV (for example ± 15%), then no 
significant difference was observed, however if the concentrations were not within the 
limits of the relative error as described by the CV, then the concentrations were deemed 
statistically different.             
 Additionally, as methodology in the MDME – toxicology laboratory changed, so 
did the methodology for this project.  As a result, some of the quantitative drug results 
were collected on two instruments.  A two-way Analysis of Variance (ANOVA) with a 
95% confidence interval was conducted to determine if the control values obtained on 
different instruments were statistically similar.  If the F-test results generated by the 
ANOVA determined the control results were similar, then the data were treated as an 
entire population, regardless of instrumentation.  If however, there was a significant 
difference between instruments, then Tukey’s honestly significant difference (HSD) test 
(Equation 6) was employed on a post hoc basis. This was the case for clonazepam.   
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Clonazepam data for this project were originally collected by GC/ECD.  
Eventually the method was modified and analyzed by LC/MS/MS.  The F-test result 
(generated by the two-way ANOVA) equaled 26.84, while the Fcrit equaled 4.35.  Since F 
was greater than Fcrit, the results indicated that the data produced on the two instruments 
differed.  Therefore, the data were evaluated as two separate populations (one population 
per instrument), as opposed to being treated as a single population.  In an attempt to 
check the validity of the ANOVA results, Tukey’s HSD post hoc analysis was conducted. 
Post hoc analysis is only used on data that has indicated a statistical difference.  
Tukey’s HSD test compares the difference between mean values of sample populations to 
a newly calculated critical value (HSDcrit).  In the case of clonazepam, the control values 
generated by GC/ECD had a mean of 0.10 mg/L and the LC/MS mean control data 
equaled 0.13 mg/L.  The calculated mean difference between the two equaled 0.03.  
When solving for HSDcrit, the critical value equaled 0.01.  When the mean difference is 
greater than HSDcrit (as was the case with clonazepam) a significant difference exists.  
Consequently, there was a difference in the clonazepam data collected by GC/ECD when 
compared to that of the data collected by LC/MS/MS.  As a result, the data were treated 
as two separate populations, with each having its own amount of relative error (CV).     
 Not only was it important to identify an acceptable amount of variance within an 
entire population, it was also imperative to determine which PM results were reasonable 
and which were not.  Since each case had its own unique set of circumstances, it would 
not have been appropriate to implement a static scale in which to determine significance.  
Instead, dynamic calculations, which could be tailored to each case, were used.  
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Equation 2: Average of n measurements (48) 
 
 
 
 
 
 
 
 
 
 
 
 
Equation 3: F-test for Comparison of Standard Deviations (48) 
 
 
 
 
 
 
 
 
 
 
 
Equation 4: Standard deviation of n measurements (48) 
 
 
 
 
 
 
 
 
 
 
Σxi = sum of all the measurements 
n = number of measurements 
s = standard deviation 
s= sample 
xi= sum of all measurements 
 = mean 
n = number of measurements 
n - 1 = degrees of freedom 
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Table 6: Example of One-WAY ANOVA Data Output by Microsoft Exel® Generated 
when Comparing the Three Diphenhydramine Control Lots 
  
Anova: Single Factor     
        
 SUMMARY      
 Groups Count Sum Average Variance   
 lot 1 15 8.624 0.574933 0.013845   
 lot 2 19 10.5 0.552632 0.00242   
 lot 3 7 3.46 0.494286 0.001762   
        
        
 ANOVA       
 
Source of 
Variation Sum of Squares 
degrees 
of 
freedom 
Mean 
Square F F crit  
 Between lots 0.031157 2 0.015579 2.387292 3.244818  
 Within lots 0.247973 38 0.006526    
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If F > F crit: Significant difference exists 
If F < F crit: no significant difference exists 
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Equation 5: Coefficient of Variation (48) 
 
 
 
 
 
 
 
Equation 6: Tukey’s Honestly Significant Difference Equation  (70) 
 
 
 
HSDcrit = newly calculated critical value 
q = reference value obtained from a studentized range table 
MSwithin = Mean Square within value obtained from the ANOVA data output 
n= population size 
*if mean difference > HSDcrit, a significant difference exists 
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 Ratio calculations are common tools used in postmortem casework to determine if 
postmortem redistribution could have influenced the results.  Whenever both postmortem 
and antemortem samples (for the same case) have been tested and rendered quantitative 
results a PM to AM ratio can be calculated.  This comparison allows the interpreter to 
determine the true extent of the concentration disparity, as any time the ratio is ≥ 1.0 it is 
said that postmortem redistribution was likely a factor.  Similarly, when comparing two 
postmortem sources (central and peripheral) if the resultant ratio is ≥ 1.0, postmortem 
redistribution is believed to be the cause.  When interpreting the results of both ratios, the 
higher the value is above 1.0, the more likely that redistribution has occurred.  While both 
ratios are useful, only about 33% of the cases submitted at the MDME Department are 
sent with AM specimens.  In contrast, greater than 75% are submitted with both central 
and peripheral PM sources.  Therefore, if a question about the occurrence of PMR arises, 
it is the central to peripheral that will most likely be available.  For the purposes of this 
study, however, both central to peripheral as well as postmortem to antemortem 
calculations were applied whenever possible to better assess the intra-case relationships. 
Finally, it was imperative to determine what drug concentrations would be expected at 
the time of death.  The pharmacodynamic process (section 1.4.2), which governs the 
body’s ability to remove substances from its system, had to be taken into account when 
attempting to identify any concentration expectations.  As indicated in Equation 7, when 
substituting the antemortem concentration for Nt, the antemortem to death (AMD) 
interval for T and separately inputting the minimum and maximum elimination half-life 
values for t1/2, an expected drug concentration range at the time of death could be 
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calculated.  The PM concentrations that fell within their expected ranges were believed to 
demonstrate drug metabolism (and elimination) occurring in a predicted fashion.    
 
Equation 7: Calculated Expected Drug Concentration Range at the Time of Death(22) 
 
 
 
 
 
 
 
 
 
 
 
The use of both the minimum and maximum elimination half-life values, resulted 
in a concentration range that could likely account for the majority of people (both fast 
and slow metabolizers).  The range was critical in determining whether or not 
postmortem concentrations were significantly different than expected.  The expected 
ranges vary by case and are addressed on a case-by-case basis in Chapter 6: Results and 
Discussion.  
 
 
6.0 Results and Discussion  
 The data discussed in the following sections were from cases obtained by the 
Miami-Dade County Medical Examiner’s Department.  At the time of the sample testing 
for this project, the cases were no longer being actively analyzed in the toxicology 
laboratory.  However, initial analyses were conducted by laboratory staffers to identify, 
 = Estimated concentration at the time of death 
 = AM concentration of the sample 
T= Time between AM and death 
t ½= elimination half-life of the drug 
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and in most instances, quantify the drugs of interest, as part of the death investigative 
process.  Any sample whose volume was not sufficient for repeat analyses by the 
researcher was still included in the study if a quantitative value was obtained as a part of 
routine laboratory analyses.  Since it is of the utmost importance that the identities of the 
subjects remain private, each case has been assigned an alpha-numeric combination, not 
related to their actual case numbers. 
6.1 Opiates 
 
As discussed in section 1.7.2, opiates are drug class characterized by their 
analgesic properties.  Users often establish a tolerance, which can make it difficult to 
interpret the true meaning of a given concentration determined in blood.  The following 
sections will cover both prescription and illicit opiates.  Through December 2008, the 
MDME- toxicology laboratory divided opiates into two analytical methods of analysis.  
The Opiate I method included morphine, codeine and 6- monoacetylmorphine (6-MAM), 
while the Opiate II method included hydrocodone, hydromorphone and oxycodone.  Both 
methods were analyzed on an Agilent GC/MSD instrument (SIM-mode) and had a linear 
range of 10 – 1,000 ng/mL.  As of January 2009, the opiate methods were combined and 
analyzed by GC/MS/MS using Varian’s 1200L system.  The six previously mentioned 
analytes, plus the addition of oxymorphone were included in this comprehensive method.  
Hydrocodone had a linear range of 5 – 500 ng/mL, all other opiates had a linear range of 
5 – 1,000 ng/mL by GC/MS/MS.  All three opiate methods were validated according to 
the procedures implemented by MDME- toxicology laboratory.  
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6.1.1 Heroin, Morphine and Codeine  
 While, heroin, morphine and codeine are all separate drugs in their own right, 
they are being discussed collectively because they are often detected together.  As 
described in Section 1.7.2, heroin synthesis also produces the byproduct acetylcodeine.  
As a result, when heroin is metabolized, codeine, 6-monoacetylmorphine (6-MAM) and 
morphine may also be produced.  Additionally, even in the absence of heroin usage, 
morphine and codeine can still be detected together, as morphine is also the demethylated 
metabolite of codeine.  Therefore, in cases where codeine has been identified, morphine 
is also commonly found.  The cases investigated here have been divided into two 
sections.  The first includes those morphine/ codeine (MOC) cases whose antemortem 
was collected within two elimination half-lives before death.  Those cases are listed in 
Table 9 in order of increasing antemortem to death interval.  Codeine has an elimination 
half-life ranging from 1.9 – 3.9 hours with morphine ranging from 1.4 – 6.7 hours and 
volumes of distribution of 3.5 L/ kg and 2- 5 L/kg, respectively (50)(51).  The second 
section covers the MOC cases whose AM was collected beyond two elimination half-
lives. 
Because two instruments were used to obtain the data for this chapter, atwo-way 
ANOVA (α = 0.05) was conducted to determine if there were any statistical differences 
between the two methods (Table 7).  The ANOVA F-test values for morphine, codeine 
and 6-MAM were 48.8, 3.7 and 17.6, respectively.  While the Fcrit values were 6.0, 7.7 
and 7.7 for morphine, codeine and 6-MAM, respectively.  When the F-test value is 
greater than the Fcrit, a significant difference exists.  Therefore, analysis of variance 
concluded that the F-test values for both morphine and 6-MAM resulted in statistically 
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different results between the two instruments, while codeine detection did not differ as a 
function of analytical methods.  Subsequently, the morphine and 6-MAM intra-sampling 
data could not be evaluated as one population.  Tukey’s honestly significant difference 
(HSD) post hoc test was applied to both morphine and 6-MAM to determine how the data 
sets differed.  The calculated critical values for Tukey’s HSD were less than the mean 
differences calculated for morphine and 6-MAM (Table 7).  When the mean difference > 
HSDcrit, a significant difference does in fact exist.  Therefore, the post hoc analysis 
supported the ANOVA results, which indicated that the populations were different.  
Consequently, the coefficient of variation for morphine and 6-MAM differed depending 
on the instrumentation used (Table 8).  Conversely, since there was no significant 
difference among the codeine data, the populations (GC/SIM-MS and GC/MS/MS data) 
were combined and evaluated as one. 
 The morphine/ codeine (MOC) cases discussed were separated into two sections.  
The first being those cases whose antemortem blood was collected within two elimination 
half-lives before death (Table 9).  The second section is comprised of the remaining 
MOC cases whose antemortem blood collection time exceeded two elimination half-lives 
(Table 10).  All of the cases are presented in order of increasing antemortem to death 
(AMD) interval, as opposed to numerical order.   
The antemortem sample for morphine/ codeine case 14 was collected 9 minutes 
before death.  Analysis of the sample detected 48 ng/mL of morphine present.  Aorta and 
iliac vein bloods were submitted for postmortem analyses.  Aorta blood contained 339 
ng/mL of morphine, 18 ng/mL of codeine and 6.5 ng/mL of 6-MAM.  Similarly, iliac 
vein blood was positive for morphine, codeine and 6-MAM as well, with concentrations 
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Table 7: Two-Way Analysis of Variation Results for Morphine, Codeine and 6-MAM by Comparing Control Data for 
GC/SIM-MS to GC/MS/MS  
 
Drug Source of Variation Sum of Squares df 
Mean 
Square 
F-test 
result 
F critical 
value 
Tukey’s 
critical 
value 
Mean 
Difference 
Morphine GC/MS vs. GC/MS2 666.80 5 666.80 48.80 5.99 4.27 14.14 
Codeine GC/MS vs. GC/MS2 70.66 3 70.66 3.69 7.71 N/A N/A 
6-MAM GC/MS vs. GC/MS2 240.97 3 240.97 17.60 7.71 5.21 13.50 
 
 
 
 
 
 
 
Table 8: Coefficient of Variation Results for Morphine, Codeine and 6-MAM 
 
Drug Method CV 
Morphine GC/SIM-MS 10.0% GC/MS2 9.1% 
Codeine GC/SIM-MS and GC/MS2 9.8% 
6-MAM GC/SIM-MS 8.8% GC/MS2 5.1% 
 
 If F > F critical, then results are significantly different 
 If F < F critical, then results are similar 
 If mean difference > Tukey’s crit, then the results are 
significantly different 
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of 139 ng/mL, 7 ng/mL and 5 ng/mL, respectively.  Statistical analyses determined that 
the PM aorta blood concentrations were different from the iliac vein blood 
concentrations.  Additionally, both PM morphine concentrations were dis-similar to the 
antemortem concentration.  Antemortem blood analysis was negative for codeine and 6-
MAM; however, urine screen results identified the presence of all three drugs.  The 
detection of codeine and 6-MAM in the urine, but their absence in the AM blood 
suggested that during the time of AM blood collection the drugs were no longer being 
distributed.  Instead they had been eliminated into liquid waste.  The detection of both 
codeine and 6-MAM in the PM blood samples indicated storage of the drugs in tissues (at 
the time of the AM collection) and then their release upon death.  During the 26 hour 
PMI, all three drugs were able to redistribute themselves.  Aorta blood: AM, as well as 
ILBL:AM ratios equaled 6.8 and 2.8 for morphine and codeine, respectively.  
Additionally, C:P ratios equaled 2.4, 2.6 and 1.3 for morphine, codeine and 6-MAM, 
respectively.  All the ratio data in this case were consistent with PMR.     
  At 23 minutes before death the AM blood for MOC 12 was collected.  Upon 
analysis it was determined that 1,544 ng/mL morphine and 40 ng/mL of codeine were 
present.  The presence of both morphine and codeine were the result of heroin usage. 
Heroin has an elimination half-life of 2-6 minutes (30).  Because of this rapid 
metabolism, heroin is quickly eliminated from blood and metabolized into urine.  Heroin 
has an elimination half-life of 2-6 minutes (30).  Because of this rapid metabolism, heroin 
is quickly eliminated from blood and metabolized into urine.  Heroin was detected only 
in the urine.  However since urine is not a suitable sample for quantitative analyses 
(section 1.6.2) and heroin is rarely detected in blood, many laboratories (including 
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Table 9: Morphine, Codeine and Heroin Antemortem samples collected within 2 elimination half-lives 
Heroin t1/2 = 2-6 minutes 
6-MAM t1/2 = 2- 25 minutes 
Morphine t1/2 = 1.4 – 6.7 hours; Vd = 2-5 L/ kg 
Codeine t1/2 = 1.9 – 3.9 hours; Vd = 3.5 L/kg  
 
AM-
Death Case # 
Source 
(whole blood) 
Concentration 
(ng/mL) 
AM 
concentration 
(ng/mL) 
Analyte PM:AM C:P PMI (hours) Race/Sex Age 
9 min MOC 142 
Aorta 
morphine 339 
codeine 18 
6MAM 6.5 morphine 48 
MO 
CO 
6MAM 
7.1 
- 
- 
2.4 
2.6 
1.3 
 
26.5 WM 49 
Iliac 
morphine 139 
codeine 7 
6MAM 5 
MO 
CO 
6MAM 
2.9 
- 
- 
23 min 
MOC 
122 
 
Mixed 
morphine 2,945 
codeine 76 
6MAM 858 morphine 1,544 codeine 40 
6-MAM 90 
MO 
CO 
6MAM 
1.9 
1.9 
9.5 N/A 18 WM 49 
IVC 
morphine 2,539 
codeine 83  
6MAM 1,255 
MO 
CO 
6MAM 
1.6 
2.1 
13.9 
45 min 
MOC 
132 
 
CHBL* morphine 259 codeine 9.75 
morphine 104 
codeine 20 
 
MO 
CO 
 
2.5 
0.49 N/A 48 BM 40 
1 hour 
MOC 
051 
 
Aorta morphine 48 codeine 25 morphine 65 MO 0.7 N/A 13.5 WM 57 
2 hours 
MOC 
031 
 
Aorta morphine 52 codeine 698 morphine 17 
codeine 65 
MO 
CO 
3.0 
10.7 N/A 47 BF 31 
Chest morphine 71 codeine 1,397 
MO 
CO 
4.2 
21.5 
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AM-
Death Case # 
Source 
(whole blood) 
Concentration 
(ng/mL) 
AM 
concentration 
(ng/mL) 
Analyte PM:AM C:P PMI (hours) Race/Sex Age 
2 hours 
MOC 
081 
 
HTBL morphine 105 codeine 10 morphine 205 
MO 
CO 
0.5 
- 1.4 
1.0 23 BM 37 ILBL morphine 76 codeine 10 
MO 
CO 
0.4 
- 
5 hours 
MOC 
021 
 
Mixed* morphine 30 morphine <LOQ codeine 25 MO N/A N/A 19 WF 81 
 
 
 
 
 
 
 
Table 9, continued
1GC/MS linear range: 10-1,000 ng/mL 
2GC/MS2 linear range: 5-1,000 ng/mL 
*Average concentration 
Morphine = MO 
Codeine = CO 
6-Monoacetylmorphone = 6-MAM 
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MDME-toxicology lab) do not have a blood quantitative method for heroin.  Instead 6-
monoacetlymorphine (t1/2= 6-25 minutes), the major metabolite of heroin, is more often 
encountered and quantitated, as it is more likely to be identified in whole blood (section 
1.6.3). 
Postmortem mixed blood (MXBL) and inferior vena cava blood (IVC BL) were 
submitted for analysis following autopsy.  Mixed blood had a morphine concentration of 
2,945 ng/mL with a codeine concentration of 76 ng/mL.  Inferior vena cava blood had 
concentrations of 2,539 ng/mL and 83 ng/mL for morphine and codeine, respectively.  
All samples (PM and AM) were diluted to bring their concentrations within the linear 
range (ULOQ = 1,000 ng/mL) of the assay.  The PM results for morphine were 
determined to be statistically similar to each other.  This was also true for the PM results 
of codeine.  However, both morphine and codeine results were determined to be 
statistically different from the AM concentrations (morphine CV ± 9.1%, codeine ± 
9.8%).  On the basis of the AM results the expected concentration range for morphine 
was 1,277 – 1,484 ng/mL.  Codeine had an expected range of 34.8 – 37.4 ng/mL.  The 
PM results for both drugs exceeded their linear range.  The MXBL:AM ratio equaled 2.0 
for both morphine and codeine, while IVC BL:AM ratio equaled 1.7 and 2.0 for 
morphine and codeine, respectively.  When comparing the PM to AM data, one could 
conclude that PMR occurred during the 18 hour PMI.  While PMR may have contributed 
to the elevated postmortem concentrations, it is more likely that the drug was still being 
absorbed at the time of death.  The oversaturation of the body’s system, due to an 
overdose of heroin, can significantly hinder the pharmacokinetic process.   
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Morphine/codeine case 13 had AM blood drawn 45 minutes before death.  
Analysis of this sample detected the presence of both morphine and codeine at 
concentrations of 104 ng/mL and 20 ng/mL, respectively.  Chest blood (CHBL) samples 
in both red-top (RT) and gray-top (GT) tubes were submitted for postmortem analyses.  
The red-top chest blood sample had 228 ng/ml of morphine and 8.5 ng/mL of codeine.  
Gray-top chest blood had 290 ng/mL of morphine and 11 ng/ml of codeine.  Since the 
PM samples were from the same source, their drug concentrations were averaged to give 
259 ng/mL and 9.75 ng/mL for morphine and codeine, respectively.  Chest blood to AM 
ratios for morphine and codeine equaled 2.6 and 0.49, respectively.  The ratio values 
suggested that PMR occurred for morphine, but not for codeine.  The expected 
concentration ranges were in agreement with the ratio data, as PM morphine 
concentrations exceeded its expected range (71.7 – 96.2 ng/mL), while codeine was 
below its range of 15.2 – 17.5 ng/mL.  The decrease in codeine concentration from AM 
to PM sample, may appear to be due to metabolism.  However, the 45 minute antemortem 
to death (AMD) interval would not have been enough time for that amount of 
metabolism.  Conversely, the PMI lasted 48 hours.  In that amount of time, anaerobic 
conversion could be a possibility.  This could account for the decrease of codeine’s 
concentration and the increase of morphine, as morphine is the demethylated metabolite 
of codeine.  So while PMR may have caused the concentration changes, anaerobic 
activity cannot be ruled out.  In which case, the process of chemical conversion was 
ceased once the samples were aliquoted into RT and GT tubes which contain the 
antimicrobial agent sodium fluoride. 
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The antemortem blood for MOC 05 was collected within one hour of death and 
had a postmortem interval of 13.5 hours.  The AM blood had a morphine concentration of 
65 ng/mL and was negative for codeine.  Postmortem aorta blood was collected at 
autopsy and submitted for testing.  Quantitative analysis determined that morphine was 
present at a concentration of 48 ng/mL and codeine at 25 ng/mL.  The concentration 
differences for AM and PM morphine values were statistically different (CV ± 10%).  
The PM:AM ratio of morphine was 0.8, which indicated a lack of PMR.  Based on the 
data, it would appear as though before the collection of the AM sample, the body 
metabolized codeine to the extent to which it was undetectable.  The presence of codeine 
in the PM does seem to indicate the sequestering of codeine in or around the heart tissue 
and released upon death.  This equates to PMR of codeine, but not morphine.  Morphine 
had an expected concentration range of 36.6 – 54.1 ng/mL.  The AOBL concentration fell 
within this range, reiterating that PMR did not occur for morphine.    
Antemortem blood for MOC 03 was collected 2 hours before death.  The AM 
results determined that morphine and codeine were present at concentrations of 17 ng/mL 
and 65 ng/mL, respectively.  The decedent in this case was prescribed Tylenol 3®, a 
mixture of codeine and acetaminophen.  Therefore, the presence of morphine in the AM 
was likely the result of drug metabolism.  The expected calculated concentration range 
for morphine was 7.4 – 16.3 ng/mL, while the range for codeine was 28.9 – 42.0 ng/mL.  
Postmortem aorta (AOBL) and chest (CHBL) blood samples were also submitted for 
analysis (PMI = 47 hours).  Quantitative analysis of the aorta blood had a morphine 
concentration of 52 ng/ml and codeine of 698 ng/mL.  The chest blood had 
concentrations of 71 ng/mL and 1,397 ng/mL for morphine and codeine, respectively.  
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The PM results were not only statistically different from the antemortem concentration, 
but they were also different from each other.  Additionally, the actual postmortem 
concentrations for both morphine and codeine well exceeded their expected concentration 
ranges.  The AOBL:AM ratios equaled 2.6 and 11.6 for morphine and codeine, 
respectively.  The CHBL:AM ratio for morphine was calculated at 3.55, while codeine 
was 23.3.  Both of the PM:AM ratios indicated PMR of morphine and codeine.   
In MOC 03, both AOBL and CHBL samples were collected from the central 
region of the body.  However, the data indicated a more extensive redistribution present 
in the chest blood.  The term ‘chest blood’ is a generic designation for pooled blood 
collected from inside the chest cavity.  Therefore, a chest blood sample is often a mixture 
of blood that has been released from the lungs, liver, stomach and/ or various chambers 
of the heart.  Further review of the medical records determined that the decedent vomited 
prior to the arrival of the ambulance.  Therefore, it is possible that some of the stomach 
contents were aspirated into the lungs, thereby contaminating the chest blood sample.  
This in turn could account for chest blood codeine concentrations that were significantly 
higher than both the aorta and antemortem bloods (50% and 96%, respectively).  
Morphine/ codeine (MOC) 08 was submitted with AM blood that was collected 2 
hours before death.  The AM sample had 205 ng/mL of morphine but no codeine 
detected.  Upon autopsy, both postmortem heart and iliac vein bloods were submitted.  
Heart blood (HTBL) had a morphine concentration of 105 ng/mL and codeine of 
10ng/mL.  Iliac vein blood (ILBL) analyses determined concentrations of 76 ng/mL and 
10 ng/mL of morphine and codeine, respectively.  While the PM codeine concentrations 
were equal, the PM morphine concentrations were statistically different.  Additionally, 
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both PM morphine concentrations were also different from the AM concentrations.  The 
central to peripheral ratios equaled 1.4 and 1.0 for morphine and codeine, respectively.  
The HTBL:AM ratio of morphine equaled 0.5, while the ILBL:AM morphine ratio 
equaled 0.4.   
For MOC 08, the central to peripheral ratios indicated that PMR was present for 
both morphine and codeine.  However, the PM:AM ratios did not support this finding for 
morphine.  A codeine ratio could not be calculated, as codeine was not detected in the 
AM sample.  Therefore, upon examining the data, the researcher determined that PMR of 
codeine was present.  The lack of codeine in the AM, but its presence in both PM 
samples indicated that codeine had both metabolized (to the point of non-detection in the 
AM) and sequestered itself during life.  The 23 hour PMI was enough time to allow 
codeine to be released in both the central and peripheral regions of the body, thereby 
facilitating its PM detection.  However, the same conclusion could not be drawn for 
morphine. 
Morphine’s elimination half-life varies from 1.3 to 6.7 hours.  Based on this, the 
expected PM morphine concentrations would have been between 76.2 – 166.7 ng/mL.  
Both HTBL and ILBL concentrations fell within this range, suggesting that metabolism 
occurred as expected.  Therefore, based on this information it would appear as though 
PMR was not present.  However, the value calculated for the central to peripheral blood 
ratio did exceed 1.0, thereby suggesting the presence of PMR.  In a situation when 
calculated values used to indicate PMR disagree, it can be difficult to determine if it 
actually occurred or not.  However, in this case, the PM concentrations were within their 
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expected concentration range; therefore, the researcher determined that PMR was not a 
factor in this case.  
Antemortem blood for MOC 02 was collected 5 hours before death.  Antemortem 
codeine concentration equaled 25 ng/mL, while morphine was detected below the LOQ 
(10 ng/mL by Agilent 5890 GC/MS system).  Postmortem mixed blood samples (PMI = 
19 hours) were submitted for analysis in both red-top and gray-top tubes.  Both tubes 
were analyzed (on the same day as the antemortem) and both detected 30 ng/mL of 
morphine.  Codeine was not detected in either PM tube.  Since the PM results were 
identical and of the same source, the results were combined into one averaged value.  The 
elimination half-life for codeine ranges between 1.9 - 3.9 hours.  As a result, the expected 
codeine concentration after five hours of metabolism would have between 4.0-
10.3ng/mL.  The upper limit of the expected range would have just been equal to the 
LOD and the LOQ for the GC-SIM/MS method.  When interpreting the PM data, it 
appears as though codeine was extensively metabolized into morphine during the AMD 
interval.  This resulted in both the lack of codeine detection and the increase of morphine 
in the PM sample (relative to the AMBL sample).          
Those cases whose antemortem samples were collected within one elimination 
half-life illustrated many different considerations when trying to interpret toxicological 
data.  For example, when AM blood is collected more than a few minutes before death, 
drug metabolism can change both the content of the drugs detected as well as their 
concentrations.  This was illustrated in MOC 02 when the AM sample (collected 5 hours 
before death) had a quantifiable amount of codeine.  However, PM analysis was negative 
for codeine and had increased levels of morphine.  Similarly, during the metabolic 
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process some drugs sequester themselves in organs.  In these situations, AM blood results 
can be negative, but PM analysis can give a positive result.  Morphine/ codeine case 05 
and 08 were examples of this.  In both cases, only morphine was present in the 
antemortem samples.  However, upon PM analysis, both morphine and codeine were 
detected in quantifiable amounts.  Additionally, in both of these cases, the PM morphine 
concentrations fell within their expected concentration ranges, indicating a lack of PMR.  
This illustrates that, while under the same conditions two drugs can respond differently.  
While codeine was sequestered and released after death, morphine was eliminated at a 
predictable rate.   
In MOC 03, both morphine and codeine were quantified in the AM blood.  
Postmortem submission included aorta and chest blood samples.  Both PM samples 
contained morphine with concentrations at least three times greater than that of the AM, 
as well as codeine, which had 10 times greater than the AM sample.  Since two hours 
elapsed between AM collection and death, it would be expected that the concentrations of 
morphine and codeine would have decreased.  Instead the increased amount of drugs led 
to PM:AM ratios of 3.0 and 10.7 for morphine and codeine, respectively in the aorta 
blood.  While, the chest blood sample had PM:AM ratios of 4.2 and 21.5 for morphine 
and codeine, respectively.  Chest blood concentrations of morphine and codeine exceeded 
those of the other two specimens (morphine by > 25% and codeine by > 98%).  This was 
probably due to the contamination present in a pooled blood sample taken from the chest 
cavity.  Such a sample is predisposed to redistribution of drugs being released from any 
of the organs present within the chest cavity.  In this case, there was a 47 hour PMI which 
would be ample time for the process of PM release and redistribution to occur.   
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In cases where it has been determined that postmortem redistribution was a factor, 
two important considerations are needed.  First, the length of the PMI should be 
considered.  Secondly, identification of the major source of contamination that led to the 
redistribution.  Morphine/ codeine 03 was a case where PMR was present in both the 
aorta and chest blood samples.  The collection of the PM samples was 47 hours after 
death.  During this time, the codeine concentration from the chest blood sample was 
almost twice that of the aorta blood.  The significantly increased amount of codeine in the 
chest may suggest that the main source of contamination for this sample came from the 
stomach.  The stomach holds un-metabolized drugs and is anatomically positioned within 
close proximity to the chest cavity.  Additionally, the concentration of codeine in the 
aorta blood was more than 11 times greater than was detected in the AM blood sample.  
While the aorta blood also had a significant amount of PMR, it is not located close 
enough to the stomach to have been contaminated by it directly.  Instead, the aorta was 
likely contaminated by the lungs, as well as the pooled chest blood.  Based on the data, 
the chest blood had a more significant contamination than the lungs. 
Finally, testing more than one sample matrix can give additional information to 
aid in the interpretive process.  In the case of MOC 12, for example, blood as well as 
urine samples were tested.  While urine is only used for qualitative purposes, it was the 
only sample in which heroin was detected.  Although the extremely high morphine 
concentration would be indicative of heroin usage, actually identifying heroin in the urine 
eliminated the need to infer its role in this case.  Morphine/ codeine case 12 is a good 
example of how gathering as much data as possible (toxicological, as well as social and 
medical history) can aid in the interpretative process.   
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The following cases had antemortem blood collected greater than or equal to 2 
elimination half-lives before death (Table 10).  While their AM sample collection times 
are not the most ideal, they still offer quantitative information of value.  The AM blood 
for MOC 09 was collected 6.5 hours before death.  The sample had a codeine 
concentration of 48 ng/mL, however morphine was not detected.  Postmortem aorta and 
iliac vein bloods were also submitted for analyses.  Codeine concentrations were 
determined to be 34 ng/mL and 27 ng/mL for aorta blood and iliac vein blood, 
respectively.  Statistical analyses determined that the CV range for codeine in the AOBL 
was 30.6 – 37.4 ng/mL.  The range for the ILBL sample was between 24.3 – 29.7 ng/mL.  
Therefore, although the range values were close, ultimately the AOBL and ILBL 
concentrations are dis-similar to each other.  Additionally, as with the AM sample neither 
postmortem sample detected the presence of morphine.  The C:P ratio for codeine 
equaled 1.2, suggesting PMR.  However, both PM:AM ratios were less than 1.0 
(AOBL:AM = 0.68; ILBL:AM = 0.54), which would indicate a lack of PMR.  The 
expected concentration range of codeine would have been between 4.5 – 15.1 ng/mL.  
The concentrations of both PM samples exceeded this range.  Therefore, it can be 
determined that while the drug continued to metabolize and decrease in concentration 
during the 6.5 hours between AM collection and death, during the 33.5 hour PMI drug 
redistribution did occur.  This, thereby, resulted in elevated PM sample concentrations.     
Morphine/ codeine case 11 had antemortem concentrations of 92 ng/mL and 
17ng/mL for morphine and codeine, respectively.  The AM sample was collected 10 
hours prior to death.  As a result, the expected PM morphine concentrations would range 
between 0.65 – 32.7 ng/mL, with codeine ranging from 0.4 – 2.9 ng/mL.  Mixed heart as 
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well as inferior vena cava bloods was submitted for PM analyses.  Nine and a half 
nanograms per milliliter of morphine were detected in the mixed heart sample, while 
8ng/mL was detected in the IVC blood.  These concentrations were determined to be 
statistically similar.  Codeine was not detected in either PM sample.  The lack of codeine 
was consistent with the expected concentration range, as the values obtained there were 
below both the LOD (3 ng/mL) and LOQ (5 ng/mL) of the GC/MS/MS analysis. 
However, the morphine concentration detected fell within its expected range.  Therefore, 
there is no reason to believe that PMR affected this case. 
The antemortem blood submitted for MOC 06 was negative for morphine and 
codeine.  However, the antemortem urine sample was positive for morphine.  As a result, 
the PM blood was analyzed by the researcher to determine if morphine or codeine could 
be detected.  The postmortem blood submission consisted of both aorta and iliac vein 
blood samples.  Morphine concentrations of 17 ng/mL for both AOBL and ILBL samples 
were detected.  Codeine had concentrations of 25 ng/mL and 27 ng/mL in aorta and iliac 
vein bloods, respectively.  These samples were analyzed by SIM GC/MS and had a LOD/ 
LOQ of 10 ng/mL.  Therefore, if morphine and codeine were present in the AM sample, 
their concentrations would have been below 10 ng/mL.  As a result, the detection of 
morphine and codeine in both PM samples was indicative of increased concentrations for 
both drugs.  This would suggest that during the 48 hour PMI, PMR occurred.   
Morphine/ codeine case 15 had an AM blood sample collected 12 hours before 
death.  The AMBL had a morphine concentration of 98 ng/mL.  Based on this 
information the expected morphine concentration would be between 0.3 – 28.9 ng/mL.  
Heart blood was submitted for PM analysis in both red-top and gray-top tubes.  Red-top   
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Table 10: Morphine, Codeine and Heroin Antemortem samples collected after 2 elimination half-lives 
Heroin t1/2 = 2-6 minutes 
6-MAM t1/2 = 2- 25 minutes 
Morphine t1/2 = 1.4 – 6.7 hours; Vd = 2-5 L/ kg 
Codeine t1/2 = 1.9 – 3.9 hours; Vd = 3.5 L/kg  
 
AM –Death 
 (hours) Case# 
Source 
(whole blood) 
Concentration 
(ng/mL) 
AM 
concentration 
(ng/mL) 
Analyte PM:AM C:P PMI (hours) Sex Age 
6.5 MOC 091 
Aorta codeine 34 
48 codeine 
CO 0.7 
1.2 33.5 BM 38 
Iliac codeine 27 CO 0.6 
10 MOC 112 
Mix heart morphine 9.5 92 morphine 
17 codeine 
MO 0.1 
- 19.5 WF 34 
IVC morphine 8 MO 0.1 
< 10 MOC 061 
Aorta morphine 17 codeine 25 
NDD3 
MO 
CO 
- 
- 1.0 
0.9 48 WM 41 Iliac morphine 17 codeine 27 
MO 
CO 
- 
- 
12 MOC 152 Heart* morphine 156 98 morphine 
MO 1.5 - 23 WF 62 MO 1.7 
≤ 20 MOC 041 
Mix heart morphine 1,170 codeine 10 298 morphine 
MO 3.9 
- 34 BF 65 
IVC morphine 111 codeine 9.5 MO 0.4 
24 MOC 101 
Heart morphine 20.5 codeine 14 Detected4 
MO/CO - 
- 31.5 WM 39 
Heart morphine 17 codeine 14 MO/CO - 
< 24 MOC 011 
Aorta morphine 403 codeine 35 226 morphine 
32 codeine 
MO 
CO 
1.8 
1.1 0.2 
0.5 20 BM 40 Iliac morphine 2,185 codeine 72 
MO 
CO 
9.7 
2.2 
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AM –Death 
 (hours) Case# 
Source 
(whole blood) 
Concentration 
(ng/mL) 
AM 
concentration 
(ng/mL) 
Analyte PM:AM C:P PMI (hours) Sex Age 
unknown MOC 071 
Iliac morphine 33.5 codeine 81 10 codeine 
CO 8.1 
- 46.5 WF 43 
Iliac morphine 30.5 codeine 42.5 CO 4.2 
 
 
 
 
 
 
 
 
 
 
Table10, continued 
Morphine = MO 
Codeine = CO 
1GC/MS linear range 10-1,000 ng/mL 
2GC/MS2 linear range  5-1,000 ng/mL 
3AM blood was negative, but qualitative screen of urine was positive for morphine 
4Sample quantity only sufficient for blood drug screen, not quantitation 
* Average concentration 
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morphine concentration was 149 ng/mL, while the gray-top equaled 164 ng/mL.  
Statistical analysis determined the PM morphine concentrations were similar.  Since these 
samples were statistically similar and of the same source their morphine concentrations 
were averaged to equal 156 ng/mL.  The PM results not only exceed their expected range, 
they also surpassed the AM concentration, resulting in a HTBL:AM ratio of 1.6.  The 
data supports the idea that PMR occurred during the 23 hour postmortem interval. 
  Antemortem blood for MOC 04 had 298 ng/mL of morphine present.  Codeine 
was not detected in the sample.  The AM tube did not indicate the time of collection; 
therefore, the exact time between the AM collection and death was not known.  However, 
based on the hospital records the decedent was in the hospital for 20 hours before death, 
therefore the AM sample would have been collected within the same time frame.  When 
using 20 hours as the time between AM collection and death, the expected morphine 
concentration at the time of death would have been between 0.15 – 37.7 ng/mL.  
Postmortem mixed heart (MXHT) and IVC bloods were submitted for analyses.  The 
MXHT blood sample had 1,170 ng/mL of morphine and 10 ng/mL of codeine.  One 
hundred - eleven nanograms per milliliter of morphine and 9.5 ng/mL of codeine were 
detected in the IVC blood sample.  Both PM morphine concentrations exceeded their 
expected ranges.  Morphine PM:AM ratios were calculated to be 3.9 and 0.37 for mixed 
heart and IVC bloods, respectively.  Codeine, which was not detected in the AM sample, 
was present in both PM samples, near the LOQ of 10 ng/mL (GC- SIM/MS) detection.  
The increased codeine concentration did suggest PMR of codeine.  While the ratio data 
for morphine in the MXHT sample was indicative of PMR, it’s concentration in the IVC 
BL sample did not.  However, both PM morphine concentrations exceeded the calculated 
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concentration at the time of death.  Therefore, the researcher determined that both PM 
morphine values were a result of PMR.   
The volume of AM blood submitted for MOC 10 was only sufficient for 
morphine identification (codeine was not detected) in a routine blood screen.  Before 
quantitative analysis could be conducted, the sample was depleted.  Heart blood was 
submitted in both gray-top and red-top tubes.  Analysis of the RT tube detected 
20.5ng/mL of morphine and 14 ng/mL of codeine.  Gray-top tube analysis detected 17 
ng/mL of morphine and 14 ng/mL of codeine.  Since morphine was not quantitated in the 
AM sample, it is not known how the 31.5 hour PMI affected the sample concentration, if 
at all.  The emergence of codeine in the PM does suggest PMR for that drug.  
Additionally, the consistent drug concentrations between the two tubes shows how 
similar results can be obtained when a sample is properly homogenized with the 
antimicrobial agent present within the tubes.   
Morphine/codeine 01 had antemortem concentrations of 226 ng/mL and 32 ng/mL 
for morphine and codeine, respectively.  As a result, the expected concentration range for 
morphine was 0.001 – 18.9 ng/mL, while codeine was 0.005 – 0.45 ng/mL by GC/MS 
(LOD and LOQ = 10 ng/mL).  Postmortem analysis was conducted on aorta and iliac 
vein blood samples.  The aorta blood had concentrations of 403 ng/mL of morphine and 
35 ng/mL of codeine.  The iliac vein blood sample had a morphine concentration of 
2,185ng/mL and codeine of 72 ng/mL.  The PM concentrations of both morphine and 
codeine exceeded the antemortem concentrations and calculated concentration ranges at 
the time of death.  Aorta blood to AM ratio equaled 1.8 and 1.1 for morphine and 
codeine, respectively.  The iliac blood to AM ratio equaled 9.7 and 2.25 for morphine and 
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codeine, respectively.  All of the PM:AM ratios were consistent with PMR being a factor 
in this case.  However, since the iliac vein blood had higher concentrations than the aorta 
blood, the C:P ratios for both morphine and codeine were below 1.0.  Regardless, the 
increased PM concentrations were enough evidence to support the possibility of PMR 
being present within this case.    
Alternatively, while heroin was not detected in MOC 01’s biological samples, the 
significant difference between morphine and codeine blood concentrations for MOC 01 
suggested the possibility of heroin usage.  A review of the circumstances surrounding the 
decedent’s death indicated that his body was found with a syringe in close proximity.  If 
heroin was injected in the leg or foot area, this would account for the elevated morphine 
concentration in the iliac vein blood as compared to the aorta blood.  Under those 
circumstances, heroin would have metabolized out of the blood stream, but morphine and 
codeine remained.  If this were true, then incomplete drug distribution, not PMR, was the 
reason for the concentration differences.   
  Ten nanograms per milliliter of codeine were detected in the AM sample 
collected for MOC 07.  In this case, the exact time of the AM sample before death was 
unknown.  Based on the medical records obtained by the MDME Department, the 
decedent was hospitalized for three days before her death.  Postmortem iliac vein blood 
was submitted in both gray-top and red-top tubes for analyses.  The RT sample had 
morphine and codeine concentrations of 35.5 and 81 ng/mL, respectively.  The GT 
sample had 30.5 ng/mL of morphine and 42.5 ng/mL of codeine detected.  Since 
morphine is a metabolite of codeine, its presence in the PM samples and absence in the 
AM sample, may suggest that metabolism continued between the time of AM sample 
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collection and death.  However, since both morphine and codeine concentrations were 
elevated in the PM samples, it is also likely the PMR occurred for both drugs.  The 
inconsistent codeine concentration within the RT and GT iliac vein blood samples could 
be indicative of two separate blood draws.  In instances such as this, one draw will be 
used to fill the red-top tube (which can hold up to 50 mL of blood), while a second draw 
can be used to fill the gray-top tube (10 mL total volume).  If two draws occurred, then it 
is possible that the blood was drawn from two different regions of the iliac vein, which 
resulted in the significant codeine concentration discrepancy between the two tubes.     
Those cases whose antemortem collection were greater than or equal to two 
elimination half-lives add value to this section by highlighting the importance of time.  In 
the time between antemortem blood draw and death, drug concentration and 
identification can be altered.  In morphine/codeine case 09, the 6.5 hour interval between 
AM and death was sufficient time for codeine (which was detected in both the AM and 
PM samples) to metabolize, resulting in a lower concentration.  While the PM 
concentration did decrease, it still exceeded its expected concentration range, which was 
believed to be due the PMR that occurred during the 33.5 hour PMI. 
In comparison, morphine/codeine case 11 had AM samples collected 10 hours 
before death, but had a PMI of 19.5 hours.  Therefore, the time difference between AM to 
death increased, but the PMI decreased when comparing it to MOC 09.  In MOC 11, both 
morphine and codeine were detected in the AM, but only morphine in the PM sample.  It 
is believed that in this case, codeine metabolized to concentrations below that of 
detection.  Morphine decreased as well, to a concentration that would be expected of a 
drug that metabolized in a linear fashion.  While it cannot be said for certain, the 
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differences in PMI (14 hours) may have made the difference in these two cases.  If the 
PMI of MOC 09 had been shorter or the PMI of MOC 11 had been longer, the results 
may not have been the same. 
Morphine/codeine 06 had an extended PMI of 48 hours.  In this case, neither 
morphine nor codeine was detected in the AM sample.  However, they were both 
detected in the PM samples.  This suggests that PMR was a factor here and the PMI may 
have contributed to this.  This was also seen in MOC 04 where only morphine was 
detected in the AMBL, but both morphine and codeine were detected in the PM blood 
samples (PMI = 34 hours).   
Morphine/codeine 04 was also of interest because it illustrated the significant 
concentration differences that can be present within different sourced PM blood samples.  
In this case, a mixed heart sample had a 10 fold increase in morphine concentration over 
the IVC BL sample.  The mixed heart sample, which was blood collected from more than 
one unspecified region of the heart, is susceptible to contamination from both the liver 
and the lungs.  The inferior vena cava blood is typically drawn from the lower abdominal 
region of the body (52).  While both samples are considered central sourced blood, their 
anatomical location can result in very different drug concentrations.     
Morphine/codeine 01 was of interest because the peripheral source blood (ILBL) 
greatly exceeded the concentration of both the aorta and antemortem bloods.  The reason 
for this large increase cannot be definitively determined.  Based on the other MOC cases 
examined here, there is no reason to believe that the 20 hour PMI was sufficient to cause 
such a great concentration inconsistency.  While it is understood that drug concentrations 
do not always respond in a predictable manner, it would seem that this case would be an 
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exception to the rule.  An alternative explanation would suggest that the drug was 
injected intravenously into the leg or foot region of the body.  This would account for the 
significantly higher morphine concentration found in the iliac vein blood.   
An additional factor in blood concentration, regardless of half-life time intervals 
would be the anatomic location of blood draws.  In MOC 07, iliac vein blood was 
submitted in both blood collection tubes.  In situations like this, it is expected that blood 
concentrations from either tube would be comparable to each other.  However, the 
codeine concentration in the red-top tube was almost twice that of the gray-top.  This 
could have suggested that the blood drawn from both tubes were either collected from 
different regions of the same iliac vein or collected from different iliac veins all together 
(i.e. left and right leg veins).  Either scenario is plausible, as the sample volume from the 
iliac vein is relatively limited.  Similarly, the HTBL sample submitted in both RT and GT 
tubes for MOC 10 had a morphine concentration discrepancy.  While the difference in the 
drug concentration seen here was < 20%, it was greater than the significance limit (± 
10%).  This shows that even a relatively abundant source of blood (as compared to the 
iliac vein) may not offer a homogenous sample.  Conversely, since the morphine heart 
blood concentrations for MOC 10 were statistically similar (± 9.1% by GC/MS) the 
results were averaged.  The data produced by these three cases indicates that while one 
would like to believe that same source samples collected at the same time would render 
statistically similar results, it is definitely not guaranteed.   
And finally, a debatable issue in PM toxicology is whether or not peripheral blood 
sources most closely resemble the blood drug concentration around the time of death.  
Chart 3 displays the peripheral results for both morphine and codeine.  Each chart also 
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displays the calculated expected concentration range, denoted with the symbol “[” for 
morphine and “]” for codeine.  In MOC 01, the morphine sample concentration 
(2,185ng/mL) was not fully displayed, as it would have made it difficult to see the results 
of the cases with the lower concentrations.  Additionally, MOC 06 did not have an 
expected range because morphine was not detected in the AM sample.  Likewise, MOC 
cases 14, 08 and 06 did not have expected codeine ranges, as codeine was not identified 
in their respective AM samples.  Also, MOC 07 has two codeine results displayed.  This 
was because codeine was detected in both RT and GT tubes; however, their 
concentrations were not similar enough to be averaged into one.  As a result, the data 
from both tubes is represented. 
 Of the cases that had calculated expected ranges, only one (MOC 08) had its 
morphine concentration within the expected range.  The other cases, whether it be for 
morphine or codeine, had peripheral concentrations that significantly exceeded their 
expected values.  This indicated that for morphine and codeine cases, peripheral blood 
results are not likely to be reflective of perimortem blood concentrations.   
One additional note of interest was how the central and peripheral blood 
concentrations compared to each other.  Chart 4 and Chart 5 show the central versus 
peripheral data for morphine and codeine, respectively.  Again, the peripheral morphine  
concentration for MOC 01 was truncated so that the data from the other cases would be 
visible.  When examining the morphine data, only MOC 06 had central and peripheral 
data that rendered statistically similar results.  Of the five codeine cases, only MOC 08 
and MOC 06 had statistically similar intra-case central and peripheral results.  Among the 
remaining dis-similar results, 66% of the morphine cases had higher central sourced  
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Chart 3: Morphine and Codeine Peripheral Data 
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Chart 4: Morphine Central versus Peripheral Data 
         
 
 
 
 
Chart 5: Codeine Central versus Peripheral Data 
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concentrations, while 66% of codeine did as well.  Based on this data, it would appear 
that among statistically dis-similar data, peripheral blood results would likely offer drug 
concentrations with fewer instances of increase.  However, as indicated by Chart 3, 
peripheral blood results still may not render drug concentrations that are indicative of 
drug levels in the body at the time of death.  
 
6.1.2 Methadone  
 Methadone, which is often used for the treatment of opioid addiction, is a 
synthetic opioid whose plasma half-life ranges from 15 to 55 hours (42).  It has an 
apparent volume of distribution (Vd) of 4 -5 L/kg (42).  In total, six cases were examined 
in order to establish a drug concentration trend between antemortem and postmortem 
samples.  This section was divided into two parts, with both sections listing the cases in 
order of increasing antemortem to death interval, as opposed to case number.  The first 
section encompasses those cases whose AM samples were collected within one 
elimination half-life (Table 13).  The second data set includes those cases where the AM 
blood was collected longer than one elimination half-life before death (Table 14).  As 
discussed in section 1.4.3, half lives measure the amount of time needed for an ingested 
substance to be removed from the system.  With each half-life accounting for a 50% 
decrease in concentration, it is estimated that at the end of five to six half-lives, the body 
will rid itself of a drug in its entirety.  Depending on the administered concentration and 
the detection limits of an instrument, methadone taken within 4 half-lives (60 – 220 hrs) 
of death, could still be present at detectable, if not quantifiable concentrations.     
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 Methadone analysis was conducted solely on GC/NPD.  All samples were 
prepared as discussed in Section 4.3 Basic Drugs: Quantitative Blood Analysis by 
GC/NPD.  The controls, which were run thirty-one times, had two lot numbers.  A one-
way ANOVA (α = 0.05) was conducted on the two lots to determine if the data produced 
within them was statistically similar.  The summary results shown in Table 11 give the 
breakdown information (including control averages and variances) for each lot.  The 
ANOVA results (Table 12) give an F-test value of 1.28 and an Fcrit of 4.18.  Since F is 
less than Fcrit, the two lots were determined to be statistically similar, resulting in the 
methadone data being treated as one population.  The percent error (CV) was calculated 
to be 12.52%. Therefore, only drug concentrations that differ beyond that percentage 
were considered significantly different. 
 Antemortem serum and postmortem iliac vein blood were received for MDN 04.  
Initial laboratory analysis determined that the AM serum (collected 45 minutes before 
death) was negative for methadone.  Postmortem analysis conducted by the researcher 
determined that methadone was present in the iliac vein blood samples.  Iliac vein blood 
received in both vacutainer and red-top polypropylene tubes were positive for methadone, 
each with a concentration of 0.1 mg/L.  Since the PM samples were of the same source, 
their concentrations were averaged (average = 0.1 mg/L).  In this case, the methadone 
was self administered (as opposed to being given in the hospital).  Based on the low PM 
concentrations, it can be inferred that either a small dose of methadone was ingested 
shortly before death (less than 48 hours) or a larger dose was taken more than 48 hours 
before death.  In either instance, the absence of methadone in the AM sample and 
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Table 11: One-Way ANOVA Summary Results for Methadone Controls (0.50 mg/L) 
n=31 
 
Groups Count Sum Average Variance 
Lot 1 14 6.80 0.48 0.003457 
Lot 2 17 8.60 0.50 0.001563 
         
 
 
 
 
Table 12: One-Way ANOVA Results for Methadone Controls 
95% Confidence Limit 
 
Source of 
Variation 
Sum of 
Squares df 
Mean 
Square 
F-test 
value P-value F crit 
Between Lots 0.003 1 0.003 1.28 0.266 4.18 
         
 
 
 If F > F critical, then results are significantly different 
 If F < F critical, then results are similar 
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quantifiable presence of it in the PM samples, suggested the presence of PMR (PMI=28.5 
hours).   
 Methadone (MDN) case 01 was received with antemortem blood collected eight 
hours before death and a postmortem interval (PMI) of 23 hours.  The AM sample had a 
methadone concentration of 0.26 mg/L.  Postmortem specimens including central (mixed 
heart) and peripheral (iliac vein) blood sources, had concentrations of 0.53 mg/L and 
0.58mg/L, respectively.  When using Equation 7, the expected concentration range at the 
time of death would have been between 0.19 mg/L to 0.24 mg/L.  However, the results 
determined by PM analysis were more than twice that.  A review of the medical records 
for this case did not indicate any additional methadone dosing after the time of AM 
collection to account for the increase in drug concentration detected in the PM samples. 
 An 8 hour AMD interval, as seen in MDN 01, is less than the minimum amount of 
time needed for one elimination half-life (15 hours).  However, metabolism was still 
occurring.  Therefore, the drug concentrations detected in the PM samples should have 
been lower than the AMBL concentration.  Instead, the PM concentrations showed a 
substantial increase.  The increased PM blood concentrations suggested postmortem 
release of methadone from the tissues that surrounded the blood collection sites at 
autopsy.  The ratio of mixed heart:AM was 2.0 and iliac vein:AM was 2.2.  Additionally, 
the mixed heart:iliac vein ratio was calculated to be 0.9.    Independent studies have 
demonstrated (19)(20)(21) that central, rather than peripheral, blood sources are more 
susceptible to PMR.  Because of this, it is often believed that peripheral blood sources 
offer more reliable data than central sources.  However, in this case, less than 10% 
separated the concentration of the two sources.  The central (0.53 mg/L) and peripheral 
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(0.58 mg/L) concentrations were statistically similar, indicating that both sources were 
equally susceptible to the PM redistributive effect.       
 The decedent in MDN 05 died during a surgical procedure.  Upon admission into 
the hospital he acknowledged his use of cocaine and heroin.  The hospital released the 
AM blood collected prior to surgery to the Medical Examiner’s Department.  Analyses 
detected the presence of hospital administered medications (e.g. phenobarbital and 
lidocaine), as well as non-hospital administered drugs such as cocaine, benzoylecgonine 
(a major metabolite of cocaine), morphine (a metabolite of heroin, as well as a prescribed 
pain medication) and hydromorphone.  Unfortunately, by the end of this testing, there 
was not enough AM blood remaining to test for the presence of methadone.  Laboratory 
testing did include a urine analysis (qualitative screen), which was positive for 
methadone.  Subsequent quantitative analysis by the laboratory was conducted on PM 
blood in lieu of AM blood.   
 Routine laboratory analysis of the chest blood submitted for MDN 05 (PMI = 16 
hours) detected 0.26 mg/L of methadone.  Medical records indicated that methadone was 
administered by the hospital 2.5 hours before death.  One month after routine laboratory 
testing, the researcher re-analyzed both postmortem chest blood tubes (red and gray).  
Each had a concentration of 0.25 mg/L, since the PM samples were of the same source 
their concentrations were averaged (0.25 mg/L).  The lack of AM testing meant that this 
case could not be evaluated for differences between AM and PM drug concentrations; 
however it is an example of another goal of the project.  While it is understood that one 
sample is not a relevant population, the re-analysis suggested that when a preserved 
methadone sample is stored in refrigeration for 30 days, degradation may not be a factor.  
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Drug stability is an important variable to consider when trying interpreting the meaning 
of toxicological data.   
 Methadone (MDN) 02 was submitted for laboratory testing with AM blood 
collected 12 hours before death.  The postmortem submission consisted of both aorta and 
iliac vein bloods (PMI= 54 hours).  Routine analysis determined that the AM 
concentration of methadone was 2.3 mg/L.  Subsequent analysis of the PM samples 
determined concentrations of 5.32 mg/L and 4.62 mg/L for the aorta (AOBL) and iliac 
vein (ILBL) bloods, respectively.  The linear range of methadone for this project was 
from 0.1 – 1.0 mg/L.  Therefore, the samples were diluted to bring their concentrations 
within the appropriate range.  The decedent had a history of opiate abuse (specifically, 
heroin and morphine).  However, none of the records available to the researcher 
suggested that the decedent was receiving methadone treatment to help alleviate the 
withdrawal symptoms associated with opiate addiction.  Typically people receiving such 
treatment are given daily doses ranging from 100 – 200 mg (42).  Studies have shown 
that when following this dosing regimen, the average peak plasma concentration is 
0.83mg/L (42).  The concentrations encountered in MDN 02, well exceeded this level.  
Based upon the AM concentration of 2.3 mg/L, the expected concentration range at the 
time of death would have been between 1.38 – 2.05 mg/L.  The calculated ratios of 
AOBL:AM and ILBL:AM was 2.3 and 2.0, respectively.  The central to peripheral ratio 
of AOBL:ILBL equaled 1.1.  All three of the ratio calculations were greater than 1.0, 
suggesting that PMR occurred during the 54 hour PMI.  However, while the aorta blood 
appeared to receive a larger redistribution effect than the iliac vein blood, the differences 
in their concentrations were not statistically significant.  The significant range for the   
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Table 13: Methadone Antemortem samples collected within one elimination half-life  
t1/2 = 15 – 55 hours 
Vd = 4 – 5 L/ kg 
CV = 12.5% 
Linear range: 0.1 – 1.0 mg/L 
 
AM-
Death Case # 
Source 
(Whole blood) 
Concentration 
(mg/L) 
AM 
Concentration  
(mg/L) 
Specimen PM: AM C: P 
PMI 
(hours) Race/Sex Age 
45 min MDN 04 Iliac* 0.10 Not detected AM Blood - - 28.5 WM 44 
8 hrs MDN 01 Mixed heart 0.53 0.26 AM Blood 
2.0 0.91 23 WM  33 Iliac 0.58 2.2 
12 hrs MDN 05 Chest* 0.25 0.26 PM
1 
Blood 0.96 - 16 
WM 
 38 
12 hrs MDN 02 Aorta 5.32 2.3 AM Blood 
2.3 1.1 54 WM 68 Iliac 4.62 2.0 
 1Quantity not sufficient for antemortem quantitation 
 *Average concentration
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AOBL was 4.65 – 5.98 mg/L, while ILBL was 4.04 – 5.20 mg/L.  The critical ranges for 
the two samples overlap, indicating that they are not statistically different. 
 When comparing these four cases, there were a few observations to note.  First, 
methadone concentrations were stable regardless of the collection tube.  In MDN 05 chest 
blood was collected in both tubes, while MDN 04 had iliac vein blood in both tubes.  
Regardless of the anatomical source or collection tube, the blood drug concentration of 
methadone was stable when stored under the same conditions. 
 Additionally by convention, toxicologists prefer to use peripheral blood for 
quantitative analysis.  Out of the four cases examined, two (MDN 01 and MDN 02) were 
received with both central and peripheral blood.  Both MDN 01 and 02 were affected by 
PMR and their intra-sample results were statistically similar.  This meant, that despite the 
region of anatomical collection, the PM results returned analogous results.  While there 
are not enough cases available to make any absolute decisions, it would appear that 
regardless of the PMI (MDN 01 = 23 hrs., MDN 02 = 54 hrs.), PMR of methadone can 
affect central and peripheral blood sources similarly.   
 Finally, the overall data collected from these four cases illustrated that AM 
methadone concentrations are consistently lower than their PM counterparts.  This trend 
was observed in all of the quantifiable data produced.    
Included in the second part of this section are two methadone cases (Table 14).  
One case had an AM collection of 72 hours before death.  While this amount of time may 
seem significant, in actuality it is within two elimination half-lives of methadone. As a 
result, it is reasonable to believe that PM drug analysis could still be positive for 
methadone.  The second case had an AM collection of 20 hours after death.  Blood 
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samples can be collected after brain death for patients who are being maintained 
artificially for the purpose of organ donation.    
 The decedent in MDN 03 was found unresponsive at home by a family member.  
He had a history of heart disease and heroin addiction.  He sought out treatment for his 
addiction and was prescribed a methadone treatment regimen of 80 milligrams per day.  
The hospital submitted AM Blood collected 72 hours prior to his death.  The AM 
methadone concentration was 0.7 mg/L, resulting in an expected concentration range at 
the time of death of 0.02 – 0.28 mg/L.  Postmortem analysis (PMI = 24.5 hours) detected 
methadone concentrations of 1.06 and 0.51 mg/L for aorta and inferior vena cava (IVC) 
bloods, respectively.  While both AOBL and IVC BL are commonly considered central 
sourced bloods, the data they produced were statistically significantly different.  In 
situations like this, it becomes increasingly important to identify the actual region of 
collection for the IVC BL.  
 The inferior vena cava is the largest vein in the body.  It begins at the joining of 
the common iliac vein and continues to the right atrium, where it delivers deoxygenated 
blood (53).  Contamination of the IVC, depends greatly upon the region of collection.  
Conversely, the aorta’s primary function is to distribute oxygenated blood away from the 
heart and to the other tissues of the body.  The aorta is comprised of three continuous 
parts (ascending, arch and descending components), which based on its location can 
receive direct contamination from both lungs, as well as the pulmonary artery.  Upon 
investigating the source of the IVC BL, it was explained that at the MDME Department, 
IVC blood is collected from the lower abdominal region of the body (52).  This means 
that the IVC BL is peripherally located in comparison the AOBL.  When examining the 
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data, the AOBL:AM ratio equaled 1.5, while the IVC BL:AM ratio equaled 0.73.  
According to this ratio data, no PMR was observed in the IVC BL sample.  However, the 
AOBL ratio of 1.5 was indicative of PMR.  These results do follow the conventional idea 
that more centrally located blood specimens are more susceptible to PMR. 
The decedent in methadone 06 was an organ donor; whose AM sample was 
collected 20 hours after brain death (refer to section 1.6.5).  Upon analysis, the AM blood 
was negative of methadone.  The postmortem aorta and iliac vein bloods however had 
methadone concentrations of 0.15 mg/L and 0.10 mg/L, respectively.  With a methadone 
CV of 12.52% the critical ranges for the AOBL and ILBL concentrations were 0.13 – 
0.17 mg/L and 0.09 – 0.11 mg/L, respectively thereby making these concentrations 
statistically dis-similar.  The AOBL:ILBL ratio equaled 1.5.  The ratio data suggested 
that during the 31.5 hour postmortem interval, drug redistribution occurred.  This 
redistribution effect was more pronounced in the aorta blood, rather than iliac vein blood.  
The ratio data, along with the lack of drug detection in the AM sample, but its presence in 
both PM samples indicated that PMR was a factor in this case.    
 When examining all six cases as a whole it became apparent that the methadone 
data could have been grouped as it was (by increasing antemortem to death interval) or 
based upon their blood collection sites.  Three of the cases examined were submitted with 
both peripheral and central blood, plus the addition of MDN 03, which had a more 
peripherally located IVC BL and the more centrally located AOBL, as well.  One case 
came with central blood only.  Typically blood collected from the central vessels is more 
abundant than that available from the periphery.  For that reason, it is not unusual to 
receive more central only, rather than peripheral only cases.  Of the three cases with both  
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Table 14: Methadone Antemortem samples collected after one elimination half-life  
t1/2 = 15 – 55 hours 
Vd = 4 – 5 L/kg 
CV = 12.5% 
Linear range: 0.1 -1.0 mg/L 
 
 
AM - 
Death Case # 
Source 
(whole blood) 
Concentration 
(mg/L) 
AM 
concentration 
(mg/L) 
Specimen PM:AM C:P PMI (hours) Age Race/Sex 
20 hrs 
AFTER1 
MDN 
06 
Aorta 0.15 Not detected AM Blood 
- 1.5 31.5 38 BM Iliac 0.10 - 
3 days MDN 03 
Aorta 1.06 
0.7 AM Blood 
1.5 
- 24.5 60 WM Inf. Vena 
Cava 0.51 0.7 
      1 AFTER denotes collection time after brain death 
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central and peripheral sources, all four had higher PM, rather than AM concentrations.  
Among those PM concentrations the two cases whose AMD interval exceeded one 
elimination half-life not only had intra-sample concentrations significantly different from 
each other, but they also had higher central sourced blood concentrations.   Neither of 
these factors was observed in the cases collected within one elimination half-life. 
 Those cases submitted with central only bloods (as well as the lone case of 
peripheral only blood) had PM concentrations much higher than their AM counterparts.  
The combined effect of all the data showed that regardless of the AMD interval or the 
PM interval, PMR of methadone can occur.  However, the data trend suggested that those 
AM samples that were collected within one elimination half-life before death could have 
had a PM redistributive effect that influenced two anatomically different PM sources 
similarly.   This was reiterated by the lack of statistically different concentrations 
obtained in those cases that had both central and peripheral blood collected.  In most 
instances PM concentrations can greatly exceed both the AM concentration and the 
expected concentration range at the time of death, as long as the autopsy is conducted in 
less than 54 hours, it may not matter which PM sample is used for quantitation.    
 
6.2 Diphenhydramine 
Diphenhydramine is classified as an antihistamine, but has a much wider array of 
applications.  It does relieve allergy related symptoms (e.g. itchy, irritated, watery eyes 
and sneezing) (54) but is often also utilized for its sedative and antiemetic properties.  
Over-the-counter formulations of diphenhydramine can range in concentration from 10 – 
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50 mg doses and are obtained as elixirs, pills or creams (55).  In high doses (≥ 300 mg) it 
has been known to produce psychoactive delusions.  This, in combination with its ease of 
accessibility, has made this drug particularly appealing to adolescents (56).   
During the course of this project, three separate diphenhydramine controls 
(concentration = 0.5 mg/L; each with their own lot numbers) were made.  The control 
values produced for each lot were analyzed using a one-way ANOVA (α = 0.05) to 
determine if a significant variation existed among the collected data.  The summary data, 
produced by Microsoft Excel, displayed in Table 15 shows the average concentrations, as 
well as the amount of variance present within each lot.  The ANOVA results in Table 16 
gave an F-test value of 2.39 and a critical F (Fcrit) value of 3.24.  Since F < Fcrit the data 
produced by the 3 lots was considered statistically similar, which allowed the data was 
treated as one population.  Equation 5 was used to calculate the coefficient of variation 
for the total population.  This value was determined to be 15%.  Therefore, any 
quantitative diphenhydramine case data that fell within a ± 15% range was considered 
similar.  Data that exceeded these limits were considered dis-similar. 
On average it takes diphenhydramine 3–14 hours for one elimination half-life to 
occur.  The twelve cases that are presented here were separated into two sections.  The 
first encompasses those cases whose antemortem bloods were collected within two 
elimination half-lives before death (Table 17).  While the second section, includes those 
cases that exceed this limit (Table 18).  In both sections, the cases were evaluated in the 
order of increasing antemortem to death (AMD) interval, as opposed to numerical case 
order.  All samples were prepared as described in Section 4.3 Basic Drugs: Quantitative 
Blood Analysis by GC/NPD (linear range 0.1 – 1.0 mg/L). While the sedative affects of 
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diphenhydramine may have contributed to some of the deaths discussed here, it was 
never listed as the sole cause of death.    
 Diphenhydramine (DPN) case 10 had antemortem blood collected 5 minutes 
before death and had a diphenhydramine concentration of 0.11 mg/L.  As a result, when 
using Equation 7 the expected concentration range of diphenhydramine at the time of 
death would have been between 0.10 – 0.11 mg/L.  At autopsy, heart and mixed blood 
samples were collected and submitted for analyses (PMI = 24 hours).  Heart blood 
(HTBL) had a concentration of 0.28 mg/L, while the mixed (MXBL) sample had a 
concentration of 0.73 mg/L.  Both PM concentrations exceeded the calculated range of 
the expected concentration at the time of death.  The PM:AM ratios for HTBL and 
MXBL were 2.5 and 6.6, respectively.  Statistical analysis of the two PM concentrations 
determined that the HTBL and MXBL amounts were different.  The term mixed blood is 
a non-descript way of indicating a mixture of blood collected from various regions of the 
body (potentially both central and peripheral).  Trying to determine the significance of 
the increased concentration obtained in the MXBL, as compared to the other two samples 
cannot be accurately evaluated.  Additionally, the C:P ratio calculation would not be 
appropriate for this case.  What can be shown was that regardless of the origin of the 
source, both PM samples had concentrations that were higher than expected and they 
each had PM:AM ratios greater than 1.0.  This information suggested that PMR did take 
place. 
The antemortem blood for DPN 03 was collected 10 minutes before death.  While 
diphenhydramine was detected in the AM, the amount was below the LOQ.  As a result, 
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Table 15: One-Way ANOVA Summary Results for Diphenhydramine Controls 
(0.5mg/L) 
 (n=41)  
 
Groups Count Sum Average Variance 
lot 1 15 8.62 0.57 0.013 
lot 2 19 10.50 0.55 0.002 
lot 3 7 3.46 0.49 0.002 
 
 
 
 
 
Table 16: One-Way ANOVA Results for Diphenhydramine Controls 
95% Confidence Limit 
 
Source of 
Variation Sum of Squares df Mean Square F-test value F crit 
Between lots 0.03 2 0.015 2.39 3.24 
 
 
 
 If F > F critical, then results are significantly different 
 If F < F critical, then results are similar 
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it would also be expected that the PM concentrations would be below the LOQ as well.  
Iliac vein blood was submitted in both gray and red-top tubes.  Each had a 
diphenhydramine concentration of 0.1 mg/L.  While this value was just at the LLOQ, it 
did show increased blood concentration after death. 
The antemortem blood for DPN 08 was collected four hours before death and had 
a concentration of 0.15 mg/L.  As a result, the expected concentration at the time of death 
would have been between 0.06 – 0.12 mg/L.  Upon autopsy aorta and iliac vein bloods 
were submitted for postmortem analyses.  Aorta blood had a concentration of 0.48 mg/L, 
while iliac vein blood had a concentration of 0.57 mg/L.  Both PM samples exceeded the 
expected concentration range.  In this case, the amount of diphenhydramine in the 
peripheral blood exceeded that of the central sourced blood.  However, the concentrations 
for both PM sources fell within the acceptable limits of variation (± 15%) established for 
diphenhydramine.  As a result, the concentrations were considered to be statistically 
similar.     
Ratio calculations for DPN 08 rendered C: P results equaling 0.84, while PM: AM ratios 
were 3.2 and 3.8 for AOBL and ILBL, respectively.  The C:P ratio indicated a lack of 
PMR, while both PM:AM ratios suggested the presence of PMR.  An obvious 
discrepancy between the ratio calculations existed.  However, the combination of the 
PM:AM data as well as the fact that both PM sources had concentrations that were at 
least four times higher than the expected concentration range, was used by the researcher 
to determine that PMR was a factor.   
Nine and a half hours passed between the AM sample collection and death in case 
DPN 01.  Diphenhydramine was detected in the antemortem, but was at an amount below  
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Table 17: Diphenhydramine antemortem samples collected within two elimination half-lives  
t1/2 = 3-14 hours 
Vd = 3 – 4 L/kg 
CV = 15.0 % 
Linear range: 0.1 – 1.0 mg/L 
 
AM-
Death Case # 
Source 
 (Whole Blood) 
Concentration 
(mg/L) 
AM 
Concentration 
(mg/L) 
Specimen PM: AM C: P 
PMI 
(hours) Race/Sex Age 
5 min DPN 10 
Heart 0.28 0.11 AMBL 2.5 - 24 WM 61 Mix 0.73 6.6 
10 min DPN 03 Iliac 0.1 <LOQ AMBL - - 28.5 WM 44 
4 
hours 
DPN 
08 
Aorta 0.48 0.15 AMBL 3.2 0.84 19 WF 49 Iliac 0.57 3.8 
9.5 
hours 
DPN 
01 Mix* 0.12 <LOQ AMBL 
- - 23 BM 57 - 
10 
hours 
DPN 
05 
Iliac 0.20 0.18 AMBL 1.1 - 11 BM 43 Iliac 0.14 0.78 
11 
hours 
DPN 
06 
Heart 2.96 <LOQ AMBL - 4.17 25 BM 36 Iliac 0.71 - 
14 
hours 
DPN 
04 
Mix 0.12 0.10 AMBL 1.2 - 19 WF 49 Iliac 0.11 1.1 
14 
hours 
DPN 
07 
Heart 0.53 0.27 AMBL 2.0 0.93 17 WF 65 Iliac 0.57 2.1 
 
 
1 Pulmonary Artery 
* Average concentration 
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the LOQ (0.1 mg/L).  Postmortem mixed blood was collected in both the red and gray-
top tubes.  The red-top MXBL sample had 0.11 mg/L of diphenhydramine and the gray-
top MXBL had 0.13 mg/L.  As would be expected for PM samples of the same source, 
their concentrations were determined to be statistically similar.  Additionally, since they 
were of the same source and of similar concentrations, their results were averaged 
(0.12mg/L).  While the exact amount in the AM sample is unknown, it would be expected 
that during the 9.5 hours between AM sample collection and death, that the amount of 
diphenhydramine would have continued to decrease, rendering the PM concentration 
below the LOQ as well.  However, that was not the case.  Instead, during the 23 hour 
PMI, the amount of diphenhydramine increased to just within the quantifiable limits of 
the assay.  The apparent increase of drug in the PM sample was indicative of PMR. 
Antemortem blood for diphenhydramine 05 was collected ten hours before death 
and had a concentration of 0.18 mg/L.  The expected concentration range at the time of 
death would have been between 0.02 – 0.11 mg/L.   Iliac vein blood was submitted for 
PM analyses in both red and gray-top sampling tubes (PMI = 11 hours).  The red-top tube 
had a concentration of 0.20 mg/L and the gray-top tube had 0.14 mg/L.  These values 
resulted in PM: AM ratios of 1.1 and 0.78 for the RT and GT, respectively.  While one 
PM sample indicated an increase in drug concentration (relative to the antemortem 
sample), the other PM specimen did not.  Statistical evaluation of the PM samples 
determined that their concentrations were statistically dis-similar.  While it is expected 
that samples collected from the same source would have virtually identical 
concentrations, this is not always the case.  Since the amount of iliac blood is relatively 
limited, it would not be uncommon for the iliac blood to have been collected from more 
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than one site along the vein, or from both veins.  In either instance, a concentration 
discrepancy between tubes can arise.  Despite the overall dis-similarity between the 
tubes, both iliac blood concentrations exceeded the expected concentration range at the 
time of death.  Therefore, it is likely that a small amount of PMR occurred in this case.   
In diphenhydramine case 06, the antemortem was collected 11 hours before death. 
The antemortem sample had a diphenhydramine concentration below the LOQ.  After 
autopsy, heart and iliac vein bloods were submitted (PMI = 25 hours).  Heart blood had a 
concentration of 2.96 mg/L, while iliac vein blood had a concentration of 0.71 mg/L.  
While both the central and peripheral blood sources showed increased concentrations 
over the AMBL, the central sourced blood was more than four times greater than both the 
peripheral and antemortem bloods when considering the LOQ.  The resulting C:P ratio 
was 4.17.  The increased PM blood concentrations and the high central to peripheral ratio 
indicated that PMR was a factor in this case.  Additionally, the largely elevated heart 
blood concentration signifies that, diphenhydramine was largely stored in the tissues of 
the chest cavity and/ or liver and subsequently released during the 25 hour PMI. 
 The antemortem blood for DPN case 04 had a concentration of 0.10 mg/L and 
was collected 14 hours before death.  The low concentration and the relatively long AMD 
interval caused the expected diphenhydramine concentration range (0.003 – 0.05 mg/L) 
to be less than the LOQ.  Upon autopsy, mixed and iliac vein bloods were submitted for 
postmortem analyses.  The mixed blood had 0.12 mg/L of diphenhydramine, while the 
iliac vein blood had 0.11 mg/L.  Postmortem: antemortem ratios equaled 1.2 and 1.1 for 
MXBL and ILBL, respectively.  Both postmortem samples were at least double the upper 
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limit of the expected concentration range.  This was indicative of diphenhydramine being 
released and redistributed postmortem, during the 19 hour PMI. 
 Antemortem for DPN 07 was collected 14 hours before death.  The AM sample 
had 0.27 mg/L of diphenhydramine.  Heart and iliac vein bloods were collected during 
autopsy.  Heart blood had a concentration of 0.53 mg/L and iliac vein blood had 
0.57mg/L.  The expected concentration range at the time of death was between 0.01 and 
0.13mg/L.  Both PM samples had amounts that exceeded this range, resulting in PM:AM 
ratios of 1.96 and 2.11 for HTBL and ILBL, respectively.  These values were indicative 
of PMR.  However, the peripheral blood sample exceeded the concentration of the central 
blood sample, resulting in a C:P ratio of 0.93, which would indicate a lack of PMR.  
While the ILBL did have a higher concentration than the HTBL, the difference between 
the two values was not statistically significant.  The PM:AM ratios, as well as the 
increased levels of diphenhydramine in the PM samples lead the researcher to conclude 
that PMR did occur.   
 Seventy-four percent of cases whose AM was collected within two elimination 
half-lives before death had postmortem concentrations that were statistically greater than 
their respective AM concentrations.  One-hundred percent of the data had PM 
concentrations greater than their respective calculated concentration range at the time of 
death.  As a result, the overwhelming majority of the first half of the diphenhydramine 
data returned results that were consistent with PMR.  The average Vd for 
diphenhydramine is 3.5 L/kg (range = 3- 4 L/kg).  Any apparent volume of distribution 
greater than 1 L/kg is said to be reflective of a drugs ability to redistribute.  In the case of 
diphenhydramine (who’s apparent Vd ranges from 3 to 4 times greater than the critical 
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limit) the propensity for redistribution is great.  A few of the cases had mixed blood 
submitted as a PM sample.  While the exact location of the sample procurement cannot 
be resolved, these samples give a generalized view of what is occurring within the body 
after death.  Changes in drug concentrations can be identified in mixed samples, just as 
they are in ‘pure’ samples.  In the absence of the latter, a comparison between a mixed 
and AM sample can still give important information about the tendency of a drug. 
 As demonstrated in other chapters of this manuscript, PM:AM ratios and C:P 
ratios calculated for the same case do not always agree.  This was exhibited here in DPN 
08 and 07, where both PM:AM ratios were greater than 1.0, but their C:P values were 
less than 1.0.  In the absence of an AM sample, it would have been incorrectly 
determined that PMR was not present.  Perhaps it would be best to view the C:P ratio as 
proof of PMR occurring as predicted (e.g. more extensively in the central cavity), rather 
than actual evidence of PMR existing at all.   
 Also observed within these cases was a discrepancy between two postmortem 
samples of the same source.  Diphenhydramine case 05 had a relatively short PMI of 11 
hours.  Upon collection, iliac vein blood was stored in both the red and gray-top sample 
tubes.  However, the diphenhydramine drug concentration varied significantly between 
the two tubes.  This case serves as a reminder that assumptions made about sample 
homogeneity may not always be appropriate. 
 The second half of this section focuses on the diphenhydramine cases that had 
antemortem samples collected beyond two elimination half-lives (Table 18) before death.  
Only two cases fell into this category.  While two cases may not be enough data to draw 
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any formal conclusions, the addition of these cases to the totality of the diphenhydramine 
data can be used to reinforce some ideals discussed in the earlier part of this chapter.  
 Diphenhydramine case 02 had antemortem blood collected 48 hours before death.  
The AM blood had a concentration of 0.33 mg/L. Aorta and iliac vein bloods were 
submitted for postmortem analyses.  The PM concentrations were 0.56 mg/L and 
0.40mg/L for AOBL and ILBL, respectively.  After 48 hours (approximately four half-
lives), the expected concentration range would have been 5.0 x 10-6 to 0.03 mg/L.  
Instead, the amount of drug in both PM samples exceeded that of the AM blood and its 
expected range.  The AOBL:AM ratio equaled 1.70, while the ILBL:AM ratio was equal 
to 1.21.  Additionally, the C:P ratio equaled 1.4.  A review of the medical records 
reported the administration of multiple medications during the 48 hour hospitalization, 
some of which included naloxone (an opioid antagonist), epinephrine and atropine; 
however, diphenhydramine administration was not reported.  Therefore, there was 
nothing to suggest that the concentration of the drug would have increased as a result of 
additional dosing or incomplete distribution.  Consequently, it appears that the drug was 
released and redistributed during the 13 hour PMI.    
Statistical analyses of the data collected on DPN 02 showed that the aorta blood sample 
concentration was significantly different from that of the iliac vein blood.  Additionally, 
when comparing the PM to the AM concentrations, the aorta blood was also significantly 
different from the antemortem blood concentration.  Conversely, the concentration 
obtained for the iliac vein blood was determined to be similar to the antemortem sample.  
The comparisons of the PM and AM samples seemed to indicate that while both PM  
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Table 18: Diphenhydramine antemortem samples collected after two elimination half-lives  
t1/2 = 3-14 hours 
Vd = 3 – 4 L/kg 
CV = 15.0 % 
Linear range: 0.1 – 1.0 mg/L 
 
AM –
Death 
(hours) 
Case # Source (whole blood) 
Concentration 
(mg/L) 
AM 
concentration 
(mg/L) 
Specimen PM: AM C: P PMI (hours) Race/ Sex Age 
20 DPN 09 Mixed* Heart 0.96 <LOQ AMBL - - 21 BF 65 
48 DPN 02 
Aorta 0.56 0.33 AMBL 1.7 1.4 13 WF 59 Iliac 0.40 1.2 
 
 
* Average concentration 
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specimens were influenced by redistribution, the aorta blood was affected more 
extensively.  
Diphenhydramine case 09 had an antemortem concentration lower than the LOQ 
of the assay.  Mixed heart blood was submitted in both red-top and gray-top tubes.  The 
RT MXHT blood had a concentration of 0.97 mg/L, while the GT had 0.96 mg/L.  Since 
the PM samples were of the same source and had statistically similar concentrations, the 
PM results were averaged to equal 0.96 mg/L.  The AMBL concentration was below the 
LOQ; therefore, it can be inferred that the PM concentration was at least 90% higher than 
the AM.  In this case the AM blood was collected approximately 20 hours before death.  
There was no indication in the medical records that re-administration was a factor.  As a 
result, it appears as though during the 21 hour PMI, PMR likely occurred.    
When reviewing all of the cases as a whole, it became apparent that postmortem 
redistribution was a real factor when trying to interpret PM blood drug concentrations of 
diphenhydramine.  The data discussed here seemed to suggest that on average at least a 
50% increase in PM concentrations (when compared to AM results) could be expected.  
While it is generally accepted that blood concentrations obtained from the central cavity 
have higher concentrations (because of increased sources of possible contamination), this 
is not necessarily the case for diphenhydramine.   
 Of all the cases discussed, only four were submitted with both central and 
peripheral blood for comparison (Chart 6).  Two out of the four had statistically higher 
central concentrations than peripheral.  The other two cases (DPN 08 and 07) had central 
and peripheral data that gave statistically similar results.  Admittedly, the amount of 
central vs. peripheral data was limited.  However, it did seem to reinforce the idea that 
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redistribution may not always follow the expected pattern, which assumes that 
quantitative values obtained from peripheral sourced blood are more accurate than central 
blood.  To the contrary, this data would seem to indicate that central and peripheral 
concentrations may not differ that significantly from each other.  Again, reiterating the 
idea that using the C:P ratio as an indicator for PMR may not be the most reliable 
predictor. 
Diphenhydramine 02 had one of the shortest PMI (13 hours) of the cases 
presented.  Despite this, it not only produced data that was indicative of PMR, but it also 
demonstrated that central and peripheral results could vary significantly in a short amount 
of time.  This would suggest that PMR may begin rather quickly after death.  
Finally, for each case discussed, the expected drug concentration range at the time 
of death was calculated (Equation 7).  Chart 7 displays the peripheral blood 
concentrations as they compare to that of the expected range, denoted by the symbol “[.”   
Diphenhydramine cases 03 and 06 had AM concentrations that were below the LOQ; 
therefore a quantitative range could not be determined.  However if PMR did not occur, 
the PM concentrations would have been expected to be below the LOQ as well.   
Diphenhydramine 05 was submitted with two peripheral sources, the results of 
both tubes are displayed.  When examining the Chart 7 data as a whole, 100% of the 
cases exceeded their calculated ranges.  Therefore, while a peripheral sourced blood may 
be the preferred postmortem specimen for quantitative analyses, in the case of 
diphenhydramine, it likely will not be reflective of the blood drug concentration around 
the time of death.      
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Chart 6: Diphenhydramine Central versus Peripheral Data 
Error rate: 15% 
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Chart 7: Diphenhydramine Peripheral Source Data 
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6.3 Benzodiazepines  
Benzodiazepines are a class of drugs with a wide array of uses, including muscle 
relaxation, sedation and anxiety relief.  The broad application of benzodiazepines has 
helped to make them among the most widely prescribed medications in the world.  This 
study examined diazepam, nordiazepam, alprazolam, midazolam, clonazepam and 7-
aminoclonazepam specimens in whole blood and serum.  As described in section 2.2, the 
samples were analyzed by GC/ECD (linear range: 0.01–0.2 mg/L), HPLC/MS/MS (linear 
range: 0.01–1.0 mg/L) or by HPLC/DAD (linear range: 0.1–10 mg/L).  Identification of 
the instrumental analysis is addressed in each of the following sections on a case-by-case 
basis.       
 
6.3.1 Alprazolam 
 Alprazolam analyses were conducted on two instruments.  All data collected as 
part of routine laboratory analyses were performed on a gas chromatograph/ electron 
capture detector (GC/ECD).  This same instrument was used for research purposes until 
March 2008.  Since that time, the quantitative benzodiazepine research was analyzed by 
high performance liquid chromatography/ tandem mass spectrometry (HPLC/MS/MS) 
(refer to section 4.2.2 (b)).  The switch from GC/ECD to HPLC/MS/MS allowed for an 
extended linear concentration range.  In addition, the HPLC/MS/MS method monitored 
seven analytes, while the GC/ECD only quantified three. 
 The control data produced by both the GC/ECD and the HPLC/MS were 
statistically analyzed by using a two-way ANOVA (α = 0.05).  The purpose of the two-
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way ANOVA was to determine if the control data collected from the two systems 
significantly varied.  The F-test result for that comparison was 0.33, while the Fcrit value 
equaled 4.4.  Since F < Fcrit the ANOVA results determined that no significant variation 
was observed between the two instruments (Table 19).  Additionally, the amounts of day 
to day variability, as well as the interaction between the sources of variation, were not 
considered significantly different either.  Since it was determined that the GC/ECD and 
LC/MS control data were statistically similar, the data generated from both systems were 
treated as one population.  The coefficient of variation for the population equaled 
18.73%.  Intra-case drug concentrations that were included within the ± 18.73% range 
were considered similar.   
 Alprazolam is a benzodiazepine with an average elimination half-life (t1/2) of 11 
hours (ranging from 6 – 27 hours (57)).  It has an apparent volume of distribution (Vd) of 
0.9 – 1.3 L/ kg (57). For this study, 14 cases were evaluated.  The data is presented in 
order of increasing antemortem to death intervals.  Those cases whose AM blood was 
collected within two AMD intervals were included within the first section.  Two 
additional donor cases whose blood was collected within hours of brain death were also 
included here (Table 20).  The second section covers those cases that exceed two 
elimination half-lives between AM sample collection and death (Table 21).  Additionally, 
one donor case, whose AM blood was collected seven days after death was also included 
in the second section.   
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Table 19: Two-Way Analysis of Variation for Alprazolam Comparison of GC/ECD 
versus HPLC/MS/MS Controls 
 
Source of 
Variation 
Sum of 
Squares df 
Mean 
Square 
F-test 
value F crit 
Day to Day 0.001191 8 1.49E-04 1.76 2.51 
GC/ECD vs. 
LC/MS 2.84E-05 1 2.84E-05 0.33 4.41 
Interaction 0.000744 8 9.3E-05 1.10 2.51 
 
 
 Antemortem blood for Alprazolam (Alp) 09 was collected 13 minutes before 
death.  The AM concentration was 0.09 mg/L.  Such a short AM to death time interval 
would suggest that in the absence of PMR, the postmortem blood concentrations would 
be similar to that of the AM (ranging from 0.088 – 0.089 mg/L).  The postmortem 
samples submitted in both the red-top (RT) and gray-top (GT) tubes were iliac vein blood 
samples with a PMI of 21 hours.  The RT concentration equaled 0.080 mg/L, with the GT 
equaling 0.089 mg/L.  While, the red-top did render a slightly higher concentration 
(~11.5% higher), the difference between the two tubes was less than the 18.73% needed 
to make the difference statistically significant.  Since the PM concentrations were similar 
and of the same source, their concentrations were averaged to 0.084 mg/L.  When using 
the average, the PM:AM ratio was calculated to equal 0.89.  Additionally, when applying 
the CV percentage, it was determined that the PM and AM concentrations were 
statistically similar.  The combination of the ratio results, as well as the CV results 
indicated that PMR did not occur in this case.   
 Alprazolam 02 AM samples were collected 20 minutes before death and had AM 
alprazolam concentration of 0.01 mg/L.  The expected alprazolam concentration at the 
time of death would have been between 0.01 – 0.01 mg/L (raw data = 0.0096 –  
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Table 20: Alprazolam antemortem samples collected within two elimination half-lives 
t1/2 = (6 – 27 hours) 
Vd = 0.9 – 1.3 L/kg 
CV population = 18.73% 
 
AM - 
Death Case # 
Source 
(whole blood) 
Concentration 
(mg/L) 
AM 
concentration 
(mg/L) 
Specimen PM: AM C:P PMI (hours) Race/Sex Age 
13 min Alp 091 Iliac* 0.084 0.09 AMBL 0.9 - 21 WM 21 
20 min Alp 021 
Aorta 0.02 0.01 AMBL 2.0 0.5 45.5 WM 26 
Iliac 0.04 4.0 
40 min Alp 142 
Chest 0.04 
0.02 AMBL 
2.0 
1.3 52 WM 52 
Iliac 0.03 1.5 
1.5 hrs Alp 061 
Chest <LOQ <LOQ AMBL - - 19 WM 40 
Chest <LOQ - 
11 hrs Alp 031 
Heart NDD 
0.01 AM S 
- 
- 19 WM 50 
Iliac NDD - 
12 hrs Alp 111 
Aorta 0.48 >LOQ AM S - 1.1 54 WM 68 
Iliac 0.43 - 
15 hrs Alp 041 
Heart 0.04 
0.03 AMBL 
1.3 
0.8 32.5 WM 41 
Iliac 0.05 1.7 
30 min 
AFTER 
Alp 
052 
Heart <LOQ 
0.01 AMBL 
- 
- 89 WM 45 
Iliac <LOQ - 
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AM - 
Death Case # 
Source 
(whole blood) 
Concentration 
(mg/L) 
AM 
concentration 
(mg/L) 
Specimen PM: AM C:P PMI (hours) Race/Sex Age 
6 hrs 
AFTER 
Alp 
011 
Heart NDD 0.01 AMBL - - 14 WM 21 
Iliac NDD - 
 
 
 
 
 
 
Table 20, continued 
1GC/ECD data; linear range = 0.01 – 0.2 mg/L 
2LC/MS/MS data; linear range = 0.01 – 1.0 mg/L 
* Average concentration 
NDD = No Drugs Detected 
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0.0099mg/L).  The postmortem aorta and iliac vein blood samples had a PMI of 45.5 
hours and concentrations of 0.02 and 0.04 mg/L, respectively.  These concentrations 
significantly exceeded their expected concentration range (CV ± 18.73%).  The central to 
peripheral ratio equaled 0.5, while the aorta blood:AM blood ratio equaled 2.0 and the 
iliac vein blood: AM blood equaled 4.0.  Historically it is believed that when 
central:peripheral and/ or PM:AM ratios are greater than or equal to 1.0, PMR likely 
occurred.  However, in this case the C:P < 1.0, but both PM: AM ratios were > 1.0.  
When viewing the Alp 02 data as a whole, both PM samples were determined to be 
statistically different from their AM concentrations.  This in combination with the 
PM:AM ratio data has caused the researcher to determine that PMR was a factor in this 
case.  Additionally, the aorta and iliac vein blood samples were determined to be 
statistically dis-similar to each other.  This was of particular interest because the iliac 
vein blood concentration was greater than the aorta blood concentration (hence C:P < 
1.0).  While it is generally accepted that PMR is more pronounced in centrally located 
blood sources, this case would be an exception to that rule.   
 The deceased in Alp 14 was the victim of a homicide.  He was transported to the 
hospital and had his blood collected 40 minutes before death (AM concentration = 
0.02mg/L), making his expected alprazolam concentration at the time of death range 
between 0.018 – 0.019 mg/L.  Postmortem submission included a sample obtained from 
the left chest cavity (0.04 mg/L) and the iliac vein (0.03 mg/L).  Both PM samples had 
concentrations higher than the AM.  However, only the left chest cavity blood was 
determined to be statistically higher than the AM sample.  The CHBL:AM ratio equaled 
2.0, while the ILBL:AM ratio equaled 1.5.  Additionally, while the CHBL:ILBL ratio 
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equaled 1.3 their concentration variation was within the ± 18.73% range.  All of the ratio 
data indicated that postmortem redistribution occurred during the 52 hour postmortem 
interval, despite the statistical similarities among most of the data.  The researcher was 
not able to find any literature comparing ratio data to statistical significance.  Therefore, 
it may be possible that the two are mutually exclusive.  An alternative explanation for the 
AM and PM concentration differences could be that the victim was still absorbing 
alprazolam at the time of death.  If this were the case, the expected concentration at the 
time of death would have been slightly higher than the AM concentration, causing PM 
levels to be higher, which may not have been deemed statistically different than the AM 
concentration (as was the case with the ILBL).    
 The decedent in Alp 06 was a victim of homicide.  His AM blood was collected 
1.5 hours before death, but had an alprazolam concentration below the LOQ (GC/ECD 
limit of quantitation = 0.01 mg/L).  The postmortem chest blood samples (collected in 
both a red-top polypropylene and gray-top vacutainer tubes) had a PMI of 19 hours.  Both 
PM samples contained alprazolam at concentrations below the LOQ.  While these results 
were not quantitative, they were still important.  The AM blood had alprazolam detected, 
but at levels below quantitation.  Therefore, there was some potential for PMR.  
However, none could be identified during the 19 hour PMI.  This was an example of how 
a short antemortem to death interval and a relatively short PMI can result in a lack of 
significant change in concentration between AM and PM samples.    
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Equation 8: Alprazolam’s blood to plasma ratio 
 
 
 For Alp 03, AM blood was collected in a serum separator tube.  As a result, the 
specimen available for analysis was serum, not whole blood.  However, as indicated in 
Baselt (57), alprazolam’s blood to plasma ratio equals 0.8.  Consequently, the result of a 
given serum concentration multiplied by 0.8 would be approximately equal to that of a 
whole blood concentration (Equation 8).  For this case, the AM blood was collected 11 
hours before death and had a concentration of 0.01 mg/L.  When applying this result to 
Equation 8 the equivalent blood concentration would be 0.008 mg/L.  When rounded the 
equivalent blood concentration would equal 0.01 mg/L.  With an antemortem to death 
interval of 11 hours, the expected concentration range at the time of death would be 0.003 
– 0.007 mg/L.  Analysis of the postmortem samples (PMI = 19 hours) did not detect the 
presence of alprazolam.  This sample was analyzed by GC/ECD which had a limit of 
detection of 0.002 mg/L.  Although the expected concentration range was low, it would 
have fallen within the detectable limits of the assay.  With no PM concentrations to 
consider, it can be concluded that PMR was not a factor in this case.     
 In Alp 11, antemortem serum, as opposed to blood, was collected 12 hours before 
death.  The serum was determined to have an AM concentration greater than the upper 
limit of quantitation (ULOQ) (0.2 mg/L; analyzed by GC/ECD).  The volume of the 
sample was not sufficient for subsequent dilution and re-analysis.  The original 
paperwork documented the concentration, although exceeding the validated linear range, 
at 0.30 mg/L.  Postmortem submission (PMI = 54 hours) included aorta and iliac vein 
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bloods.  Since the AM concentration exceeded the linear range, the PM samples were 
diluted prior to analysis to ensure that their concentrations would fall within the validated 
range.  The aorta and iliac vein blood concentrations were determined to be 0.48 mg/L 
and 0.43 mg/L, respectively.  Assuming instrument linearity up to 0.30 mg/L, the 
expected concentration at the time of death would have been between 0.07 – 0.22 mg/L.  
When calculating the AOBL:AM, ILBL:AM, as well as the AOBL:ILBL ratios the 
values were determined to be 1.6, 1.4 and 1.1, respectively.  All three ratio values 
indicated that PMR did occur.  Alternatively, it should be considered that with such a 
large amount of drug in the system, it is possible that the body was still in the absorptive 
stage of the pharmacokinetic process, during the 12 hours between collection and death.  
This would have resulted in an increase of drug concentration that could have been 
detected in the PM sample.  Unfortunately, based on the information given there is no 
way of knowing the exact cause of the increased concentration.   
 Alprazolam 04 was collected 15 hours before death and had a concentration of 
0.03 mg/L.  As a result, the expected concentration at the time of death would have 
ranged between 0.005 – 0.02 mg/L.  The postmortem heart blood concentration was 
0.04mg/L and postmortem iliac vein blood concentration equaled 0.05 mg/L.  Both PM 
samples (PMI of 32.5 hours) had concentrations higher than that of the AM blood, 
although only the difference between the iliac blood and AM were determined to be 
statistically dis-similar.  The HTBL:AM and ILBL:AM ratios were 1.3 and 1.7, 
respectively.  Both of these calculations suggested the presence of PMR.  Conversely, the 
heart: iliac vein ratio, which equaled 0.8, did not.  The discrepancy observed in the ratio 
calculations were of concern as both C:P and PM:AM ratios are supposed to be indicative 
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of PMR.  Upon reviewing the data, even though the HTBL concentrations were not 
statistically different from the AM concentration, both PM concentrations greatly 
exceeded the expected concentration range.  Therefore, it was determined that PMR was 
a factor here.   
 Alprazolam 05 was the case of an organ donor.  His AM samples submitted for 
testing were drawn 30 minutes after brain death (refer to section 1.6.5).  The calculated 
concentration of alprazolam was at the limit of quantitation (LOQ) (0.01 mg/L).  The 
decedent in this case was maintained on life support for three days while awaiting organ 
procurement.  Based on the official time of brain death, his PMI would have been 89 
hours.  However, he was receiving fluids and had functioning organs for an additional 
three days.  Therefore, for the purposes of this experiment, his actual PMI (time between 
organ procurement and autopsy) was less than 24 hours, which would make his AM to 
death interval closer to 72 hours.  A 72 hour AM to death interval for alprazolam would 
result in anywhere from three to twelve elimination half-lives.  It would be expected that 
the concentration at the time of death would be very low, if detectable at all.   Analysis of 
the PM heart and iliac vein blood samples were each below the LOQ of the assay.  This 
indicated that no PMR occurred between the 24 hours of organ procurement and autopsy.   
 Alprazolam 01 was a 21 year old white male who suffered from both depression 
and anxiety.  He would self medicate by obtaining alprazolam (dosage unknown) 
whenever he felt it necessary.  The decedent ultimately committed suicide and became an 
organ donor upon family approval.  His AM blood, collected six hours after brain death, 
had an alprazolam concentration of 0.01 mg/L.  His postmortem samples (heart and iliac 
vein bloods) were both negative for alprazolam (GC/ECD limit of detection = 
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0.002mg/L).  The PMI was 14 hours, the shortest time of all 14 cases tested.  Organ 
donors often have postmortem blood negative of any drug not given in preparation of 
surgery. This is a direct result of the amount of fluids infused through the body just prior 
to surgery (in this case at least 6 hours of fluid).  Infusions often dilute drugs of 
toxicological importance to concentrations well below quantitation limits.  The detection 
of alprazolam in the AM and its subsequent absence in the PM suggested that PMR was 
not a factor in this case.    
 The majority of the above mentioned cases had AM collection times within two 
elimination half-lives before death.  There were two exceptions, Alp 05 and Alp 01, 
which were both organ donors.  It is well known that drugs of toxicological importance 
can be lost during the preparatory procedure of organ procurement.  However, this brings 
to light the importance of accurate date and time information concerning AM collection, 
brain death and organ removal.  On the surface, it appeared that the AM collection time 
was ideal for Alp 05.  However, with further investigation it was revealed that the date of 
the AM was actually collected about three days before procurement.  This would indicate 
that the patient received infusions for an additional 72 hours after blood collection.  Even 
though the presence of alprazolam was not critical in this case, this type of information 
could influence the interpretation of results from other cases.  For example, ALP 01 was 
also an organ donor.  The decedent had a history of psychological issues and intermittent 
alprazolam usage.  His AM was collected six hours after he was declared brain dead.  
From a postmortem toxicological standpoint, that means AM collection was not until 6 
hours after fluid infusion.  Although alprazolam did not contribute to the death of either 
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individual, in other situations accurate timeline information could be a crucial factor in 
accurately assessing a cause of death.  
 When the cases are organized in order of increasing AM to death interval, the first 
four cases (Alprazolam 09, 02, 14 and 06) were of particular interest.  Each case had AM 
blood collected ≤ 1.5 hours before death.  Alprazolam 09 and 06 had the shortest and 
longest AM to death interval (of the first four), respectively.  They each had relatively 
short PMI (≤ 21 hours) and both were determined to not be affe cted by PMR.  
Alprazolam 02 and 14 had AM blood collected within 40 minutes of death.  Alprazolam 
02 had a PMI of 45.5 hours, while Alp 14 had a PMI of 52 hours.  Both of these cases 
were potentially affected by redistribution.  While four cases are not sufficient to make 
any definitive decisions, it would appear that the PMI can greatly affect PM drug 
concentrations even when the AM to death collection intervals are relatively short. 
 Additionally seven cases were submitted with both central and peripheral sources.  
Of those, four had quantitative data for both sources (Alp 02, 04, 11 and 14).  Only Alp 
02 had PM source data that was statistically different, all other cases gave similar results.  
This was of particular interest because toxicologists commonly believe that central 
sourced blood is more susceptible to redistribution.  While two of the four cases did show 
higher central sourced concentrations; overall, they were not statistically different.  The 
one case that showed the dis-similarity had a higher peripheral blood concentration, 
indicating that the peripheral sample was more subject to PMR in that case.  Therefore, 
the belief that quantitative data collected from the peripheral source is less likely to be 
contaminated appears to be questionable. 
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 In most situations observed in the alprazolam data both C:P, as well as PM:AM 
ratios were in agreement as to whether or not PMR occurred.  However, Alp 02 and 04 
both had PM: AM ratios ≥ 1.0 and C:P ratio < 1.0.  Both cases were determined to be 
affected by PMR; however, because their PM concentrations exceeded their expected 
concentration ranges.  In addition discrepancies between statistical significance levels 
and ratio calculations also arose.  This was demonstrated in alprazolam cases 04 and 14, 
which were both determined to be potentially affected by PMR.  The statistical analysis 
of Alp 04 and the ILBL of Alp 14 showed concentration similarities between PM and 
AM results.  Since the relationship between statistical significance and PMR is not well 
understood, all of the data and calculations produced for each case had to be considered 
in its entirety.  Only then could a determination be made as to whether or not 
redistribution influenced the results.    
   The remaining alprazolam cases all had antemortem collection times that 
exceeded two elimination half-lives (Table 21).  The first of those was alprazolam 10.  
The antemortem blood received in the laboratory for Alp 10 was dated one day before 
death but did not specify a time.  When calculating the time between hospital arrival and 
death, no more than 38.5 hours could have passed between AM collection and death.  
Routine laboratory testing of the AM sample resulted in a concentration of 0.13 mg/L for 
alprazolam.  Sometime after the blood draw, the patient was declared brain dead and 
became an organ donor.  Organ procurement began five hours after brain death.  
Postmortem aorta blood concentrations (submitted in both red and gray tubes) were 0.01 
mg/L each.  As a result, the PM aorta blood concentrations were averaged.  All 
subsequent calculations will be based on the average value of 0.01 mg/L. 
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 If the AM blood for Alp 10 was in fact collected 38.5 hours before death, then the 
expected drug concentration range at the time of death would have been between 0.001 – 
0.06 mg/L.  The actual PM concentration was within the expected range.  This indicates 
that the infusion of fluids (given in preparation of organ procurement) did not negatively 
affect the PM drug concentration.  Additionally, the aorta:AM ratios equaled 0.08. The 
data collected for this case did not indicate that PMR occurred.    
 Alprazolam 08 had an AM concentration of 0.04 mg/L from a sample collected 45 
hours before death.  The expected concentration at the time of death ranged from 2.2 x 
10-4 – 0.01 mg/L.  The PM iliac vein and heart blood samples had a PMI of 28.5 hours 
and concentrations of 0.01 mg/L each.  The central:peripheral ratio equaled 1.0, while the 
heart blood:AM, as well as the ILBL:AM ratios each equaled 0.25.  While the C:P ratios 
indicated the possibility of PMR, the PM:AM ratios did not.  It has been determined by 
the researcher that since the PM concentrations fell within the expected range that PMR 
did not occur.     
 In Alp 13, the AM blood sample was collected three days before death.  The 
decedent was transported to the hospital as a result of an intentional drug overdose.  The 
AM alprazolam concentration was 0.26 mg/L, well above therapeutic levels (0.02 – 
0.06mg/L (57)).  The expected concentration at the time of death ranged from 6.3 x 10-5 – 
0.04 mg/L.  The aorta and iliac vein blood samples, collected 24 hours after death, had 
statistically similar concentrations of 0.1 mg/L and 0.08 mg/L, respectively.  Hospital 
records indicated that the decedent presented with overdose symptoms caused by the 
ingestion of oxycodone and alprazolam.  While both PM concentrations exceeded their 
expected range, the aorta: AM and iliac vein:AM ratios equaled 0.31 and 0.42,  
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Table 21: Alprazolam antemortem samples collected after two elimination half-lives 
t1/2 = (6 – 27 hours) 
Vd = 0.9 – 1.3 L/kg 
CV = 18.73% 
 
AM - 
Death 
 
Case # 
Source 
(whole blood) 
Concentration 
(mg/L) 
AM 
concentration 
(mg/L) 
Specimen PM:AM C: P PMI (hours) Race/Sex Age 
38.5 hrs Alp 102 Aorta* 0.01 0.13 AMBL 
0.08 - 43 WM 29 0.08 
45 hrs Alp 081 
Heart 0.01 0.04 AMBL 0.25 1.0 28.5 WF  52 Iliac 0.01 0.25 
3 days Alp 132 
Aorta 0.08 0.26 AMBL 0.31 0.72 24 WM 53 Iliac 0.11 0.42 
5 days Alp 071 IVC <LOQ 0.02 AMBL - - 16 WM 45 
7 days 
AFTER 
Alp 
122 
Aorta 0.30 0.9 AMBL3 0.33 1.8 36 WM 71 Iliac 0.17 0.19 
 
 
 
 
 
 
1GC/ECD data; linear range = 0.01 – 0.2 mg/L 
2LC/MS/MS data; linear range = 0.01 – 1.0 mg/L 
3 Not collected during the terminal event 
* Average concentration 
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respectively.  Additionally, the central:peripheral ratio equaled 0.73.  All of the ratio data 
indicated a lack of PMR; however, the PM concentrations exceeded their expected range.  
At the time of death, the body’s ability to metabolize and eliminate drugs from the system 
could have been compromised because of the overdose.  As a result, although (based on 
the concentrations) it looks as if PMR occurred, the role of the overdose cannot be 
overlooked.  Consequently, it cannot be determined if PMR was a factor. 
 The antemortem blood for Alp 07 was collected 5 days before death and had a 
concentration of 0.02 mg/L.  Medical records did not indicate the administration of 
alprazolam during the decedent’s five day hospitalization, which would suggest that the 
drug was ingested before his admittance.  The combination of the low AM blood 
concentration and the five day AMD interval resulted in an expected concentration range 
at the time of death being at levels below both the LOD and the LOQ (expected range = 
1.9 x 10-8 – 9.2 x 10-4 mg/L).  An autopsy was conducted 16 hours after death, and 
inferior vena cava (IVC) blood was submitted for toxicological analyses.  Alprazolam 
was detected in the IVC BL but at a concentration below the LOQ (0.01 mg/L).  The PM 
blood concentration was below that of the AM, indicating that metabolism did occur.  
However the fact that alprazolam was detected in the PM sample, suggests that its 
concentration greatly exceeded the expected concentration range.   
 The decedent in Alp 12 intentionally overdosed on his alprazolam prescription 
and phoned family members to make them aware.  He was transported by emergency 
services to the hospital, treated and survived.  However, he remained an inpatient for 
approximately 3.5 weeks.  The patient exhibited anxious and aggressive behavior and as 
a result was prescribed 0.5 mg tablets of alprazolam twice daily and an additional 1 mg 
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tablet at bed time.  On the date of his death, he phoned family members to inform them 
that he had taken 40 alprazolam tablets, while still an in-patient. He was treated, but 
ultimately died approximately 2.5 hours later.   
 The AM blood submitted for analysis was dated the day of his hospital admission 
(approximately 3.5 weeks before death).  This sample had a concentration of 0.9 mg/L, 
which would be indicative of an overdose.  However, he was treated and stabilized after 
this blood draw.  Any AM blood samples that may have been collected during the 
terminal event were not submitted with the original AM sample to the MDME 
Department.  Thirty-six hours after death, aorta and iliac vein blood samples were 
collected.  Upon analysis, the aorta blood concentration was 0.30 mg/L, while the iliac 
blood was almost half that at 0.17 mg/L.  Since the AM sample analyzed did not correlate 
with the terminal event, its concentration cannot be further considered.  However, when 
examining the postmortem samples, the AOBL:ILBL ratio equaled 1.8.  Additionally, the 
aorta and iliac vein blood sample concentrations were determined to be statistically dis-
similar.  In the absence of the appropriate AM sample, it cannot be determined if PMR 
was a factor for this case.  In all likelihood, a relevant AM sample would have been 
collected during the absorptive phase.  As a result any discrepancy between AM and PM 
concentrations could have been a result of incomplete distribution, as opposed to PMR.      
 The alprazolam cases discussed in the second half of this section bring to light 
some important considerations.  When AM samples are collected more than two 
elimination half-lives before death, it becomes increasingly important to have accurate 
and reliable records (including both social and medical histories), which include a 
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timeline leading up to the terminal event.  Increased time intervals may, at times, equate 
to increased confounding circumstances, as was the case in Alp 12.   
  Alprazolam 12 was an example of how important it is to view all of the 
information as a whole.  If the AM sample had been the only sample tested, then the 
cause of death would have been due to drug toxicity.  While ultimately, that would have 
been accurate, that particular AM sample was not directly related to the actual terminal 
event.  Had the decedent not overdosed the second time and died from causes unrelated to 
alprazolam, the cause of death would have been inaccurately assigned.  This is why social 
and medical histories, in combination with toxicological findings can all impact the death 
investigative process. 
 Alprazolam cases 08, 10 and 13 were useful as well.  Alprazolam 08 and 10 were 
examples of how a drug can be present and not have an influence on the cause of death.  
In contrast, in cases of overdose the overwhelming presence of a drug may hinder the 
body’s ability to eliminate the drug.  Alprazolam 13 is an example of the fact that a 
person can live for three days after an overdose and still maintain a level of drug that 
exceeds therapeutic levels.  In their entirety, the alprazolam cases show that depending on 
any one factor (or piece of information) to determine the cause of death can lead to 
inaccuracies.  Therefore it is important to consider all the facts before drawing any formal 
conclusions. 
 Finally, it was also important to combine the two alprazolam sections and 
examine the intra-case dynamics.  The relationship between central and peripheral 
results, as well as how well peripheral concentrations compare to their expected 
concentration ranges was examined.  Of the fourteen cases discussed, ten were submitted 
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with both central and peripheral sourced blood (Chart 8).  Out of those ten cases, six had 
quantifiable postmortem results.  Through statistical analyses, it was determined that in 
83% of the cases no significant difference existed between the two sources.  Although 
peripheral blood is the preferred source for postmortem analyses, this data suggested that 
in the majority of instances no measurable difference existed between the two anatomical 
locations.  The peripheral data was further evaluated in Chart 9. In order to better 
interpret the meaning of the postmortem results, each case that had quantifiable AM 
values was subjected to Equation 7 to determine the expected concentration range at the 
time of death.  This range was an important factor used throughout the chapter to help 
determine which cases were affected by PMR.  In Chart 9 the peripheral results were 
compared to the expected concentration ranges for each case.  The symbol “[” was used 
to denote the concentration range.  At times, the rounded results of the upper and lower 
ends of the range were equal.  For those cases the symbol “-” was used.  Alprazolam case 
03 had quantifiable amounts of the drug in the AM sample (0.01 mg/L); however it was 
not detected in the PM sample.  Consequently, the case was represented with the 
expected range symbol “[”, despite the absence of a peripheral result.  In 50% of the 
alprazolam cases, the peripheral blood concentrations were higher than what would have 
been expected at the time of death.  Twenty-five percent of the data was below the 
expected range, and the remaining 25% was within range.  The data produced here 
seemed to indicate that it would not be likely that PM peripheral blood results would 
accurately reflect the blood drug concentration of a person around the time of death.   
 Furthermore, when reviewing all 14 cases, regardless of anatomical location, only 
21% of them had data consistent with PMR.  Fifty percent of the cases showed a lack of 
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Chart 8: Alprazolam Central versus Peripheral Data 
Error rate = 19% 
0
0.1
0.2
0.3
0.4
0.5
0.6
Alp 02 Alp 14 Alp 11 Alp 04 Alp 08 Alp 13
Central Peripheral
 137 
 
Chart 9: Peripheral Alprazolam Results 
Error rate = 19% 
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PMR, while the remaining 29% could not be definitively qualified either way.  The 
collected data seemed to indicate that PMR was not an overwhelming factor for 
alprazolam.  This was consistent with the apparent volume of distribution of the drug (0.9 
– 1.3 L/kg), which suggested the potential for redistribution, but not necessarily a 
propensity for it.   
 
6.3.2 Diazepam 
 Diazepam (Valium®), introduced in the 1960’s, is a long-acting benzodiazepine.  
Its ability to treat anxiety, muscle spasms and alcohol withdrawal symptoms, help to 
make it one of the most popular benzodiazepines prescribed.  Acceptable therapeutic 
doses can vary from 2 to 40 mg daily (79).  This section will evaluate diazepam and its 
demethylated metabolite nordiazepam.  Elimination half-lives for diazepam and 
nordiazepam range from 21 – 37 hours and 50 – 99 hours, respectively (79).  The 
apparent volume of distribution (Vd) for diazepam ranges between 0.7 – 2.6 L/kg (79).  
Typically a Vd above 1.0 L/kg can be indicative of postmortem redistribution and it is 
possible that diazepam may exhibit some redistributive tendencies.  The cases presented 
here all had antemortem blood collected within one elimination half-life before death.  
The data is displayed in Table 24.   
Miami-Dade County Medical Examiner Department’s Toxicology laboratory 
conducted nordiazepam and diazepam quantitative testing on a Perkin Elmer HPLC/DAD 
(section 4.2.2 (b)).  While none of the postmortem results were taken from this 
instrument, due to a finite amount of antemortem sample submitted, some of the cases 
discussed here did not have sufficient volume for retesting for the purposes of this 
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project.  As a result, the AM data collected as part of routine laboratory work was 
included in this section. 
Postmortem analysis of nordiazepam and diazepam however, for the purposes of 
this project, were conducted solely on Thermo-Finnigan’s LCQ Advantage 
HPLC/MS/MS system.  In an effort to show that the results obtained from the two 
methods would not significantly differ from each other a two-way ANOVA (95% 
confidence limit) was conducted on the control data collected from both instruments.  
The nordiazepam ANOVA results (Table 22) which compared the two instruments gave 
an F-test result of 3.77 and an Fcrit of 4.35.  Additionally, Table 23 displays the diazepam 
ANOVA results in which the F-test and Fcrit values for comparing the two instruments 
were 1.63 and 4.35, respectively.  Both nordiazepam and diazepam had F-test values less 
than their Fcrit values.  Therefore, ANOVA determined that no significant difference 
existed between the two systems.  Additionally, the amounts of day to day variability, as 
well as the interaction between the sources of variation, were not considered significantly 
different.   
Since it was proven that the data obtained on both instruments were comparable, 
the intra-nordiazepam data as well as the intra-diazepam data were each treated as one 
population.  When using Equation 5 the CV for nordiazepam and diazepam was 14% and 
and 17%, respectively.  For each drug, any concentrations that fell within the ± CV range 
were considered similar.  Any concentration that exceeded the limits of the range was 
considered statistically different.     
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Table 22: Two-Way Analysis of Variation for Nordiazepam Comparison of 
HPLC/MS/MS to HPLC/UV Control Data 
 
Source of Variation Sum of Squares df Mean Square F-test Value F crit 
Day to Day 0.043 9 0.005 0.42 2.39 
LC/MS vs. LC/UV 0.044 1 0.044 3.77 4.35 
Interaction 0.072 9 0.008 0.69 2.39 
 
 
 
Table 23: Two-Way Analysis of Variation for Diazepam Comparison of 
HPLC/MS/MS to HPLC/UV Control Data 
 
Source of Variation Sum of Squares df Mean Square F-test value F crit 
Day to Day 0.13 9 0.01 0.83 2.39 
LC/MS vs. LC/UV 0.03 1 0.03 1.63 4.35 
Interaction 0.14 9 0.07 0.85 2.39 
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The antemortem blood for diazepam (DZM) case 06 was collected 1.5 hours 
before death.  Nordiazepam and diazepam were detected at concentrations of 0.01 mg/L 
each.  The expected concentration range at the time of death for nordiazepam was 0.01 – 
0.01 mg/L (raw data: 0.0098 – 0.0099 mg/L), while diazepam’s was 0.01 – 0.01 mg/L 
(raw data: 0.0095 – 0.0097 mg/L).  Upon autopsy, heart and iliac vein bloods were 
submitted.  Heart blood had concentrations of 0.03 mg/L for nordiazepam and 0.02 mg/L 
for diazepam.  The iliac vein sample had concentrations of 0.02 mg/L and 0.02 mg/L for 
both nordiazepam and diazepam, respectively (Table 24).  Both postmortem blood 
samples had concentrations of nordiazepam and diazepam that were at least twice the 
amount detected in the antemortem sample.  As a result, the heart blood:AM ratios 
equaled 3.0 and 2.0 for nordiazepam and diazepam, respectively.  The iliac vein 
blood:AM ratios each equaled 2.0 for nordiazepam and diazepam.  Additionally, the 
central to peripheral ratio equaled 1.5 for nordiazepam and 1.0 for diazepam.  Even 
though the PMI was only 6.5 hours, based on the ratio data and the increased PM 
concentrations, it would appear that PMR did occur.   
In addition, the concentration of nordiazepam in DZM 06 was higher in the HTBL 
than the ILBL.  However, statistical analyses determined that the concentrations were not 
significantly different.  The acceptable range of variability for nordiazepam in the HTBL 
sample was 0.02 – 0.03 mg/L, while its range in the ILBL sample was 0.02 – 0.02 mg/L 
(raw data 0.017 – 0.023 mg/L).  Since the ranges overlapped, the data had to be 
considered similar.   
Antemortem blood for DZM 07 was collected 1.5 hours before death.  The blood 
had a concentration of 0.01 mg/L for both nordiazepam and diazepam.  Heart and iliac 
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vein bloods were submitted for PM analysis.  The heart blood had 0.01 mg/L of 
nordiazepam, as well as 0.01 mg/L of diazepam.  The iliac vein blood had concentrations 
of 0.01 mg/L for both nordiazepam and diazepam.  As a result, all PM:AM ratios equaled 
1.0, as did the C:P ratios. 
The blood samples (AM and PM) for DZM 07 were all analyzed on the same day 
on the LC/MS instrument.  Since the results obtained were all quantitatively equal, there 
were no statistical differences among the values.  Even though all of the calculated ratios 
equaled 1.0, the lack of distinctly different data made it not possible to identify the 
presence of PMR.   
Antemortem blood for DZM 05 was collected 4.5 hours before death.  The AM 
sample had 0.29 mg/L of nordiazepam and 0.38 mg/L of diazepam.  The expected 
concentration ranges for nordiazepam and diazepam were 0.27 – 0.28 mg/L and 0.33 – 
0.35 mg/L, respectively.  Mixed heart and iliac vein bloods were submitted for PM 
analysis.  The mixed heart sample had 0.14 mg/L of nordiazepam and 0.09 mg/L of 
diazepam.  The iliac vein blood sample had nordiazepam and diazepam concentrations of 
0.07 mg/L and 0.04 mg/L, respectively.  The PM concentrations were below the expected 
concentration range.  Nordiazepam had PM: AM ratios of 0.48 and 0.24 for the MXHT 
blood and ILBL samples, respectively.  Diazepam had PM:AM ratios of 0.24 and 0.10 for 
MXHT blood and ILBL, respectively.  However, the C:P ratios were 2.0 and 2.2 for 
MXHT and ILBL, respectively.   
 The AM sample for DZM 05 was analyzed by HLPC/DAD two years prior to the 
PM analysis by LC/MS.  Unfortunately, there was not sufficient quantity of AM sample 
to submit for re-analysis.  As a result, it is likely that during this two year time period the 
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PM drug concentrations degraded.  Therefore, the comparison of the PM:AM results are 
probably skewed.  However, both PM samples were stored under the same conditions for 
that two year period.  Consequently, the degradation of those two samples should have 
occurred in a similar fashion.  While it cannot be determined for sure that PMR occurred, 
at the very least the PM results demonstrated that before collection from the body, the 
mixed heart sample was exposed to more contamination than the iliac vein sample. 
Antemortem blood for DZM 04 was collected five hours before death.  Diazepam 
was identified but at levels below the LOQ (0.01 mg/L by HPLC/MS).  Following 
autopsy (PMI = 31 hours), postmortem heart and iliac vein bloods were submitted for 
analyses.  Diazepam was also detected in the heart blood, but at concentrations below the 
LOQ.  The iliac vein sample had 0.01 mg/L of diazepam.  While the concentrations 
detected in these samples were low, it would appear that some amount of PMR was 
present in the periphery.   
The antemortem blood for DZM 01 had 0.42 mg/L of nordiazepam and 0.02 mg/L of 
diazepam.  There were 15 hours between AM collection and death.  As a result, the 
expected concentration ranges at the time of death for nordiazepam would have been 
0.34– 0.37 mg/L, while diazepam would have been 0.01 – 0.02 mg/L.  Upon autopsy, 
heart and iliac vein bloods were submitted for analyses.  The heart blood sample had 0.19 
mg/L of nordiazepam and 0.02 mg/L of diazepam.  The iliac vein blood had 0.17 mg/L of 
nordiazepam and 0.02 mg/L of diazepam.  The PM nordiazepam concentrations 
decreased more rapidly than predicted by the calculated results.  The resulting PM:AM 
ratios for nordiazepam were 0.45 and 0.40 for heart blood and iliac vein blood samples, 
respectively.  None of the data produced by nordiazepam was reflective of PMR.    
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Table 24: Diazepam and Nordiazepam antemortem samples collected within one elimination half-life 
Diazepam t1/2 = 27-37 hours Vd = 0.7 – 2.6 L/kg 
Nordiazepam t1/2 = 50-99 hours 
CV= ± 14% 
AM-
Death Case # 
Source  
(Whole blood) 
Concentration 
(mg/L) 
AM 
Concentration 
(mg/L) 
Analyte PM: AM C: P PMI (hours) Race/Sex Age 
1.5 
hours DZM 06 
Heart 0.03 nordiaz 0.02 diaz 0.01 nordiaz1 
0.01 diaz1 
Nordiaz 
Diaz 
3.0 
2.0 1.5 
1.0 6.5 WM 50 Iliac 0.02 nordiaz 0.02 diaz 
2.0 
2.0 
1.5 
hours DZM 07 
Heart 0.01 nordiaz 0.01 diaz 0.01nordiaz1 
0.01 diaz1 
Nordiaz 
Diaz 
1.0 
1.0 1.0 
1.0 24 WM 25 Iliac 0.01 nordiaz 0.01 diaz 
1.0 
1.0 
4.5 
hours DZM 05 
Mixed Heart 0.14 nordiaz, 0.09 diaz 0.29 nordiaz2 
0.38 diaz2 
Nordiaz 
Diaz 
0.48 
0.24 
2.0 
2.2 19 WF 51 Iliac 0.07 nordiaz, 0.04 diaz 
5 
hours DZM 04 
Heart NDD nordiaz <LOQ diaz NDD nordiaz1 
<LOQ diaz1 
Nordiaz 
Diaz 
- 
- - 
- 31 WM 50 Iliac NDD nordiaz 0.01 diaz 
- 
- 
15 
hours DZM 01 
Heart 0.19 nordiaz 0.02 diaz 0.42 nordiaz1 
0.02 diaz1 
Nordiaz 
Diaz 
0.45 
1.0 1.1 
1.0 63 WF 53 Iliac 0.17 nordiaz 0.02 diaz 
0.40 
1.0 
48 
hours DZM 03 Iliac 0.55 nordiaz 0.16 nordiaz
1 Nordiaz 3.4 - 26 WF 46 
66 
hours DZM 02 
Heart 0.04 nordiaz, 0.02 diaz 0.02 nordiaz1 
0.01 diaz1 
Nordiaz 
Diaz 
2.0 
2.0 2.0 
1.0 24 BM 55 Iliac 0.02 nordiaz, 0.02 diaz 
2.0 
2.0 
 1LC/MS/MS analysis (linear range 0.01 – 1.0 mg/L)      2LC/UV analysis (linear range 0.1 – 10 mg/L) 
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 The diazepam data for DZM 01 had PM concentrations just within the upper limit 
of the expected range.  The PM:AM ratios for diazepam were 1.0 and 1.0 for heart blood 
and iliac vein bloods, respectively.  While it is believed that ratios with values ≥ 1.0 can 
exhibit PMR, the cumulative diazepam data did not suggest PMR was a factor.  What is 
of particular interest in this case was that both the central and peripheral source blood 
samples returned concentration data that were similar to each other.  This would indicate 
that the overall change in drug concentration in the body progressed consistently and in 
the same direction, regardless of the anatomical collection site.  This was further 
reinforced by the C:P ratios of nordiazepam and diazepam equaling 1.1 and 1.0, 
respectively.     
 Diazepam case 03 had AM blood collected 48 hours before death.  The sample 
had 0.16 mg/L of nordiazepam, however diazepam was not detected.  While the AMD 
interval seemed long, it was actually less than the elimination half-life range for 
nordiazepam (50- 99 hours).  Postmortem iliac vein blood was submitted in a gray-top 
tube and had a nordiazepam concentration of 0.55 mg/L.  Diazepam was not detected in 
the PM sample.  The expected concentration of nordiazepam at the time of death would 
have been between 0.08 – 0.11 mg/L.  The PM concentration well exceeded this range, 
resulting in a PM:AM ratio of 3.4.  The data produced by the ILBL would suggest that 
PMR occurred during the 26 hour PMI. 
 Antemortem blood for DZM 02 was collected 66 hours before death.  Analysis of 
the AM blood sample determined that 0.02 mg/L of nordiazepam and 0.01 mg/L of 
diazepam were present.  The expected concentration range for nordiazepam was between 
0.01 – 0.01 mg/L, while the expected range for diazepam was below the LOQ.  Heart and 
 146 
 
iliac vein bloods were submitted for postmortem analysis.  The heart blood sample had 
0.04 mg/L of nordiazepam and 0.02 mg/L of diazepam.  The ILBL sample had 0.02 mg/L 
of both nordiazepam and diazepam.  The PM:AM ratios for both sources and both drugs 
equaled 2.0 each.  The HTBL concentration for nordiazepam was twice that of the ILBL 
concentration (C:P = 2.0).  However, diazepam was equal in both sources (C:P = 1.0).  
The PM data collected for DZM 02 exceeded the expected concentration ranges for both 
nordiazepam and diazepam.  Additionally, the ratio data in its entirety returned values 
that were ≥ 1.0.  The data as a whole supports the idea that PMR occurred for both 
diazepam and nordiazepam.       
The discrepancies between the AM and PM data seen in DZM 05 were likely due 
to the time elapse between AM and PM testing.  In any situation, it would be optimal to 
analyze all the relevant samples for one case within the first few months of collection.  
However, that did not occur here.  Diazepam 05 was still included in this project because 
it is a reflection of a real world scenario.  It is not entirely uncommon for toxicology 
testing requests to be submitted over a year after a sample has been collected.  In these 
situations, the MDME laboratory complies with the request and will conduct the testing.  
However, as demonstrated in this case, the analytical results obtained may not be an 
accurate reflection of the drug concentrations present at the time of sample collection.    
Postmortem redistribution was believed to be a factor in diazepam cases 06, 03 
and 02.  All three had PM concentrations at least twice that of their respective AM 
concentrations, which resulted in PM:AM ratios ≥ 2.0.  However, their antemortem to 
death intervals ranged between 1.5 to 66 hours and their postmortem intervals ranged 
from 6.5– 63hours.  The large range of the intervals made it difficult to identify a clear 
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trend for what factors may contribute to PMR of cases containing diazepam and 
nordiazepam.  It was interesting among these cases that the overall change in 
concentrations between the two drugs, typically moved in parallel to each other.  This is 
in contradiction to the data produced in the morphine codeine (MOC) cases.  The MOC 
data showed that cases which contained both morphine and codeine could have opposing 
shifts in concentration, meaning that one drug could decrease in concentration, while the 
other increased.  In diazepam and nordiazepam cases, if one drug increased in 
concentration, then they both did.   
The cumulative diazepam data identified many issues of interest.  Firstly, six out 
of the seven cases analyzed were collected with both central and peripheral sourced 
postmortem specimens (Chart 10).  In 83% of those cases, the intra-case diazepam data 
had concentrations that were statistically similar regardless of the source of anatomic 
collection.  Likewise, nordiazepam had 67% of its intra-case data return statistically 
similar results regardless of collection site.  In the majority of cases researched, the 
quantitative results would appear to be similar regardless of the PM specimen analyzed.  
As previously mentioned, the time intervals (AMD and PM) were too broad to 
definitively identify the reason(s) for concentration discrepancies.  While in most 
instances specimen choice would not matter, for the few instances in which it would, it 
would be best to use peripheral blood for all quantitative analyses.  In addition, also 
displayed on Chart 10 is DZM 04.  Since the AM concentration was below the LOQ, an 
expected range could not be calculated.  However, it would be expected that the PM 
results would not exceed the AM.  The peripheral source had a quantifiable level and that 
level was included in the chart.  
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Chart 10: Diazepam and Nordiazepam Central versus Peripheral Data 
Error rate: 14% Diazepam, 17% Nordiazepam 
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Chart 11: Diazepam and Nordiazepam Peripheral Data 
Error rate: 14% Diazepam, 17% Nordiazepam 
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Chart 11 examined the diazepam and nordiazepam peripheral sourced data only.  
The results of the peripheral data were compared to the calculated expected concentration 
ranges for each case.  The expected ranges are denoted with the symbol “[” for diazepam 
and “]” for nordiazepam.  In some instances the rounded concentrations for the upper and 
lower levels of the range were equal.  For those cases, the symbol “-” was used for either 
drug. The data in Chart 11 shows that 50% of the diazepam PM results were above their 
expected concentration range, while 17% was below.  The remaining 33% of the cases 
produced PM data that was within the expected concentration range at the time of death.  
Similarly to the diazepam data, the nordiazepam results had 50% of its PM data above the 
expected concentration range.  In addition, 33% were below the expected range and 17% 
were within range.  Based on these results, PM quantitative results for both diazepam and 
nordiazepam are not likely to be reflective of the drug concentration present in the system 
at the time of death.  To the contrary, it would appear as though peripheral blood data for 
both drugs are more likely to return results with elevated concentrations.  
   
6.3.3 Midazolam 
 Midazolam is a short-acting benzodiazepine derivative often sold under the trade 
name Versed®.  The injection of midazolam into the body is known to rapidly induce 
sedation.  As a result, in the United States, it is often administered by hospitals just prior 
to surgery.  In addition, midazolam (along with other benzodiazepines) triggers smooth 
muscle relaxation.  Consequently, it is often given by paramedics just prior to tracheal 
intubation of a distressed person.  In this situation, the use of midazolam relaxes the 
gastrointestinal tract muscles, thereby helping to prevent aspiration during intubation 
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(80).  According to Baselt (81), midazolam has an elimination half-life of 1 – 4 hours and 
an apparent volume of distribution of 1.0 – 2.5 L/kg.   
 For this study, midazolam was quantitated using only Thermo Finnigan’s LCQ 
Advantage HPLC/MS/MS system.  While midazolam can be qualitatively identified 
during the process of routine laboratory work, it is a drug that is not quantitated at the 
MDME Department’s toxicology laboratory.  The reason for this is that midazolam is 
almost exclusively given in a hospital setting and generally not prescribed in the United 
States.  For that reason, its potential for abuse is extremely low.  However, since one of 
the criteria for this study was the need of antemortem blood (which could only be drawn 
in a hospital setting) midazolam was one of the most commonly encountered drugs in the 
project.  As a result, the researcher decided to collect quantitative data (linear range 0.01 
– 1.0 mg/L).  Only one control lot, and one instrument, was used during the analysis 
process.  Therefore, ANOVA processing was not needed.  However, the CV of the 
population was determined to be 18% (Table 25).  All drug concentrations that fell within 
a ± 18% range were determined to be statistically similar.  The cases presented can be 
found in Table 26, listed in order of increasing antemortem to death interval.    
 
Table 25: Midazolam Control Data (0.1 mg/L) Statistics 
 
  Concentration Mean 0.145571 mg/L 
Standard Deviation 0.026144 
CV ± 18% 
 
 
 Midazolam (MDZ) 01 had antemortem blood collected 16 minutes before death.  
The AM sample had a midazolam concentration of 0.29 mg/L.  The expected 
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concentration at the time of death would have ranged between 0.24 – 0.28 mg/L.  Upon 
autopsy, heart and iliac vein blood samples were collected and submitted for analyses 
(PMI = 26 hours).  The heart blood sample had a concentration of 0.05 mg/L, while the 
iliac vein blood had 0.06 mg/L of midazolam.  The PM to AM ratio equaled 0.16 for the 
HTBL and 0.20 for the ILBL.  Additionally, the central to peripheral ratio equaled 0.79.  
When examining the quantitative data, it was apparent that the ILBL concentration was 
higher than the HTBL concentration.  This would lead one to believe that in the case of 
PMR, the peripheral blood was more greatly affected.  However, statistical analysis 
determined that the HTBL and ILBL concentrations were, in fact, similar.  The 
concentration effects were similar regardless of anatomical collection site.   
The overall data produced in MDZ 01 reflected a lack of PMR.  This was further 
demonstrated by the ratio data, in which all ratios had values < 1.0.  Additionally, the PM 
concentrations were not only less than the AM concentration, but they were significantly 
below the expected concentration range at the time of death.  
The antemortem blood for MDZ 04 was collected two hours before death and had 
0.16 mg/L of midazolam present.  The expected drug concentration at the time of death 
ranged between 0.04 to 0.11 mg/L.  Heart and iliac vein blood samples were collected at 
autopsy.  Postmortem blood concentrations equaled 0.02 mg/L and 0.01 mg/L for heart 
and iliac vein samples, respectively.  The central to peripheral ratio equaled 1.6, while the 
HTBL:AM and ILBL:AM ratios equaled 0.14 and 0.09, respectively.  The C:P ratio 
results were indicative of PMR, however both PM: AM ratios combated this.  The 
researcher determined that since the PM concentrations obtained were significantly less 
than expected, PMR did not occur during the 23 hour PMI.    
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Table 26: Midazolam Cases listed in order of increasing AM to death intervals  
t1/2 = 1 - 4 hours 
 Vd = 1.0 – 2.5 L/kg 
Linear range: 0.01 – 1.0 mg/L 
CV = ± 18% 
 
AM-
Death Case # 
Source  
(Whole Blood) 
Concentration 
(mg/L) 
AM 
Concentration 
(mg/L) 
Analyte PM: AM C: P PMI (hours) Race/Sex Age 
16 min MDZ 01 
Heart 0.05 0.29 AMBL 0.16 0.79 26 BF 44 Iliac 0.06 0.20 
2 hrs MDZ 04 
Heart 0.02 0.16 AMBL 0.14 1.6 23 BM 37 Iliac 0.01 0.09 
3.5 hrs MDZ 08 
Mixed <LOQ 0.02 AMBL - - 17 WF 50 Iliac <LOQ - 
6 hrs MDZ 03 
Mixed <LOQ 0.01 AMBL - - 10 BM 25 Aorta <LOQ - 
6.5 hrs MDZ 07 
Aorta <LOQ 0.01 AMBL - - 33.5 BM 38 Iliac <LOQ - 
30 hrs MDZ 06 
Mixed <LOQ 0.06 AMBL 1.0 - 37 WM 39 Aorta <LOQ 1.0 
2 days MDZ 02 Heart* <LOQ 0.06 AMBL - - 32 WM 83 
unknown MDZ 05 Aorta 0.32 0.05 AMBL 6.4 - 43 WM 29 
 
 
 
 
 
 
* Average concentration 
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Antemortem blood from MDZ 08 was collected 3.5 hours before death and had a 
concentration of 0.02 mg/L.  The expected concentration range at the time of death was 
between 1.8 x 10-3 – 0.01 mg/L.  A mixed blood sample, as well as an iliac vein blood 
sample was submitted for PM analyses.  Both PM samples had blood concentrations less 
than the LOQ.  This was consistent with the calculated expected concentration range, as 
only the upper range value was within the LOQ and it was determined that PMR was not 
present in this case.    
 Antemortem blood for MDZ 03 had a concentration of 0.01 mg/L.  Since the 
AMBL was collected 6 hours before death, it had an expected concentration range of 3.8 
x 10-8 – 4.4 x 10-4 mg/L, well below the LOD (0.002 mg/L).  Mixed and aorta bloods 
were submitted post autopsy.  Midazolam was detected in both samples, but at levels 
below the LOQ.  The fact that midazolam was detected, indicated that the concentration 
was higher than the calculated expected range.  However, the PM concentrations were 
still below the AM concentration.  As a result, it was determined that PMR was not a 
factor.   
A concentration of 0.01 mg/L was detected in the AM blood collected 6.5 hours 
before death in midazolam case 07.  The low AM concentration in combination with the 
amount of time that passed during the antemortem to death interval caused the expected 
concentration range at the time of death (1.1 x 10-4 – 3.2 x 10-3 mg/L) to be below the 
LOD.  Aorta and iliac vein bloods were analyzed and returned concentrations below the 
LOQ.  Therefore PMR did not occur.      
 In midazolam 06, the AM blood was collected 30 hours before death and had an 
AM concentration of 0.06 mg/L.  If no additional midazolam was administered during the 
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AMD interval, the expected concentration range at the time of death would have been 
between 5.6 x 10-11 – 3.3 x 10-4 mg/L.  There was a 37 hour PMI in this case.  After 
which, mixed and aorta bloods were collected and submitted for testing.  Both PM 
specimens had blood drug concentrations that were less than the limit of quantitation.  
This was consistent with the expected concentration range.     
 Antemortem blood for MDZ 02 had a concentration of 0.06 mg/L and was 
collected 2 days before death.  The expected midazolam concentration at the time of 
death was between 5.6 x 10-11 – 3.5 x 10-4 mg/L.   Analysis of the heart blood sample 
submitted post autopsy was positive for midazolam, however at a level below that of 
quantitation.  The expected concentration range was below the LOD.  While it would 
appear that the PM concentration was higher than expected, it was still at least 6 times 
below that of the AM sample.  As a result, it was determined that PMR did not occur.   
 The AM blood for midazolam 05 was submitted with only a collection time on it, 
not a date.  Upon checking the hospital records, the decedent was a patient there for 
approximately 48 hours.  Based on the time written on the tube, the AM sample was 
either collected 32 hours or 8 hours before death.  Since the exact date of collection 
cannot be resolved, an expected concentration range was not calculated.  The AM sample 
however, did have a midazolam concentration of 0.05 mg/L.  As a result, it would be 
expected that the PM concentrations would be below this value.  Aorta blood was 
submitted in both the red-top and gray-top blood collection tubes post autopsy.  The 
midazolam concentration was 0.31 mg/L and 0.34 mg/L for red-top and gray-top tubes, 
respectively.  Since the tubes were of the same anatomical source and the concentrations 
were statistically similar, the overall midazolam concentration was averaged to 
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0.32mg/L.  The increased PM concentration (relative to the AM concentration) resulted 
in a PM:AM ratio of 6.4.  A review of the medical records only indicated one 
administration of midazolam.  Therefore, the increase in the postmortem sample cannot 
be explained by re-administration.  In the absence of any contradictory information, it 
would appear as though PMR occurred during the 43 hour PMI.  If so, this would be the 
only midazolam case researched that exhibited this phenomena. 
      Although the apparent volume of distribution for midazolam (1.0 – 2.5 L/kg) does 
suggest that the drug could have some redistributive effects, with the exception of MDZ 
05, the data collected indicated otherwise. Eighty-eight percent of the cases examined 
showed no signs of PMR.  Although there were a few instances where the PM 
concentrations were higher than their expected calculated ranges (MDZ 08, 03, 07 and 
02), those concentrations were still below their respective antemortem concentrations.  
Only MDZ 05 had a PM concentration that exceeded its AM level.  The uncertainty of 
the actual AMD interval for that case makes it difficult to compare to the others.  Its PMI, 
however, was noted as being 43 hours, which would make it the longest PMI examined.  
If the true AMD interval equaled eight hours (as opposed to 32 hours) then this case 
would have a relatively short AMD coupled with a long PMI.  This was a combination 
believed to influence PMR of alprazolam.  Further studies of midazolam cases would be 
needed before any formal conclusions could be drawn. 
Additionally, midazolam cases 01 (PMI = 26 hours) and 13 (PMI = 23 hours) 
were the only two case that returned quantifiable data for both central and peripheral 
sourced samples.  In MDZ 01, the concentrations of midazolam obtained in both sources 
were statistically similar to each other, indicating that concentration changes between the 
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two regions of the body were not significantly different.  In that case, however, the AMD 
interval was only 16 minutes.  In MDZ 04, the AMD interval was slightly more 
pronounced at two hours.  The PM results obtained in that case did indicate statistically 
different results depending on the anatomical region of collection.  As would be expected 
based on conventional theory, the central sourced blood had a higher amount of 
midazolam (two times greater) than the peripheral blood.  While neither case rendered 
results indicative of PMR, the two cases did show that under certain circumstances, PM 
concentrations may still have a tendency to differ in concentration based on anatomical 
location. 
Sixty-three percent of the PM data collected was qualitative.  Since this research 
was primarily based on quantitative data, the usefulness of qualitative data may not be 
readily apparent.  In the instance of midazolam, PM data that was below the limit of 
quantitation, although within the limit of detection was reflective of an overall decrease 
in midazolam blood concentrations after antemortem sample collection.   Based on the 
results of this study, generally midazolam did not appear to store itself within the tissues 
of the body.  This was primarily of interest because the range of the apparent volume of 
distribution suggested otherwise. 
 
6.3.4 Clonazepam and 7-aminoclonazepam 
 Clonazepam is a long acting nitrobenzodiazepine (t1/2 = 19 – 60 hours) (61) often 
used to treat epilepsy, anxiety and sleep disorders.  7-aminoclonazepam is the 
pharmacologically inactive major metabolite of clonazepam, which is produced by a 
reduction reaction (62).  Nitrobenzodiazepines (including clonazepam) have been known 
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to reduce to their 7-amino analogs in storage, even when preserved (21)(33)(63).  This 
fact makes the interpretation of these drugs more difficult than other benzodiazepines 
discussed in this manuscript.  The elimination half-life of 7-aminoclonazepam could not 
be found in the literature prior to the writing of this section.  It is possible that since the 
drug is not believed to be active, its rate of elimination has not been extensively studied.   
Equation 7 was used to calculate the expected concentration range of clonazepam only, 
not 7-aminoclonazepam.  Quantitative analyses of both drugs however, were conducted 
on both the GC/ECD and HPLC/MS.  A two-way ANOVA (95% confidence) was 
conducted on the control data collected from both instruments to determine if the data 
was similar enough to be treated as one population.   
The results obtained from the two-way ANOVA indicated that the data collected 
on the two instruments were dis-similar.  This is illustrated in Table 27 (clonazepam) and 
Table 28 (7-aminoclonazepam).  The clonazepam data had an F-test value of 26.8 and an 
Fcrit of 4.3 when comparing the two instruments.  Likewise, 7-aminoclonazepam had an 
F-test value of 8.8 and an Fcrit value of 4.3.  Anytime an F-test value is greater than its 
Fcrit, the null hypothesis (that is, there is no difference between the two) is rejected, as 
was the case here.  In an effort to verify the F-test results, Tukey’s post hoc analysis was 
conducted as described in section 5.0 Calculations.  Tukey’s critical value for 
clonazepam was 0.012, with a mean difference of 0.030.  7-aminoclonazepam’s critical 
value was 0.004 and had a mean difference of 0.007.  For both clonazepam and 7-
aminoclonazepam, Tukey’s critical value was less than the mean difference, indicating 
that a difference between the instruments did in fact exist.  Therefore, it was determined 
that the ANOVA calculations were accurate.  As a result, the data produced on each  
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Table 27: Two-Way Analysis of Variation for Clonazepam Comparison of GC/ECD 
to LC/MS/MS control Data 
 
Source of 
Variation 
Sum of 
Squares df 
Mean 
Square 
F-test 
value F crit 
Tukey’s 
critical 
value 
Mean 
Difference 
Day to Day 0.001 9 0.0002 0.42 2.39   
GC/ECD 
vs. LC/MS 0.011 1 0.0107 26.86 4.35 0.012 0.030 
Interaction 0.002 9 0.0002 0.50 2.39   
 
 
 
 
Table 28: Two-Way Analysis of Variation for 7-aminoclonazepam Comparison 
GC/ECD to LC/MS/MS control Data 
 
Source of 
Variation 
Sum of 
Squares df 
Mean 
Square 
F-test 
value F crit 
Tukey’s 
critical 
value 
Mean 
Difference 
Day to Day 0.0002 9 2.34E-05 0.57 2.39   
GC/ECD vs. 
LC/MS 0.0004 1 0.0004 8.83 4.35 0.004 0.007 
Interaction 0.0009 9 0.0001 2.58 2.39   
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instrument was treated separately.  Clonazepam cases analyzed by GC/ECD had a CV of 
15%, while 7-aminoclonazepam had a CV of 17%.  The clonazepam and 7-
aminoclonazepm data collected by LC/MS had CV’s of 15% and 21%, respectively (refer 
to Table 29).   
 
Table 29: Coefficient of Variation for Clonazepam and 7-aminoclonazepam 
 
Analyte Instrument CV 
Clonazepam GC/ECD 15% 
LC/MS 15% 
7-aminoclonazepam GC/ECD 17% 
LC/MS 21% 
 
   
 The data from the clonazepam (CNP) cases used in this study can be seen in 
Table 30.  The cases are presented in order of increasing antemortem to death (AMD) 
interval.  Whenever sample quantity allowed, AM samples were re-analyzed at or around 
the same time as the PM analyses.  On occasion the sample volume was not sufficient for 
this and the concentration obtained as a part of routine analysis was used.   The results 
obtained from re-analyzed AM samples are discussed on a case-by-case basis.   
Clonazepam (CNP) case 04 had AM blood collected 10 minutes before death.  
The sample had 0.03 mg/L of clonazepam and 0.13 mg/L of 7-aminoclonazepam.  The 
expected concentration range for clonazepam at the time of death would have been 
between 0.03 – 0.03 mg/L (raw data: 0.0298 – 0.0299 mg/L).  Postmortem iliac vein 
blood was submitted in both the gray and red-top collection tubes (PMI = 28.5 hours). 
The red-top ILBL had concentrations of 0.02 mg/L and 0.15 mg/L for clonazepam and 7-
aminoclonazepam, respectively.  The gray-top ILBL had 0.02 mg/L of clonazepam and 
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0.23 mg/L of 7-aminoclonazepam.  Although the PM sources were the same, the 7-
aminoclonazepam concentrations were statistically different from each other (± 17% by 
GC/ECD).  Therefore the concentrations from both tubes could not be averaged.  The 7- 
aminoclonazepam concentration discrepancy in the PM specimens was of interest 
because as reported by Drummer (21) and Steentoft (64), 7-aminoclonazepam can be 
formed PM even in preserved blood.  It is possible that the GT ILBL had more 7-
aminoclonazepam production than the RT ILBL.   
When comparing the PM data to that of the AM, all of the concentrations, with 
the exception of the RT ILBL 7-aminoclonazepam concentration, were determined to be 
statistically dis-similar to the AM.  The PM:AM ratios for the RT ILBL were 0.67 and 
1.1 for clonazepam and 7-aminoclonazepam, respectively.  The GT ILBL had PM:AM 
ratios of 0.67 and 1.8 for clonazepam and 7-aminoclonazepam, respectively.  By 
convention, it is believed that ratio results that are greater than or equal to 1.0 are 
reflective of PMR.  Therefore, despite the discrepancy between the actual values obtained 
in the PM samples, both tubes seem to be in agreement that some amount of 
redistribution affected 7-aminoclonazepam, while none influenced clonazepam.  The fact 
that for both sources clonazepam decreased below its expected range and 7-
aminoclonazepam increased caused the researcher to determine that despite the ratio data, 
PMR did not influence either drug in this case.  Instead, the results were indicative of 
chemical conversion between the two drugs. 
The AM blood for CNP 07 was collected one hour before death and was analyzed 
as a part of routine analysis by GC/ECD.  The sample was determined to have 
concentrations of 0.03 mg/L and 0.02 mg/L for clonazepam and 7-aminoclonazepam,
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Table 30: Clonazepam antemortem samples collected within two elimination half-lives  
Clonazepam: Vd = 1.5 – 4.4 L/kg; t1/2 = 19 – 60 hours 
7-aminoclonazepam: Vd and t1/2 = unknown 
AM – 
Death 
(hours) 
Case 
# 
Source 
(whole 
blood) 
Concentration 
(mg/L) 
AM 
concentration 
(mg/L) 
Specimen PM: AM C: P PMI (hours) Race/Sex Age 
10 min CNP 041 
Iliac RT 
0.02 clonaz,  
0.15 (7amino) 0.03 clonaz 
0.13 (7amino) AMBL 
0.67 clonaz 
1.1 (7amino) - 28.5 WM 44 
Iliac GT 
0.02 clonaz,  
0.23 (7amino) 
0.67 clonaz 
1.8 (7amino) - 
1 hour CNP 072 
Heart 0.05 (7amino) 0.03 clonaz 
0.02 (7amino) AMBL 
2.5 (7amino) 0.83 
(7amino) 24 WM 25 Iliac 0.06 (7amino) 3.0 (7amino) 
1.5 
hours 
CNP 
062 
Heart 0.04 (7amino) 0.04 (7amino) AMBL 1.0 (7amino) 1.0 (7amino) 6.5 WM 50 Iliac 0.04 (7amino) 1.0 (7amino) 
6 hours CNP 021 Heart* 0.03 clonaz 0.01 clonaz AMBL 3.0 clonaz - 70.5 WF 22 
12 
hours 
CNP 
051 
Aorta 0.08 clonaz,  0.04 (7amino) <LOQ clonaz 
0.17 (7amino) AMBL 
0.23 
(7amino) 
4.0 
clonaz 
0.08 
(7amino) 
54 WM 68 
Iliac 0.02 clonaz,  0.47 (7amino) 2.8 (7amino) 
14 
hours 
CNP 
031 
Mixed NDD 0.01 clonaz AMBL - - 19 WF 49 Iliac NDD - 
15 
hours 
CNP 
082 
Heart 0.02 clonaz,  0.17 (7amino) 0.15 clonaz 
0.05 (7amino) AMBL 
0.13 clonaz 
3.4 (7amino) 
1.0 
clonaz 
1.7 
(7amino) 
63 WF 53 
Iliac 0.02 clonaz,  0.10 (7amino) 
0.13 clonaz 
2.0 (7amino) 
66 
hours 
CNP 
092 
Heart 0.04 (7amino) 0.04 (7amino) AMBL 1.0 (7amino) 1.0 (7amino) 24 BM 55 Iliac 0.04 (7amino) 1.0 (7amino) 
  1 GC/ECD (linear range: 0.01 – 0.2 mg/L) 
2 LC/MS (linear range: 0.01 – 1.0 mg/L) 
* Average concentration 
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respectively.  The expected concentration of clonazepam at the time of death would have 
been between 0.03 – 0.03 mg/L (raw data: 0.0289 – 0.0296 mg/L).  However, there was 
sufficient quantity of the AM blood sample to be re-tested for research purposes.   
Four months after the original analysis of CNP 07, AM blood as well as PM heart 
and iliac vein bloods (PMI = 24 hours) were analyzed (as part of one batch) by LC/MS.  
At that time the AM blood concentration for 7-aminoclonazepam was 0.05 mg/L, while 
clonazepam was not detected (LOD by LC/MS = 0.002 mg/L).  The heart blood sample 
had 0.05 mg/L of 7-aminoclonazepam and the iliac vein blood had 0.06 mg/L of 7-
aminoclonazepam.  The central to peripheral ratio equaled 0.83.  Clonazepam was not 
detected in either PM sample.   
In, and of itself, the absence of clonazepam in the re-test of the AM sample would 
be indicative of drug instability of the drug in the AM tube during the 4 month storage 
period.  However, the decrease of clonazepam was coupled with a 50% increase in 7- 
aminoclonazepam.  It is more likely that drug reduction in the AM sample occurred.  
Also of interest was that the PM samples rendered concentrations that were statistically 
similar to each other, as well as being similar to the re-tested AM values.  The data 
produced for this case was not indicative of PMR, rather the apparent conversion of 
clonazepam into 7-aminoclonazepam caused this concentration discrepancy.    
The AM and PM samples for CNP 06 were analyzed on the same day as part of 
one batch on the HPLC/MS system.  The AM sample had 0.04 mg/L of 7-
aminoclonazepam while clonazepam was not detected.  Since the elimination half-life for 
7-aminoclonazepam is not known, an AMD interval could not be calculated.  However, 
the AMD interval was only 1.5 hours, suggesting that the expected concentration range at 
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the time of death would not have deviated significantly from the AM.  Heart and iliac 
vein bloods were submitted post autopsy (PMI = 6 hours).  Both PM samples had 
concentrations of 0.04 mg/L for 7-aminoclonazepam.  Similarly to the AM, neither PM 
blood detected the presence of clonazepam.  The C:P ratio as well as both PM: AM ratios 
were equal to 1.0, leading one to believe that PMR occurred.  However, the short AMD 
interval combined with the short PMI (6 hours) may not have been sufficient time to 
observe a significant decrease in drug concentration.  The amount of 7-aminoclonazepam 
in the PM samples was likely within its expected concentration range at the time of death, 
suggesting a lack of PMR.   
 Antemortem blood for CNP 02 had 0.01 mg/L of clonazepam detected.  The 
sample was collected six hours before death, and had an expected concentration range of 
8.3 x 10-3 – 9.3 x 10-3 mg/L (GC/ECD limit of detection = 0.001 mg/L).  Heart blood was 
submitted in both gray and red-top collection tubes.  Both tubes rendered clonazepam 
concentrations of 0.03 mg/L.  As a result, the PM concentrations were averaged 
(0.03mg/L).  The increase of clonazepam in addition to a PM: AM ratio equaling 3.0, 
resulted in the determination that PMR occurred in this case.    
Antemortem blood for CNP 05 was collected 12 hours before death.  In this 
sample, 7-aminoclonazepam had a concentration of 0.17 mg/L and clonazepam was 
detected, but at limits below the level of quantitation for the GC/ECD (0.01 mg/L).  Aorta 
and iliac vein bloods were submitted post autopsy (PMI = 54 hours) for analyses.  Aorta 
blood had 0.08 mg/L of clonazepam and 0.04 mg/L of 7-aminoclonzepam.  The ILBL 
had 0.02 mg/L and 0.47 mg/L of clonazepam and 7-aminoclonazepam, respectively.  
Both PM samples had increased levels of clonazepam with respect to the AM sample.  
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However, for 7-aminoclonazepam, only the ILBL had a higher level than the AM blood.  
The PM:AM ratios for 7-aminocloanzepam were 0.23 and 2.8 for the AOBL and ILBL, 
respectively.  Central to peripheral ratios of clonazepam and 7-aminoclonazepam equaled 
4.0 and 0.08, respectively.   
 The samples analyzed for CNP 05 were all tested on the same day.  The PM data 
showed a clear increase in the concentration of clonazepam with respect to the AM 
sample.  This would suggest that PMR did occur for this drug.  However, other 
observations were made as well.  The AOBL returned results that showed an increase in 
clonazepam and a decrease in 7-aminoclonazepam.  So while clonazepam was affected 
by PMR during the 54 hour PMI, 7-aminoclonazepam levels were reduced as a result of 
metabolism (AMD interval = 12 hours).  Conversely, there was an increase in both 
clonazepam and 7-aminoclonzepam concentrations in the iliac vein.  This was indicative 
of PMR influencing both drugs.   
 The antemortem blood for CNP 03 was collected fourteen hours before death.  
Clonazepam was detected at a concentration of 0.01 mg/L, while 7-aminoclonazepam 
was not detected.  The expected clonazepam concentration range at the time of death 
would have been between 0.01 – 0.01 mg/L (raw data: 0.006 – 0.008 mg/L).  Postmortem 
mixed and iliac vein bloods were submitted as well (PMI = 19 hours).  Neither PM 
sample had detectable levels of clonazepam or 7-aminoclonazepam (LC/MS LOD = 
0.002 mg/L).  This would suggest that during the AMD interval clonazepam was 
effectively eliminated from the body.  As a result, PMR was not a factor for this case.   
 The original analysis of the AM blood for CNP 08 had 0.15 mg/L of clonazepam 
and 0.05 mg/L of 7-aminoclonazepam detected (AMD interval = 15 hours).  The sample 
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was re-tested four months later in a batch which included the cases postmortem (HTBL 
and ILBL) specimens.  The reanalyzed AM blood saw a decrease in clonazepam (0.09 
mg/L) and an increase in 7-aminoclonazepam (0.17 mg/L), which is likely indicative of 
clonazepam reduction reaction.  When using the data from the re-analysis the expected 
clonazepam concentration at the time of death ranged between 0.05 – 0.07 mg/L.  The 
heart blood sample had 0.02 mg/L of clonazepam and 0.17 mg/L of 7-aminoclonazepam.  
The iliac vein blood had 0.02 mg/L of clonazepam and 0.10 mg/L of 7-aminoclonazepam 
(PMI = 63 hours).  The PM:AM ratios for clonazepam were 0.22 for both the HTBL and 
ILBL samples, with a C:P ratio of 1.0.  While the PM:AM ratios for 7-aminoclonazepam 
were 1.0 for HTBL and 0.59 for ILBL, with a C:P ratio of 1.7.   
 Clonazepam case 08 had conflicting ratio data.  Both PM: AM samples suggested 
a lack of redistribution, while the C:P indicated its presence.  With a 15 hour AMD 
interval, one could expect to see a decrease in both drugs.  However, only clonazepam 
levels decreased in the HTBL, which the 7-aminoclonazepam concentration was 
maintained.  Alternatively, this data could be an example of clonazepam reduction.  It is 
not likely that 7-aminoclonazepam would have maintained its concentration under these 
circumstances.  The possibility of clonazepam converting causing the 7-
aminoclonazepam results to appear unchanged cannot be overlooked.  Conversely, the 
iliac vein data was consistent with metabolism reducing the concentration of both drugs.  
Therefore, PMR was not a factor for either drug.   
The AM and PM samples for clonazepam case 09 were analyzed on the same day 
as part of a single batch analysis by HPLC/MS.  The AM blood, which was collected 66 
hours before death, had a 7-aminoclonazepam concentration of 0.04 mg/L.  Clonazepam 
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was not detected within this sample.  Heart and iliac vein bloods were submitted after a 
24 hour postmortem interval.  Both heart and iliac vein blood samples had 7-
aminoclonazepam concentrations of 0.04 mg/L.  As a result, the PM to AM ratios, as well 
as the C:P ratio equaled 1.0.  All of the ratio data suggested that this case was affected by 
PMR.  With such a long AMD interval, it would be expected that the concentration of 7-
aminoclonzepam would have decreased, not remained steady.  Therefore, it does seem 
that PMR affected the results of this case. 
When reviewing the clonazepam data as a whole, it was hard to identify a pattern 
for when (and if) redistribution would influence the results.  For other drugs (e.g. 
morphine and codeine) reviewed in this manuscript, it was helpful to re-arrange the cases 
in order of increasing PMI (as opposed to increasing AMD interval).  Therefore, the 
clonazepam data displayed in Table 30 was reorganized to show the cases in order of 
increasing PMI (Table 31).  Six out of the eight cases reviewed had clonazepam present. 
Of those, only two cases (CNP 02 and 05, 33.3%) showed signs of postmortem 
redistribution.  This contradicts the apparent Vd 1.5 – 4.4 L/kg which is indicative of a 
moderate level of redistribution.  Intertwined within those two cases were CNP 04 and 08 
(ordered as 04, 05, 08 and 02).  Clonazepam cases 04 and 08 had data consistent with 
chemical reduction of clonazepam into 7-aminoclonazepam.  If one were to only look at 
case 05 and 02 (both with antemortem to death interval ≤ 12 hours and PMI ≥ 54 hours) it 
would appear that longer PMI may correlate to increased incidences of clonazepam PMR.  
When focusing specifically on those last 4 cases (PMI ≥ 28.5 hours, AMD intervals  
between 10 minutes – 15 hours) it became evident that the role of chemical conversion 
cannot be overlooked.     
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Table 31: Clonazepam cases listed in order of increasing postmortem interval 
 
PMI 
(hours) 
AM –Death 
(hours) Case # 
Source 
(whole blood) 
Concentration 
(mg/L) 
AM 
concentration 
(mg/L) 
Specimen PMR Clonaz 
PMR 
7-amino 
6.5 1.5 hours CNP 062 Heart 0.04 (7amino) 0.04 (7amino) AMBL NDD ± Iliac 0.04 (7amino) 
19 14 hours CNP 031 Mixed NDD 0.01 clonaz AMBL - NDD Iliac NDD 
24 1 hour CNP 072 Heart 0.05 (7amino) NDD clonaz 0.05 (7amino) AMBL - - Iliac 0.06 (7amino) 
24 66 hours CNP 092 Heart 0.04 (7amino) 0.04 (7amino) AMBL NDD √ Iliac 0.04 (7amino) 
28.5 10 min CNP 041 
Iliac 0.02 clonaz 0.15 (7amino) 0.03 clonaz 0.13 
(7amino) AMBL - - Iliac 0.02 clonaz 0.23 (7amino) 
54 12 hours CNP 052 
Aorta 0.08 clonaz 0.04 (7amino) <LOQ clonaz 
0.17 (7amino) AMBL √ √ (ILBL) Iliac 0.02 clonaz 0.47 (7amino) 
63 15 hours CNP 082 
Heart 0.02 clonaz 0.17 (7amino) 0.09 clonaz 0.17 
(7amino) AMBL - - Iliac 0.02 clonaz 0.10 (7amino) 
70.5 6 hours CNP 021 Heart 0.03 clonaz 0.01 clonaz AMBL √ NDD Heart 0.03 clonaz 
NDD = No Drug Detected 
±  Possible PMR 
√ = PMR occurred 
- = no PMR 
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Six out of the eight cases tested had 7-aminocloanzepam present.  Of those six, 
1.5 cases (25%) had data consistent with the redistribution of 7-aminoclonazepam.  The 
half percent accounted for CNP 05, where only the ILBL results were consistent with 
PMR.  Not included within the 25% was case 06, which was possibly influenced by 
redistribution, but data could not be definitively qualified.  Of the cases that exhibited 
redistribution, case 05 had AMD interval of 12 hours and a PMI of 54 hours, while case 
09 had an AMD of 66 hours with a PMI of 24 hours.  With such a broad range for both 
intervals, it was not possible to correlate PMR with either one.  Additionally, neither of 
the remaining two clonazepam cases (CNP 07 and 08) were influenced by PMR either.  
Instead, chemical conversion affected their results. 
 Both CNP 07 and 08 had their AM blood analyzed twice.  In both instances, the 
result was four months from the original test date.  The re-test results showed AM 
conversion of clonazepam to 7-aminoclonazepam for both cases.  However in CNP 07 
the PM results maintained the same concentration as the AM results, which could be 
expected here, as the AMD was only one hour.  As for CNP 08, the ILBL results were 
actually reflective of metabolism and elimination occurring during the 15 hour AMD 
interval.  The HTBL sample had results consistent with clonazepam reduction. 
Additionally, an interpretive issue arose.  Clonazepam cases 06 and 09 each had 
AM and PM data (both central and peripheral) return concentrations of 0.4 mg/L.  While 
on the surface it would appear that those two cases should have similar conclusions, it 
was the AMD intervals, as well as the PM intervals that made the distinction.  
Clonazepam case 06 had an AMD of 1.5 hours and a PMI of 6.5 hours.  Neither interval 
appeared to be a sufficient amount of time to allow redistribution to occur.  It was more 
 170 
 
likely that a slight reduction in drug concentration occurred after the AM collection and 
the short PMI was not enough time to allow for the release and distribution of the drug 
postmortem.  Conversely, CNP 09 had an AMD interval of 66 hours, which according to 
the elimination half-life (19 – 60 hours) would have been enough time to see a 50% 
decrease in drug concentration.  Instead of a decrease, the PM samples appeared to 
maintain their drug concentrations.  It is likely that during the 24 hour PMI, the drug was 
released and redistributed. 
 In all, clonazepam is a drug that may not be easily interpreted postmortem.  The 
effects of pharmacokinetics, PMR and time intervals could not be clearly defined.  The 
data collected here was a stark contradiction to what would be expected when 
considering the apparent volume of distribution of the drug.  In fact, more cases were 
influenced by chemical conversion than redistribution.  As a result, anytime clonazepam 
needs to be measured, it would be advisable to monitor the levels of 7-aminoclonazepam 
as well.  Quantitative results for both drugs may be helpful when trying to determine the 
meaning of the PM results.  If AM blood is available, it should be tested immediately, as 
chemical conversion can affect the results of that specimen as well.   
 
6.4 Microbial Study 
 The main purpose of the microbial study was to determine if microbial growth 
could contribute to changes in drug concentration.  This was assessed in two ways.  First, 
it was important to know if microbes could use drugs as a food source.  Second, but of 
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equal importance, was to determine if the addition of sodium fluoride (anti-microbial 
agent) to the blood samples was a sufficient means of halting bacterial growth. 
 
6.4.1 Codeine and Hydrocodone as a Food Source for Bacteria 
 A 96-well MT plate (Figure 5) was set-up as described in section 4.5.4 Assessing 
the Usefulness of Codeine and Hydrocodone as a Food Source for Bacteria.  On day 0 
the initial reading was taken.  At that time the cells were inoculated with the bacteria, as 
well as the drug standards at concentrations of 100, 200 and 600 ng/mL.  The amount of 
growth was monitored for 6 consecutive days thereafter.   
The codeine data is displayed in Chart 12.  On average the Pseudomonas growth 
patterns exceeded those of E. coli by three times or more.  The Pseudomonas bacteria 
mixed with the 100 ng/mL standard saw the most growth, while the 600 ng/mL standard 
saw the least.  Conversely, the opposite was true for E. coli as the 600 ng/mL grew the 
best, with the 100 ng/mL growing the least.  Despite the growth discrepancy observed 
among the inter-bacterial data, statistical analysis proved that the intra-bacteria growth 
patterns were not significantly different throughout the observation period.   
Chart 13 displays the results of the hydrocodone containing cells.  The growth 
pattern observed among this data set was similar to that of the codeine results.  Again, 
Pseudomonas had at least three times the growth of E. coli.  However, throughout the 
seven day period, it was E. coli that had the least amount of variation.  The best growth 
was observed when Pseudomonas was combined with the 200 ng/mL standard.  
Conversely, E. coli grew the best when mixed with the 100 ng/mL standard.   For both 
data sets, the 600 ng/mL standards saw the least amount of growth.      
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Overall, the drug standards that contained Pseudomonas outgrew the cells containing E. 
coli.  A subsequent photometer reading of the microbial solutions used to inoculate the 
plates was taken.  The results determined that the density of Pseudomonas (1.5) was 
approximately 87% higher than that of E. coli (0.23).  As a result it would be expected 
that Pseudomonas would outperform E. coli.  Also working to the advantage of 
Pseudomonas is that it is amenable to a multitude of environments.  While it is known to 
grow in locations such as skin and soil, it is not a microbe commonly associated with the 
human decomposition process.  It was included in this study more as a gauge to 
determine if it would be possible for bacteria to use the carbon structures of drugs as a 
source of food.  Conversely, Escherichia coli are known to be present within the 
intestines.  As tissues breakdown, the bacteria can release and spread throughout the 
body.  Therefore, the way E. coli responded to the project was of special interest.  So 
while, Pseudomonas responded better to the growth conditions, both Pseudomonas and 
E. coli proved this was possible for bacteria to be sustained by nothing more than the 
carbon structure of drugs.    
 
6.4.2 Aerobic and Anaerobic Study 
 In order to assess the ability of sodium fluoride to halt microbial growth upon 
sample collection, antemortem and postmortem bloods containing the agent were 
inoculated onto nutrient agar plates.  The AMBL was collected and stored in a GT tube 
until the time of testing.  The PM blood (collected in both red-top and gray-top tubes) 
came from a single decomposing cadaver.  The liquefied blood from both tubes, as well 
as the dried blood accumulating around the lid of the RT, was inoculated.  The plates   
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Chart 12: Pseudomonas and E. coli Growth Patterns When Using Codeine as a Food Source 
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Chart 13: Pseudomonas and E. coli Growth Patterns When Using Hydrocodone as a Food Source 
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were prepared in duplicate, with one set stored under aerobic conditions and another in an 
anaerobic environment.  Both sets were maintained for 11 days at 17 ºC.  The results for 
the aerobic and anaerobic studies can be seen in Table 32 and Table 33, respectively. 
The initial results of the aerobic study saw growth on one of the RT chest blood 
replicates, but not the other.  As a result, the blood from that tube was retested in 
duplicate.  The re-analysis did not show any growth on either plate.  While the agar and 
the plastic loops (used for both the original and re-test experiments) were sterile, the 
pipette tips (used to spike the 75 µL of blood onto the plates) were not.  In all likelihood, 
the non-sterile tip, used to spike the original plate that showed growth, was contaminated.  
The AM and PM red-top, as well as the PM gray-top, showed no signs of growth when 
stored in an anaerobic environment.  However, both replicates of the dried RT blood did.  
Since both replicates grew, this was not believed to be a contamination issue.  In order to 
determine what type of anaerobe was growing, the plates were sent for microbial 
identification at the International Forensic Research Institute’s DNA profiling laboratory 
on the campus of Florida International University.  The identification results are still 
pending.   
Overall, it was determined that under aerobic conditions sodium fluoride is a 
suitable additive for the prevention of microbial growth.  When properly prepared, 
neither AM or PM samples saw any growth.  This is of the utmost importance, as once 
the blood is collected it is maintained in an aerobic environment.  Conversely, growth 
was detected in the anaerobic experiment.  The anaerobic experiment, however, was not 
without flaws, as the blood used had already been exposed to oxygen for several 
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Table 32: Growth Activity of Preserved Blood Stored in an Aerobic Environment 
 
Sample Type Source Tube Growth Action 
AM AMBL GT X N/A 
PM CHBL RT √1 Re-streaked 
PM CHBL GT X N/A 
PM CHBL RT dried blood X N/A 
 
  
  
 
Table 33: Growth Activity of Preserved Blood Stored in an Anaerobic Environment 
 
Sample Type Source Tube Growth Action 
AM AMBL GT X N/A 
PM CHBL RT X N/A 
PM CHBL GT X N/A 
PM CHBL RT dried blood √ sent for identification 
  
 
 
 
 
 
 
 
 
 
X = no growth 
√ = growth 
√1= growth on one replicate only 
N/A = not applicable 
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months prior to testing.  This would result in the death of the strict anaerobes, but the 
possible survival of the facultative anaerobes (those that can survive in either oxygen-rich 
or oxygen-depleted environments).  Bearing that in mind, the only growth detected was 
on the dried blood sample.  Out of the samples tested, it was the only one with an obvious 
depletion of oxygen.  Therefore, any organism that could survive those conditions would 
likely thrive in an oxygen-free environment.   
This portion of the experiment showed that under the current storage conditions, 
continued growth of bacteria in the collected blood samples is not a concern.  However, 
the effect of bacterial growth in the body prior to sample collection may impact drug 
concentrations.   
 
6.4.3 Cumulative Microbial Results 
The combination of the MT plate and agar plate experiments rendered some 
results of interest.  Drugs can in fact be used as a food source for bacteria.  However, as 
shown in the agar plate experiment, once the blood is collected and preserved (in an 
aerobic environment) bacteria, including E. coli, were no longer viable.  On the other 
hand, under anaerobic conditions some bacteria (potentially facultative anaerobes) did 
grow.  This was not deemed a problem for two reasons.  First, once collected, all of the 
samples are stored aerobically, not anaerobically.  Second, the only growth seen in the 
anaerobic study came from a dried blood sample.  When drug identification and 
quantitation are performed, fluid blood, not dried blood, is used.  The results of the 
anaerobic study showed no growth on any of the fluid blood samples.  The presence of 
those bacteria should not negatively influence the results.     
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6.5 Stability Study 
 Hydrocodone and codeine standards, prepared in dilute phosphate buffered saline 
solution, were spiked in whole blood to give a final concentration of 200 ng/mL.  
Analytical analysis conducted by GC/MS/MS quantitatively monitored codeine and its 
metabolite morphine, while hydrocodone and its metabolite hydromorphone were 
analyzed by GC/ SIM-MS.  The initial analysis of both drugs was conducted by 
GC/MS/MS; however, an interference causing the ion suppression of the hydrocodone-d3 
ion (288) resulted in the inability to detect the internal standard ion.  It was decided that 
the Opiate II quantitative method (4.4.2 (b) Opiate II by GC/MS (SIM)) could be used 
alternatively.  In that method, hydrocodone-d3 was still the internal standard; however, 
the 331 ion was monitored instead.  For both methods, the metabolites of the parent drugs 
were also monitored, as it was imperative to determine if any concentration changes 
could be attributed to chemical conversion.  Initial analysis of codeine was conducted on 
the same day of the spike.  As a result of the interferent, hydrocodone’s initial analysis 
was delayed by three days.  For both drugs however, re-analyses were performed 30 and 
60 days later.  In between testing dates, the blood samples were refrigerated at 2 ºC.  The 
results are displayed in Table 34. 
Codeine, a drug evaluated in section 6.1.1 Heroin, Morphine and Codeine, had an 
error rate (established during research testing) of 10%.  Hydrocodone was not assessed in 
any other part of this study.  Therefore, in order to determine the amount of error 
associated with the drug, the standard deviation (2.988) and concentration mean 
(22ng/mL) of the controls collected as part of routine analysis were calculated.  When 
using Equation 5 the CV was determined to be 13%. Any concentrations which fell 
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within the established limits of error were considered statistically similar, while those that 
exceeded the limits were not. 
Codeine had an initial reading of 191 ng/mL in the RT and 197 ng/mL in the GT.  
Both concentrations were similar to each other, as well as being similar to the 200 ng/mL 
spiked concentration.  At the second reading, concentration discrepancies began to 
emerge in the RT tube.  Its blood concentration decreased to 179 ng/mL.  While this level 
was statistically similar to the previous concentration reading, it exceeded the limits of 
the CV (± 10%), thereby making it significantly different from the originally spiked 
concentration.  Conversely, the amount of drug in the GT tube (183 ng/mL) was similar 
to both the spiked and the initial concentrations.  The third and final reading again 
showed a decrease in codeine concentrations.  This time, both RT and GT (166 ng/mL 
each) levels were statistically lower than both the spiked amount and the initial reading. 
 
Table 34: Results of the 60 Day Drug Stability Study of Refrigerated Blood 
 
Analyte Spiked Concentration Tube 
Initial 
Reading 
(ng/mL) 
30 Day 
Reading 
(ng/mL) 
60 Day 
Reading 
(ng/mL) 
Codeine 200 ng/mL RT 191 179 166 GT 197 183 166 
Morphine 
(metabolite) N/A 
RT not detected not detected not detected 
GT not detected not detected not detected 
Hydrocodone 200 ng/mL RT 131 131 130 GT 126 127 126 
Hydromorphone 
(metabolite) N/A 
RT not detected not detected not detected 
GT not detected not detected not detected 
   
 
 
 
Red-top tube = RT 
Gray-top tube = GT 
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 The steady decline in the codeine concentration for both tubes indicated that 
under the current storage conditions, codeine may not be stable.  The lack of morphine 
detection would suggest that while chemical conversion did not seem to be a factor, drug 
degradation should still be considered.  This conclusion was in direct contrast to the 
results found in both the Holmgren (45) and Peters (44) studies.  They each determined 
that codeine was stable in storage for a period of at least one year.  Their blood samples 
were frozen at temperatures of -20 ºC and -18 ºC, respectively.  Based on this 
information, it would appear that drug preservation of codeine is much more reliable 
when the sample is frozen, not refrigerated.   
 After the collection of the hydrocodone data, the results were determined to be 
skewed.  As previously mentioned, hydrocodone had to be analyzed by GC/SIM-MS as a 
result of an internal standard interference observed in the GC/MS/MS data.  Upon initial 
analysis (using the SIM method) a prominent internal standard peak was detected and the 
instrument switch was made.  The initial reading saw a concentration decrease of 65% in 
the RT (131 ng/mL) and 63% in the GT (126 ng/mL) tubes.  At the time, the reason for 
the significant concentration decrease was not known.  The analyses continued 30 days 
(RT= 131 ng/mL; GT = 127 ng/mL) and 60 days (RT = 130 ng/mL; GT = 126 ng/mL) 
later.  Although significantly decreased from the spiked amount (200 ng/mL), the 
monthly readings were consistent to each other, regardless of sample tube.   
After careful review of the hydrocodone standard preparation procedure and the 
resultant analytical findings, it was determined that the internal standard was again 
causing a problem.  While the MS/MS method saw ion suppression of the internal 
standard, the SIM method saw ion enhancement.  The internal standard for the sample 
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produced area responses that ranged from 11 – 18% higher than the calibrators on any 
given run.  The increased internal standard resulted in decreased sample concentration, as 
concentrations are calculated based on an area response ratio between the sample and 
internal standard.  In theory, if the problem had been caught in the beginning the SIM 
method still could have been used.  However, the sample should have been extracted 
using the method of standard additions. 
The method of standard additions is used to resolve problems associated with 
matrix effects (e.g. ion suppression or enhancement).  To account for this problem, the 
sample itself should have been spiked with known drug concentrations to produce a 
calibration curve.  The sample concentration could then have been calculated against that 
curve.  While this would have fixed the miscalculation, in actuality the volume of the 
sample available for testing would not have been sufficient to allow for three separate 
methods of addition calculations.  Each batch, which consisted of a blank, a five-point 
calibration curve, four controls (low and high concentrations in duplicate) and sample 
extraction in duplicate, would have required a minimum of 12 mL of sample.  The gray-
top tubes used hold 10 mL each (2 tubes total) and there was 30 mL in the red-top.  In 
addition, sample blood for the GC/MS/MS method was needed as well.   
In the absence of the standard addition data, the internal standard responses were 
corrected for in each batch.  While this is a practice never used at the MDME- toxicology 
laboratory, using a corrective calculation in this instance is the resource available to the 
researcher in the absence of additional blood.  It was important to use this particular 
blood sample because it was the same blood used in the microbial study.  Therefore, the 
results could be better compared.   
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In order to correct for the internal standard bias, the average internal standard 
response was calculated for the 5-point curve.  The internal standard response for the RT 
and GT tubes were then averaged based on their respective collection tube, followed by 
an average calculation for the sample (RT and GT) tubes.  The percent difference 
between the calibration curve and sample internal standard responses were calculated.  
For example, in one batch the red-top and gray-top internal standard responses exceeded 
the curve response by 11% and 16%, respectively.  The internal standard response of the 
case was decreased by its appropriate percentage based on the sample tube.  After this, 
the hydrocodone concentrations were recalculated using the adjusted internal standard 
responses.  Applying this correction, resulted in sample concentrations ranging from 151 
to 164 ng/mL.  When comparing these results to the method CV (13%), all of the 
recalculated values remained statistically similar to each other regardless of sample tube.  
Although the concentrations were still significantly lower than the spiked concentration, 
the adjusted concentrations were between 18 – 25% lower.  This was a vast improvement 
over the non-adjusted calculations which resulted in discrepancies ranging from 63 – 
65% lower.              
 In all, this experiment showed that refrigerated storage may not be the best option 
for analyte preservation of some drugs (specifically codeine).  However, since the gray-
top tubes are made of glass, freezing them may not be a wise alternative either.  In lieu of 
changing the type of collection tube used, it would be in the best interest of the analyst(s) 
to conduct quantitative analyses relatively quickly, as concentration levels may change in 
storage.  This instability may not affect all drugs, as was seen here with hydrocodone.   
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While hydrocodone levels were consistently lower than the spiked amount, the 
concentration remained constant over the three month testing period.  In addition, while 
this study was not intended to account for the difficulties that matrix effects can present, 
their influence on this drug was evident.  This is an issue that can present itself at 
anytime.  It is especially important to consider when testing postmortem biological 
samples.  In this instance, the sample was from a decomposing cadaver.  In such a 
situation, multiple biological processes are occurring and interferences may result.  This 
issue did not present itself in other samples used for this study.  However, none of the 
other samples were taken from a cadaver in such a state of decomposition.  Regardless, in 
real-life instances the role of matrix effects should be considered when reviewing the 
analytical data. 
 
 
7.0 Conclusions:    
The goals of this project were to 1) evaluate the differences in drug concentrations 
between antemortem and postmortem specimens, 2) determine how the presence of 
microbes influence drug concentrations, 3) determine the stability of drugs in whole 
blood and 4) define an interpretive framework to aid in the interpretation of postmortem 
drug concentrations in whole blood.  In Chapter 6: Results and Discussion, the first three 
goals were discussed in great detail.   
 
7.1 Microbes and Stability: Potential Influences on Postmortem Concentrations 
 
In all, it was determined that in the absence of a preservative, both Escherichia 
coli and Pseudomonas aeruginosa can use drugs (specifically codeine and hydrocodone) 
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as a carbon source for food.  It is however important to keep in mind that the drugs 
analyzed for this study were preserved in tubes that contained the anti-microbial agent 
sodium fluoride.  After inoculating preserved blood samples, it was determined that under 
the current storage conditions, sodium fluoride effectively eliminated microbial activity.   
The same PM blood and drug standards used for the microbial experiment were 
also used for the stability study.  Aliquots of the blood (stored in both gray-top vacutainer 
and red-top polypropylene tubes) were spiked with both codeine and hydrocodone to give 
a final concentration of 200 ng/mL each.  The blood was analyzed by GC/SIM-MS and 
the GC/MS/MS monthly for a period of 60 days.  Included in the analytical method were 
morphine and hydromorphone, the metabolites of codeine and hydrocodone, respectively.  
By monitoring both parent and metabolite concentrations the role of chemical conversion 
could be considered.  The results indicated the refrigerated storage can effectively 
maintain hydrocodone concentrations.  Unfortunately, the same was not true for codeine, 
which steadily declined in concentration throughout the study.  However, when 
combining the microbial and stability results it was determined that instances of 
concentration instability were not a result of microbial degradation.  In addition, at least 
for these two drugs, chemical conversion did not contribute either.  For a future study, the 
role of storage temperature and photo-degradation should be considered, as those two 
factors may have influenced the codeine results.   
The data generated from the microbial and stability experiments played a 
fundamental role in achieving the first goal of the experiment, which was to evaluate the 
differences in drug concentrations observed in antemortem and postmortem samples.  
When differences were identified, it was important to determine the cause of the 
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discrepancy.  Some drugs (e.g. diphenhydramine, morphine and codeine) produced data 
that was overwhelmingly consistent with being influenced by postmortem redistribution.  
This was apparent when the postmortem results were consistently greater than the drug 
levels in their respective antemortem samples.  In contrast, other drugs like midazolam 
were efficiently metabolized and eliminated from the body.  Unfortunately, not all of the 
data collected was as straight forward. 
 
7.2 Interpretive Guidelines 
 
The combined information gained from the first three goals was used to achieve 
the fourth goal, which was to develop an interpretative framework for the postmortem 
results.  Upon examining the data, it quickly became apparent that strict interpretative 
rules would not work.  Just as decomposition is a dynamic process that can vary 
drastically based on a number of different factors, the interpretation of postmortem 
results can too.  Even analytes within the same drug class do not necessarily behave 
similarly.  In lieu of developing strict guidelines, a list of important interpretative 
considerations was developed. 
According to its apparent volume of distribution (3 – 4 L/kg), diphenhydramine is 
a drug that has a propensity for postmortem redistribution.  The experimental data 
collected for this study was in agreement with that.  The study results indicated that PMR 
can begin as quickly as 11 hours after death.  The results consistently indicated that PM 
diphenhydramine levels will likely be significantly higher than their AM counterparts.  In 
addition, while it is often believed that peripheral blood concentrations most closely 
resemble drug levels at the time of death, the data generated here contradicted that, 
 186 
 
indicating that there was no direct correlation between PM peripheral and AM blood 
concentrations.  In actuality, PM diphenhydramine concentrations (whether central or 
peripheral) typically will greatly exceed both their AM and expected concentrations 
levels at the time of death.  As a result, when reviewing diphenhydramine postmortem 
results, it would be advisable to bear in mind that the concentrations obtained are likely 
elevated. 
The benzodiazepines alprazolam, midazolam, diazepam and clonazepam are a 
class of drugs known for their central nervous system depressant and muscle relaxant 
properties.  Although pharmacologically related, it should not be assumed that they all 
respond similarly in a postmortem environment.  Alprazolam data suggested that the drug 
was subject to PMR when the combination of a short antemortem to death interval 
(≤40min) was coupled with a long postmortem interval (≥ 45.5 hours).  The results 
obtained in this study determined that any other variation of those two intervals likely 
would not result in redistribution.  These results were reasonable, as its apparent volume 
of distribution (Vd = 0.9 – 1.3 L/kg) did not reflect a strong tendency for redistribution.  
In addition, when comparing postmortem central to peripheral concentrations, 71% of the 
cases showed no significant difference between the two sources.  In most instances, 
quantitative analysis could be conducted on either PM specimen.  That is not to say that 
the PM results would be equivalent to the expected concentration range at the time of 
death.  In fact only 25% of the PM data collected fell within its expected range at the time 
of death.  The remaining 75% were either above or below the calculated expectation.  In 
all, although alprazolam is not likely to redistribute, a skew of the PM results may still 
exist.    
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Midazolam is a benzodiazepine which rapidly metabolizes from the body (t1/2 = 1- 
4 hours).  While its apparent volume of distribution (1.0 – 2.5 L/kg) was indicative of a 
drug that could effectively undergo postmortem redistribution, the data collected refuted 
this.  In 100% of the cases no signs of redistribution could be identified, regardless of 
AMD (range: 16 min – 48 hours) or PM (10 – 37 hours) intervals.  In all instances, it 
appeared as though metabolism and elimination effectively decreased (and in many 
instances removed) the drug from the body prior to death. 
The benzodiazepine diazepam was monitored along with its pharmacologically 
active metabolite nordiazepam.  With elimination half-lives of 21 – 37 hours and 50 – 99 
hours for diazepam and nordiazepam, respectively, both drugs are considered to have a 
long-lasting effect.  When comparing their postmortem concentrations to their 
antemortem’s, there was an expectation that signs of chemical conversion between the 
two would be evident.  However, that was not the case.  In most instances when 
comparing PM to AM concentrations, both parent and metabolite would move in parallel 
to each other, meaning they would both either increase or decrease within the same case.  
This could be reflective of diazepam’s stability in storage, as drug instability may have 
led to more instances of opposing concentrations shifts between the parent and 
metabolite.  Their similar concentration shifts did not negate the influence of PMR on 
either drug, as 50% of the data (for both drugs) was indicative of PMR.  The remaining 
50% of the cases had PM concentrations either within or below their expected 
concentrations at the time of death.  When comparing central to peripheral data in most 
instances either specimen could be used to quantify diazepam, however peripheral 
nordiazepam concentrations were typically lower.  Since diazepam and nordiazepam are 
 188 
 
monitored together in most labs, peripheral blood would be the preferred source for 
quantitative analyses.  However, for both drugs, it should not be expected that peripheral 
results are reflective of drug concentrations at the time of death, as only 17% of diazepam 
and 0% of nordiazepam results were within their calculated concentration ranges. 
Clonazepam was a drug that presented many challenges.  It is classified as a long-
acting benzodiazepine (t1/2 = 19- 60 hours), but a prolonged effect in a living person, did 
not equate to drug stability in a postmortem specimen.  Clonazepam, monitored here with 
its pharmacologically inactive metabolite, 7-aminoclonazepam, was largely susceptible to 
chemical reduction in storage.  As a result, the levels of clonazepam would reduce, while 
7-aminoclonazepam levels would increase.  This was of particular interest because 
clonazepam’s apparent volume of distribution (1.5 – 4.4 L/kg) suggested that the drug 
was prone to PMR.  The results of this study determined that only 37% of the cases were 
susceptible to redistribution.  When examining the results, it became rather difficult to 
identify a predictable pattern for when and how drug concentrations would change.  As a 
result, in instances of quantitative analysis, interpretation should be done with caution.  In 
an effort to reduce these PM concentration concerns, it may seem like a good idea to only 
analyze the AM blood for this particular drug.  However, the reanalysis of antemortem 
blood samples (n= 2) determined that clonazepam concentrations can decrease as early as 
four months in storage (2 ºC).  Although two samples do not equate to a significant 
populations size, the data did suggest that when clonazepam levels are a concern, the 
samples should be analyzed as close to collection as possible.  In addition the 7-
aminoclonazepam concentration should be monitored as well.    
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The synthetically derived opioid methadone, as well as the naturally occurring 
opiates morphine and codeine were also examined for this study.  In keeping with its 
apparent volume of distribution (4 – 5 L/kg), methadone consistently produced data that 
was influenced by PMR, with the impact being greater on the central sourced blood.  The 
postmortem results (regardless of source) were routinely greater than both the expected 
concentration ranges at the time of death, as well as the AM concentrations.  The data 
indicated that PMR would occur for this drug regardless of AMD (45 min – 72 hours) or 
PM intervals (16 – 54 hours), as their ranges varied greatly.  When interpreting PM 
methadone levels, it would be advisable to consider the drug concentrations elevated. 
 Because of the pharmacological similarities, morphine and codeine are two drugs 
that are not commonly prescribed together.  However, they are often detected together, as 
morphine is a major metabolite of codeine.  In addition morphine (as a metabolite) and 
codeine (as a by-product) are also produced as a result of heroin metabolism.  It was only 
logical to review their results together.  In keeping with their apparent volumes of 
distribution, both morphine (Vd = 2 -5 L/kg) and codeine (Vd = 3.5 L/kg) exhibited a 
strong predisposition for PMR.  By re-arranging the data in order of increasing 
postmortem interval, it became very clear that both drugs exhibited increased incidences 
of redistribution with longer PM intervals.  Conversely, the influence of the antemortem 
to death interval (range: 9 minutes – 24 hours) was negligible.   
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7.3 Additional Considerations 
The role of chemical conversion between codeine and morphine was a minor 
issue, as only 15% of the cases were affected.  When comparing PM central and 
peripheral results, it became apparent that in most instances the extent of PMR was site 
dependent, with the central source seeing a greater affect.  However, factors such as the 
location of intravenous injection (in the case of heroin abuse) should not be overlooked as 
this can alter the redistribution effect.  Overall the peripheral sourced blood had lower 
drug concentrations, only 1 morphine case had a level within its expected concentration 
range at the time of death.  The interpretation of both morphine and codeine in 
postmortem specimens should be done with caution. 
Finally, throughout the data collection process, central: peripheral, as well as 
postmortem: antemortem ratio results were being collected and compared.  The ratio 
results conflicted in 54% of the cases.  When comparing both ratios, to the final 
determinations made by the researcher, it was the PM: AM ratio that was most often in 
agreement.  As a result, it was determined that while the C:P ratio could be a great tool in 
determining whether or not redistribution occurred in a predicted fashion (e.g. 
redistribution was more pronounced in the central sourced blood), it may not be the most 
reliable way of evaluating whether or not PMR actually happened. 
 
7.4 Final Thoughts and Future Work 
Overall, the goals for this project were met.  While in some instances definitive 
conclusions could not be drawn, the body of work in its entirety is an examination of the 
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various issues that plague a postmortem toxicologist.  A drug concentration alone carries 
no weight.  The understanding of what it means, its application and whether or not its 
presence influenced the death of someone is of the utmost importance.  This study 
investigated theories and ideas common to toxicological professionals.  While some 
concepts were reinforced, others were not.  It would be advisable that future experiments 
continue to examine the importance of ratio data (e.g. central:peripheral and 
postmortem:antemortem), as well as the affect clonazepam stability has on postmortem 
interpretations.  Additionally, further studies concerning the impact of microbial activity 
on drug concentrations prior to sample collection are needed.  By examining factors such 
as temperature, the addition of biological carbon sources (mixed with drug carbon 
sources) and environment (e.g. aerobic or anaerobic), the true impact bacteria have on 
toxicological findings may be better identified.  
  
 192 
 
LIST OF REFERENCES 
 
1. Miami-Dade County- Medical Examiner's Department. [Online] [Cited: October 26, 
2008.] http://www.miamidade.gov/medexam accessed on 10.26.08. 
 
2. State of Florida - Senate. [Online] [Cited: October 26, 2008.] 
http://www.flsenate.gov/Statutes/index.cfm?App_mode=Display_Statute&URL=Ch0406
/ch0406.htm/10.26.08. 
 
3. Miami-Dade County - Toxicology. [Online] [Cited: October 26, 2008.] 
http://www.miamidade.gov/medexam/toxicology. 
 
4. Accreditaion Board of Forensic Toxicologists (ABFT). [Online] [Cited: October 26, 
2008.] http://www.abft.org . 
 
5. Society of Forensic Toxicologists (SOFT). [Online] [Cited: October 26, 2008.] 
http://www.soft-tox.org/default.aspx?pn=Introduction&sp=Introduction . 
 
6. Brunton, Laurence, [ed.]. Goodman and Gillman's The Pharmacological Basis of 
Therapeutics. 11th. s.l. : McGraw-Hill medical publishing division, 2006. p. 1744. 
 
7. Brunton, Laurence, [ed.]. Goodman and Gillman's The Pharmacological Basis of 
Therapeutics. s.l. : McGraw-Hill Medical Publishing Division, 2006. pp. 33-37. 
 
8. McKee, T and McKee, J. Biochemistry An Introduction. 2. s.l. : WCB McGraw-Hill, 
1999. p. 241. pg. 241. 
 
9. McKee, T. and McKee, J. Biochemistry An Introduction. 2. s.l. : WCB McGraw-Hill, 
1999. p. 240. 
 
10. Brunton, Laurence, [ed.]. Goodman and Gillman’s The Pharmacological Basis of 
Therapeutics. 11. s.l. : McGraw-Hill medical publishing division, 2006. p. 7. 
 
11. Trevor, A., Katzung, B., Masters, S. Katzung & Trevors Pharmacology Examination 
Board Review. 8. New York : McGraw Hill Medical, 2008. p. 21. 
 
12. Cornell University - Vetenary Medicine. [Online] [Cited: November 26, 2008.] 
http://web.vet.cornell.edu/public/pharmacokinetics/sitesDT/phase1vs2.html. 
 
13. Creighton University. [Online] [Cited: November 26, 2008.] 
http://pharmacyonline.creighton.edu/pha443/pdf/pkin03.pdf. 
 
14. Medical Terminology - Online. [Online] [Cited: November 26, 2008.] 
http://www.medterms.com. 
 193 
 
15. Beyond the Grave – Understanding Human Decomposition. Vass, Arpad. s.l. : 
Microbology Today, 2001, Vol. 28, pp. 130-132. 
 
16. Sledzik, P. Forensic Taphonomy: Postmortem Decomposition and Decay. Forensic 
Osteology. p. C. 5. 
 
17. Missouri - Case Studies in Forensic Entomology. [Online] [Cited: November 26, 
2008.] http://www.missouri.edu/~agwww/entomology/casestudies.html. 
 
18. Farmer's Almanac Online. [Online] [Cited: December 29, 2008.] 
almanac.com/weatherhistory . 
 
19. Weather online. [Online] [Cited: December 29, 2008.] almanac.com/weatherhistory . 
 
20. Mechanisms underlying postmortem redistribution of drugs: A review. Pelissier-
Alicot, A. and Gaulier, J, et al. s.l. : Journal of Analytical Toxicology, 2003, Vol. 27, pp. 
533-543. 
 
21. Postmortem toxicology of drugs of abuse. Drummer, O. 2004, Forensic Science 
International, Vol. 142, pp. 101-113. 
 
22. Estimating antemortem drug concentrations from postmortem blood samples: the 
influence of postmortem redistribution. Cook, D., Braithwaite, R. and Hale, K. 53, s.l. : J. 
Clin Pathol, 2000, pp. 282-285. 
 
23. Goodman and Gillman’s The Pharmacological Basis of Therapeutics. 9. 1996. 
 
24. Hearn, W.L. Toxicology: Interpretation of results. [ed.] Jay A. Siegel. s.l. : 
Encyclopedia in Forensic Sciences, 2000. pp. 1391-1397. 
 
25. Hepler, B. and Isenchmid, D. Specimen selection, collection, preservation and 
security. [ed.] S. Karch. Drug Abuse Handbook. s.l. : CRC Press, 1998, 12.2, pp. 876-
880. various biological specimens. 
 
26. The extent of postmortem drug redistribution in a rat model. Hilberg, T., et al. 44, 
s.l. : J Forensic Sci, 1999, Vol. 5, pp. 956-962. 
 
27. Hepler, B. and Isenschmid, D. Interpretation of postmortem drug levels. [ed.] S. 
Karch. Drug Abuse Handbook. s.l. : CRC Press, 1998, p. 881. bile, vitreous humor. 
 
28. Interpreting results of ethanol analysis in postmortem specimens: A review of the 
literature. Kugelberg, F and Jones, A. 165, s.l. : For Sci Int, 2007, pp. 10-29. 
 
29. Jones, G. Interpretation of postmortem drug levels. [ed.] S. Karch. Drug Abuse 
Handbook. s.l. : CRC Press, 1998, pp. 973-974. 
 194 
 
30. Baselt, R., [ed.]. Diposition of toxic chemicals and drugs in man. 7th. s.l. : 
Biomedical Publications, 2004. pp. 532-534. Heroin. 
 
31. Recent discoveries in pharmacokinetics of drugs of abuse. Cone, E. s.l. : Toxicology 
Letters, 1998, Vols. 102-103, pp. 97-101. 
 
32. Free Oxycodone Concentrations in 67 Postmortem Cases from the Hennepin County 
Medical Examiner's Office. Thompson, J. s.l. : JAT, 2008, Vol. 32, pp. 673-679. 
 
33. Benzodiazepines- Effects on human performance and behavior. Drummer, O. 1, s.l. : 
Forensic Science International, January 2002, Vol. 14. 
 
34. Effectiveness of benzodiazepines - do they work or not? Lader, M. 8, s.l. : Expert 
Reviews Neurotherapeutics, 2008, Vol. 8, pp. 1189-1191. 
 
35. The diagnosis and management of benzodiazepine dependence. Ashton, H. s.l. : 
Current Opinion in Psychiatry, 2005, Vol. 18, pp. 249-255. 
 
36. The effects of benzodiazepines on cognition. Stewart, S. s.l. : Journal of clinical 
psychiatry, 2005, Vol. 66, pp. 9-13. 
 
37. Justice, US Department of. Drug Enforcement Administration, benzodiazepines. US 
Department of Justice. [Online] [Cited: March 18, 2009.] 
http://www.usdoj.gov/dea/concern/benzodiazepines.html. 
 
38. Bono, J. Criminalistics- Introduction to Controlled Substances. [ed.] S. Karch. Drug 
Abuse Handbook. s.l. : CRC Press, 1998, pp. 5-7. heroin. 
 
39. Detection of Acetylcodeine in Urine as an Indicator of Illicit Heroin Use: Method 
Validation and Results of a Pilot Study. Staub, C., Marset, M. and al, et. 2, 2001, Clinical 
Chemistry, Vol. 47, pp. 301-307. 
 
40. DEA Drug Scheduling. [Online] [Cited: July 26, 2009.] 
http://www.justice.gov/dea/pubs/scheduling.html. 
 
41. U.S. Department of Justice. [Online] [Cited: January 3, 2009.] morphine. 
http://www.usdoj.gov/dea/concern/morphine.html. 
 
42. Baselt, R., [ed.]. Diposition of toxic chemicals and drugs in man. Foster City, CA : 
Biomedical Publications, 2004. pp. 678-681. methadone. 
 
43. Oates, J. The Science of Drug Therapy. [ed.] L. Brunton. Goodman and Gilman's The 
pharmacological basis of therapeutics. 11th. New York : McGraw-Hill Medical 
Publishing Division, 2006, pp. 117-137. 
 
 195 
 
44. Postmortem forensic toxicology of trazodone. Goeringer, K., Raymon, L., et al. 4, 
2000, J. Forensic Sci, Vol. 45, pp. 850-856. 
 
45. Reference Concentrations of Antidepressants. A Compilation of Postmortem and 
Therapeutic Levels. Reis, M., Ahlner, J. and Druid, H. 2007, J. Anal. Toxicol, Vol. 31, 
pp. 255-263. 
 
46. Postmortem redistribution of fentanyl in blood. Olson, K., Luckenbill, K., et al. 2010, 
AM J Clin Pathol, Vol. 133, pp. 447-453. 
 
47. Postmortem assay of digoxin by radioimmunoassay. Holt, W. and Benstead, J. 1975, 
J. Clin. Pathol., Vol. 28, pp. 483-486. 
 
48. Determination of therapuetic and toxic serum digoxin concentrations by radio 
immunoassay. Smith, T., Butler, V. and Haber, E. 1969, New Engl J Med, Vol. 281, pp. 
1212-1216. 
 
49. Interpretation of postmortem serum levels of cardiac glycosides after suspected 
overdosage. Moffat, A. 1974, Acta Pharmacologica et Toxicologica, Vol. 35, pp. 386-
394. 
 
50. Digoxin concentrations in postmortem specimens after overdose and therapeutic use. 
DiMaio, V., Garriott, J. and Putnam, R. 2, 1975, J. Forensic Sci., Vol. 20, pp. 340-347. 
 
51. Case experience with digoxin analysis of postmortem blood. Phillips, A. 1974, J 
FORENSIC SCI SOC, Vol. 14, pp. 137-140. 
 
52. Correlation of antemortem and postmortem digoxin levels. Vorpahl T. and Coe, J. 
s.l. : J. Forensic Sci., 1978, Vol. 23, pp. 329-334. 
 
53. Postmortem changes in serum levels of the tricyclic antidepressants. Bandt, C. Los 
Angeles, Ca : s.n., 1980. presented at the American Academy of Forensic Sciences 
Meeting. 
 
54. Postmortem changes in drug concentrations in the blood. Kofoed, J. and Mayer, J. 
Niagra Falls, Canada : s.n., 1986. presented at the Canadian Society of Forensic Sciences 
Meeting. 
 
55. Postmortem increase in drug levels- a major challenge for forensic toxicologists. 
Jones, G. Montreal, Quebec : s.n., 1985. presented at the joint meeting of the Society of 
Forensic Toxicologists and the Canadian Society of Forensic Sciences. 
 
56. Documented hazards in the interpretation of postmortem blood concentration of 
tricyclic ntidepressants. Prouty, R. and Anderson, W. Anaheim, Ca : s.n., 1984. presented 
at the Americam Academy of Forensic Sciences. 
 196 
 
57. Distribution of ethanol in postmortem specimens. Briglia, E., Hauser, C. et al. 
Quantico, Va : s.n., 1986. presented at the International Symposium on Driving Under the 
Influence of Alcohol and/or Drugs. 
 
58. Blood and tissue concentrations of tricyclic antidepressant drugs in postmortem 
cases. Literature survey and a study of forty deaths. Hebb, J., Caplan, Y. et al. 1982, J. 
Anal. Toxicol, Vol. 6, pp. 209-216. 
 
59. Therapeutic and toxic drug concentrations in postmortem blood: A six year study in 
the State of Maryland. Caplan, Y., Ottinger, W. and Crooks, R. s.l. : J. Anal. Toxicol, 
September/October 1983, Vol. 7, pp. 225-230. 
 
60. Concentration of basic drugs in human myocardium. Bailey, D. and Shaw, R. 2, 
1982, J TOXICOL-CLIN TOXIC, Vol. 19, pp. 197-202. 
 
61. Site dependence of drug concentrations in postmortem blood- A case study. Jones, G. 
and Pounder, D. s.l. : J. Anal. Toxicol, September/October 1987, Vol. 11, pp. 186-190. 
 
62. Comparative study of postmortem barbiturates, methadone and morphine in vitreous 
humor, blood and tissue. Ziminski, K., Wemyss, C, et al. 3, 1984, J. Forensic Sci, Vol. 
29, pp. 903-909. 
 
63. The liver:blood ratio in cases of barbiturate poisoning. Curry, A. and Sunshine, I. 
1960, Toxicol Appl Pharmacol, Vol. 2, pp. 602-606. 
 
64. Physicians' Desk Reference. 60th. Montvale : Thompson PDR , 2006. p. 2822. 
 
65. Stability of analytes in biosamples - an important issue in clinical and forensic 
toxicology. Peters, F. and bioanalytical chemistry : s.n., 2007, Analytical, Vol. 388, pp. 
1505-1519. 
 
66. Stability of drugs stored in postmortem femoral blood and vitreous humor. Holmgren, 
P. 4, 2004, Journal of Forensic Sciences, Vol. 49, pp. 820-825. 
 
67. Preanalytical aspects in postmortem toxicolgy. Skopp, G. 142, s.l. : Forensic Science 
International, 2004, pp. 75-100. 
 
68. Stability of morphine, morphine-3-glucuronide and morphine-6-glucuronide in fresh 
blood and plasma and postmortem blood samples. Skopp, G. January/February 2001, 
Journal of Analytical Toxicology, Vol. 25. 
 
69. Miller, J. and Miller, J. Statistics and Chemometrics for Analytical Chemistry. 4th. 
s.l. : Prentice Hall, 2001. 
 
 197 
 
70. Fayetteville State University. [Online] [Cited: January 1, 2010.] 
http://faculty.uncfsu.edu/dwallace/lesson%2016.pdf. 
 
71. Baselt, R., [ed.]. Disposition of toxic drugs and chemicals in man. 7. Foster City, 
CA : Biomedical Publications, 2004. pp. 262-264. codeine. 
 
72. Baselt, R., [ed.]. Dispositon of toxic drugs and chemicals in man. 7. Foster City, CA : 
Biomedical publications, 2004. pp. 759-762. morphine. 
 
73. Hutchins, K. Pathologist at MDME Dept. Miami, September 2009. 
 
74. Health, US National Library of Medicaine and National Institutes of. Medline Plus: 
Medical Dictionary. [Online] [Cited: August 15, 2009.] 
http://www.nlm.nih.gov/medlineplus/mplusdictionary.html. 
 
75. Health, US National Library of Medicine and the National Institute of. Medline Plus. 
[Online] [Cited: September 13, 2009.] diphenhydramine.  
http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682539.html. 
 
76. Baselt, R. Disposition of toxic drugs and chemicals in man. Foster City : Biomedical 
Publications, 2004. diphenhydramine. 
 
77. The Vaults of Erowid. [Online] September 2, 2004. [Cited: September 13, 2009.] 
diphenhydramine. http://www.erowid.org. 
 
78. Baselt, R., [ed.]. Disposition of toxic drugs and chemicals in man. 7. Foster City, 
CA : Biomedical Publications, 2004. pp. 35-36. Alprazolam. 
 
79. —. Disposition of toxic chemicals and drugs in man. 7th. Foster City : Biomedical 
Publications, 2004. pp. 312-315. diazepam. 
 
80. EMS House of DeFrance. [Online] [Cited: December 5, 2009.] 
http://www.defrance.org/. 
 
81. Baselt, R., [ed.]. Disposition of Toxic Drugs and Chemicals in Man. 7th. Foster City : 
Biomedical Publications, 2004. pp. 747-749. midazolam. 
 
82. Disposition of toxic chemicals and drus in man. [ed.] R. Baselt. 7th. Foster City : 
Biomedical Publication, 2004, pp. 246-247. clonazepam. 
 
83. Clonazepam pharmazokinetics, brain uptake and receptor interactions. Greenblatt, D, 
Miller, L and Shader, R. Supplement, s.l. : Journal of Clinical Psychiatry, October 1987, 
Vol. 48, pp. 4-11. 
 
 198 
 
84. U.S. Department of Justice. [Online] [Cited: January 3, 2009.] hydrocodone. 
http://www.usdoj.gov/dea/concern/hydrocodone.html. 
 
85. Blood concentrations of clonazepam and 7-aminoclonazepam in forensic cases in 
Denmark for the period 2002 - 2007. Steentoft, A. and Linnet, K. 184, s.l. : Forensic 
Science International, 2009, pp. 74-79. 
 
 
 
 
 
 
 
 
 
 
 
 199 
 
VITA 
 
SAMANTHA SHIRELLE TOLLIVER 
 
May 6, 1979  Born, Hagerstown, MD 
   B.S., Chemistry 
   West Virginia State University 
   Institute, WV 
 
2005   M.S., Chemistry 
   Florida International University 
   Miami, FL  
 
2005   Toxicologist 
Miami-Dade County Medical Examiner Department 
Miami, FL 
 
2006 – 2010  Doctoral Candidate in Chemistry 
Florida International University 
   Miami, FL  
 
 
PUBLICATIONS AND PRESENTATIONS 
 
Recipient of the Society of Forensic Toxicology’s Educational Research Award 2010. 
 
Tolliver, S., Hearn, W.L., and Furton, K.G. (2010).  Identifying Variances between 
Postmortem and Antemortem Morphine and Codeine Concentrations.  Presented at the 
Society of Forensic Toxicology’s 40th Annual Meeting.  
 
Tolliver, S., Hearn, W.L., and Furton, K.G. (2010).  Evaluating the Relationship between 
Postmortem and Antemortem Morphine and Codeine Concentrations in Whole Blood.  
Accepted for the Special Edition of Journal of Analytical Toxicology 2010. 
 
Tolliver, S., Hearn, W.L., and Furton, K.G. (2008).  Evaluating the Significance of 
Variation of Drug concentrations in Antemortem and Postmortem Blood Samples.  
Presented at the American Academy of Forensic Sciences 60th Annual Scientific 
Meeting.  
 
 
 
